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The proportion of the global population that falls into the ‘elderly’ category is 
increasing rapidly. Poor dietary habits and inadequate nutrient intakes are of particular 
concern in this population group and may influence quality of life and health outcomes. 
The dietary intake of 208 Irish community-dwelling elderly individuals (64-93 yrs), 
participating in the ELDERMET project was assessed using a validated semi-
quantitative food frequency questionnaire (FFQ). Consumption of energy-dense, low-
nutrient foods was shown to be excessive. Older elderly subjects (≥75 yrs) consumed 
significantly more desserts/sweets than younger elderly (64-74 yrs). Intakes of dietary 
fat and saturated fat were high while dairy food consumption was inadequate in both 
males and females. Elderly females typically had a more nutrient dense diet than males 
and a considerable proportion of subjects, particularly males, had inadequate intakes of 
calcium, magnesium, vitamin D, folate, zinc and vitamin C. These findings highlight the 
need for appropriate interventions to tackle these dietary inadequacies in this vulnerable 
population group. 
Additional analysis of this elderly cohort was undertaken in order to investigate the 
association between dietary patterns, dietary glycaemic index and glycaemic load, and 
cognition. Hierarchical clustering was conducted on the FFQs to derive patterns of 
dietary intake. Elderly subjects consuming ‘prudent’ dietary patterns (high in fruit, 
vegetables, and low in red meat and white bread) had better cognition function (as 
assessed by the Mini-mental State Examination) compared to those consuming 
‘Western’ dietary patterns (high in red meat, white bread and low in fruit and 
vegetables). Furthermore, in fully adjusted models, logistic and Poisson regression 
analysis revealed that the high glycaemic diets were associated with poor cognitive 
function, demonstrating a new link between nutrition and cognition in the elderly. 
A collaborative project was undertaken with Alimentary Health Ltd., to investigate if 
Bifidobacterium-fermented milk products (BFMs) containing non-viable (‘dead’) cells 
could stimulate levels of IL-10 and TNF-α in a manner comparable to those stimulated 
by BFMs containing viable (‘live’) cells. Depending on the strain and mode of killing 
used, BFMs containing non-viable cells stimulated levels of IL-10 and TNF-α which 
were comparable to those stimulated by BFMs containing viable cells in the peripheral 
blood mononuclear cell model. In particular, killing the cells by storage at 4ºC over a 
period of 9 weeks was found to be the best method for maintaining immunomodulatory 
Abstract 
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activity for all Bifidobacterium strains. As well as eliminating shelf life problems, 
administration of such a product containing non-viable microorganisms could reduce 
the risk of microbial translocation and infection. Nonetheless, the true in vivo picture 
needs to be fully determined. 
An extensive screening study of the elderly faecal-derived microbiota was undertaken to 
examine the prevalence of antimicrobial production by intestinal bacteria and to mine 
this rich repository of metabolites for novel antimicrobials. Screening with the indicator 
organisms Lb. delbrueckii subsp. bulgaricus LMG6901 and Escherichia coli K-12 
resulted in the isolation of 16 genetically distinct strains producing antimicrobial 
substances. A number of previously characterised bacteriocins including ABP-118 
(from Lactobacillus salivarius), gassericin T (Lactobacillus gasseri), mutacin II 
(Streptococcus mutans), enterocin L-50 and enterocin P (Enterococcus faecium) were 
identified. A number of E. coli strains were also isolated which produced heat labile 
antimicrobials, most likely colicins or microcins. Interestingly, a Lactobacillus 
crispatus strain (EM-LC1) was isolated which was found to produce a potentially novel 
heat labile antimicrobial compound which was resistant to protease activity in the cell-
free supernatant.  
A genome sequencing approach was applied to attempt to identify loci which may be 
responsible for what initially appeared to be an atypical bacteriocin-like antimicrobial 
activity in the faecal isolate, Lb. crispatus EM-LC1. The draft genome sequence 
consists of 1,862,161 bp with a G+C content of 36.9%. It is predicted to contain 1,827 
putative coding DNA sequences (CDSs) representing an 87.6% coding density. A 
predicted exopolysaccharide biosynthetic cluster, a complete type I 
restriction/modification system, a complete toxin-antitoxin system and individual 
phage-like genes were identified. As expected, a number of genes related to 
carbohydrate utilisation and genes implicated in adhesion to human intestinal cells were 
identified and are likely to contribute to the ability of Lb. crispatus to colonize intestinal 
mucosa. Comparison of the genome to the published genome sequence Lb. crispatus 
ST1 (which does not exhibit antimicrobial activity) revealed a number of genes related 
to bacteriocin (helveticin) production. Indeed, the genome sequence of this strain will 
offer a clearer genomic platform for further investigation into Lb. crispatus 
Abstract 
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antimicrobial activity and will elucidate the genetic basis for its potential probiotic 
traits. 
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As a society we are facing significant health problems. The incidence of chronic 
diseases, including obesity, type 2 diabetes mellitus, cardiovascular disease and cancer, 
is increasing worldwide and places a significant burden on national health budgets. Diet 
and nutrition have been recognised for many years as important factors in the promotion 
and maintenance of good health throughout life and their role as determinants of chronic 
disease is well established. Indeed, food provides nutrients needed to fuel, build and 
maintain all body cells and over- or under-consumption of particular nutrients can lead 
to an increased risk of diet-related disease.  
Recent years have witnessed the increasing prominence of the gut microbiota as a major 
research topic in relation to health and disease, presenting new opportunities for medical 
and food applications. Indeed, while we have known for many years that certain 
microbial entities can cause diseases such as gastroenteritis, we are only starting to 
appreciate the more subtle role of the commensal intestinal microbiota in various 
intestinal conditions, such as inflammatory bowel disease (IBD) and irritable bowel 
syndrome (IBS) (Clemente et al., 2012; Power et al., 2013b) and even conditions 
beyond the gut, such as obesity and metabolic syndrome (Power et al., 2013a).  
While understanding the role of the gut microbiota in health and disease is one of the 
very topical areas in science, mechanisms to manipulate the microbiota in order to 
generate a ‘healthy’ microbiota are an obvious requirement. There are several 
approaches to modulate the gut microbiota. The administration of antibiotics has long 
been recognised as having a major, and possibly negative impact on the balance of the 
microbiota, by reducing or removing specific bacterial species or classes (Claesson et 
al., 2011; Young & Schmidt, 2004). In contrast, certain beneficial bacteria may be 
increased by the consumption of probiotics: ‘live microorganisms which when 
administered in adequate amounts confer health benefits to the host’ (FAO/WHO, 
2002). Although one of the original concepts associated with probiotics was that their 
consumption would alter the composition of the intestinal microbiota (i.e. replace ‘bad’ 
bacteria with ‘good’ bacteria) (Metchnikoff, 1908), it has since been suggested that too 
much emphasis should not be placed on the potential change in microbiota composition 
without bearing in mind any benefits to health that are accomplished (Ouwehand et al., 
2002). Indeed, for some probiotic health effects (e.g. immune modulation) it may not be 
necessary to achieve any measurable modification of the intestinal microbiota 
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composition. There is currently a vast array of proposed health effects (both direct and 
indirect) attributed to specific probiotics (Goldin, 2011) which has provided major 
commercial opportunities for a number of food companies worldwide, with a global 
market estimated at $24.2 billion in 2011(MarketsandMarkets, 2013)  
More recently, diet has been highlighted as one of the key methods for altering the 
microbiota (Claesson et al., 2012; De Filippo et al., 2010; Wu et al., 2011). Diet 
provides nutrients not only for the host but also for the bacteria in the GIT. The 
ELDERMET project has provided ground-breaking evidence which supports the link 
between diet, the gut microbiota and health in the elderly and suggests that changing the 
diet to drive a beneficial change in the microbiota composition could support better 
health and healthier ageing in the older population (Claesson et al., 2012). These 
findings represent opportunities for both the food ingredients business and the 
pharmaceutical industry to develop specific food ingredients that promote healthier 
ageing, through modification of the microbiota composition.  
Another element in the study of the intestinal microbiota is the realisation that the 
microbiota can be a source of valuable functional compounds with potential biomedical 
applications (such as bacteriocins, immunomodulatory components and 
bacteriophages). Indeed, ongoing ‘mining’ of the gastrointestinal microbiota by 
scientists in the Alimentary Pharmabiotic Centre (APC) has shown it to be a rich 
repository of functional food ingredients and even new drugs. For example, the APC 
scientists have discovered, patented and licensed a narrow-spectrum antimicrobial 
active against Clostridium difficile, which may offer an alternative treatment for 
C. difficile-associated diarrhoea (Rea et al., 2010).  
This current project was supported by the ELDERMET project, the APC and by the 
Irish Research Council under the Enterprise Partnership Scheme (in collaboration with 
the industry partner, Alimentary Health Ltd.). The overall hypothesis of this thesis is 
that diet and the intestinal microbiota independently and jointly contribute to health in 
the elderly and that the investigation of habitual dietary patterns and functional 
microbiota components, can lead to the identification of specific effector mechanisms. 
The initial phase of this project investigated the dietary intake of elderly subjects 
participating in the ELDERMET project (Chapter 3) which provided the opportunity to 
make associations with cognitive health (Chapter 4). Following on from this, a 
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collaborative project with Alimentary Health Ltd. allowed the investigation of the 
immunomodulatory effect of ‘live’ and ‘dead’ Bifidobacterium-fermented milk products 
in a cell type representative of the innate immune system (Chapter 5). Lastly, this 
project included an extensive screening study of the elderly-derived faecal microbiota in 
order to examine the prevalence of antimicrobial production by intestinal bacteria and to 
mine this rich repository of metabolites for novel antimicrobials (Chapter 6). This was 
followed by the determination of the genome sequence of Lb. crispatus EM-LC1 
(Chapter 7), an isolate selected for its potentially novel antimicrobial activity (Chapter 
6).  
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1.0  Abstract  
The human intestine is colonised by 1013 to 1014 microorganisms, the vast majority of 
which belong to the phyla of Firmicutes and Bacteroidetes. Although highly stable over 
time, the composition and activities of the microbiota may be influenced by a number of 
factors including age, diet, and antibiotic treatment. Although perturbations in the 
composition or function of the microbiota are linked to inflammatory and metabolic 
disorders (e.g. inflammatory bowel disease, irritable bowel syndrome and obesity), it is 
unclear at this point whether these changes are a symptom of the disease or a 
contributing factor. A better knowledge of the mechanisms through which changes in 
microbiota composition promotes disease states is needed in order to improve our 
understanding of the causal relationship between the gut microbiota and disease. While 
evidence of the preventative and therapeutic effects of probiotic strains against 
diarrhoeal illness and other intestinal conditions is promising, the exact mechanisms of 
the beneficial effects are not fully understood. Recent studies have questioned whether 
non-viable probiotic strains can exert health benefits on the host by influencing the 
immune system. As the potential health effect of these non-viable bacteria depends on 
whether the mechanism of the health effect is dependent on viability, future research 
needs to consider each probiotic strain on a case-by-case basis. The present review 
provides a comprehensive, updated overview of the human gut microbiota, the factors 
influencing its composition, and the role of probiotics as a therapeutic modality in the 
treatment and prevention of diseases and/or restoration of human health. 
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2.0  Introduction  
 The human intestinal microbiota plays a key role in numerous metabolic, physiological, 
nutritional and immunological processes (O'Hara & Shanahan, 2006), and perturbations 
in the composition of the microbiota influences human health (O'Toole & Claesson, 
2010). Much of the early information regarding the intestinal microbiota came from 
studies that used culture-dependent techniques which reveal only a minority of species 
constituting the microbial population (Adlerberth & Wold, 2009; O'Toole & Claesson, 
2010). However, the advent of culture-independent, DNA-based analyses has generated 
data which can be mined for information on the composition and functional properties 
for this hitherto-uncultured microbiota (Ehrlich, 2010; O'Toole & Claesson, 2010; 
Rastall, 2004).  
The microbial content of the gastrointestinal tract (GIT) changes along its length, 
ranging from a narrow diversity and low numbers in the stomach to a wide diversity and 
high numbers in the large intestine (Isolauri et al., 2004; Tiihonen et al., 2010) (Fig. 1).  
The best studied region of the gut is the distal colon, and in adults, faecal-derived 
populations are estimated to consist of 1013 to 1014 microorganisms, composed of 
approximately 1,100 prevalent species, with at least 160 such species per individual. In 
its entirety, the microbiota is estimated to contain 150-fold more genes than the human 
genome (Qin et al., 2010). The majority of bacteria belong either to the phylum 
Firmicutes (including Clostridium, Enterococcus, Lactobacillus and Ruminococcus) or 
Bacteroidetes (including Bacteroides and Prevotella genus) which constitute over 90% 
of the known phylogenetic categories found in the human intestine (Eckburg et al., 
2005; Hayashi et al., 2002b; Hold et al., 2002; Qin et al., 2010; Rajilić‐Stojanović et al., 
2009; Tap et al., 2009; Wang et al., 2003). Although there is huge range in inter-
individual variability in microbial composition (Eckburg et al., 2005; Hayashi et al., 
2002b; Hayashi et al., 2003; Qin et al., 2010), recent work has revealed that a core of 
>50 taxa are found in nearly half of human subjects sampled (Qin et al., 2010; Tap et 
al., 2009). It has also been suggested that the microbiota of most individuals can be 
categorised into three predominant variants, or ‘enterotypes’, dominated by three 
different genera: Bacteroides, Prevotella and Ruminococcus which are independent of 
age, gender, nationality and body mass index (Arumugam et al., 2011). This concept 
was partially supported by Wu et al. (2011) who identified two enterotypes, 
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distinguished primarily by levels of Bacteroides and Prevotella, which were largely 
driven by diet. More recently, considerable debate has arisen about the notion of 
enterotypes (Jeffery et al., 2012; Yong, 2012) with a number of studies (Claesson et al., 
2012; Huse et al., 2012) failing to identify the three distinct categories described by 
Arumugam et al. (2011). Researchers are now favouring the idea of a continuum or 
gradient of species functionality rather than discontinuous variation with segregated 
types (Jeffery et al., 2012).  
Studies have also identified a core microbiome at the gene rather than at the organismal 
lineage level (Serino et al., 2012; Turnbaugh et al., 2009a). These studies suggest that, 
rather than a core group of species, individuals share a core microbiome function and 
individuals exhibiting particular phenotypes (e.g. obese or non-obese) may display 
different patterns of gut microbes but share a core of functions (Turnbaugh et al., 
2009a). Changes in this core set of genes may account for different states of health and 
disease. Future research will investigate whether the metagenome predicts a risk for 
developing particular human diseases to obtain new microbial diagnostic markers that 
may allow early diagnosis of diseases and development of potentially new therapeutic 
strategies.  
Although much has been discovered in the last decade about the intestinal microbiota, 
there are biases and limitations to the current knowledge related to study design, sample 
collection and confounding variables, such as diet. Investigations into the impact of diet 
on the intestinal microbiota are challenged by the inability to carry out large-scale, 
carefully controlled trials in humans. There is also a need to better clarify the 
mechanisms through which microbial dysbiosis promotes disease states in order to 
improve our understanding of the causal relationship between the gut microbiota and 
disease. Whether a disease-prone microbial composition can be transformed to a 
healthier composition by probiotic/prebiotic/dietary interventions remains a 
fundamental unanswered question. Nonetheless the emergence and growing 
accessibility of the next generation sequencing technologies will greatly advance the 
discovery of the composition and functional capacity of microbial communities in the 
human gut. In this review, we discuss recent insights into the impact of age, diet, 
antibiotic use and disease on the intestinal microbiota. We also highlight the role of 
probiotics, in particular, the potential role of dead or inactivated microbes as a 
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therapeutic modality in the treatment and prevention of diseases and/or restoration of 
human health. 
3.0  Factors influencing the composition of the microbiota 
3.1 Age 
Development of the human microbiota is a dynamic process, with different life stages 
exhibiting differences in terms of diversity and variation (Fig. 1) (Biagi et al., 2012; 
O'Toole & Claesson, 2010; Tiihonen et al., 2010). The human microbiota is established 
at birth when the intestine becomes inhabited by a population that is characterised by 
instability (Tiihonen et al., 2010). Initially, facultative anaerobes such as 
Enterobacteriaceae, streptococci and staphylococci dominate (Marques et al., 2010). In 
recent years, more stringent hygienic conditions during delivery combined with shorter 
hospital stays have reduced bacterial exposure leading to changes in the initial 
colonisation pattern, with skin-derived staphylococci being the first colonisers of the 
infant gut rather than faecal Enterobacteriaceae (Marques et al., 2010; Morelli, 2008). 
For infants born vaginally, the first encounter with microorganisms occurs in the birth 
canal where colonisation is initiated by the maternal vaginal and intestinal microbiota as 
well as the environment (Lupp & Finlay, 2005). In contrast, for infants delivered by 
caesarean section, the environment (e.g. nursing staff and the air) is an extremely 
important source of colonizing bacteria, and these infants have lower intestinal bacterial 
counts with less diversity in the early weeks of life (Azad et al., 2013; Grölund et al., 
1999; Morelli, 2008).  
Other factors influencing the microbiota include gestational age, hospitalisation of the 
infant, antibiotic use and infant feeding. Breast-fed infants have a microbiota dominated 
by Bifidobacterium (Bezirtzoglou et al., 2011; Penders et al., 2006; Turroni et al., 2012; 
Yatsunenko et al., 2012) and Ruminococcus (Favier et al., 2002; Morelli, 2008), with 
rates of colonization by Escherichia coli, Clostridium difficile, Bacteroides fragilis-
group bacteria and lactobacilli significantly lower than those for exclusively formula fed 
infants (Penders et al., 2006; Yoshioka et al., 1983). The microbiota of formula-fed 
infants is more complex (Agans et al., 2011; Bezirtzoglou et al., 2011) and includes a 
variety of bacterial genera, including enterobacterial genera, Streptococcus, Bacteroides 
and Clostridium, Bifidobacterium (Favier et al., 2002) and Atopobium (Bezirtzoglou et 
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al., 2011). It must be noted that some reports have found no differences in the 
microbiota between breast- and formula-fed infants and have attributed this to modern 
formulas more closely mimicking the composition of human breast milk (Adlerberth & 
Wold, 2009). The composition of the microbiota changes further with the introduction 
of solid food and a complex, more stable community similar to the adult microbiota 
becomes established after weaning (at 2-3 yrs of age) (Collins & Gibson, 1999; Favier 
et al., 2002; Koenig et al., 2011; Yatsunenko et al., 2012).  
Throughout adult life, the composition of the intestinal microbiota is relatively stable 
and is only transiently altered by external disturbances (Delgado et al., 2006) as will be 
discussed below. However, this relative stability is reduced in old age (Tiihonen et al., 
2010). There is considerable variation in the reported microbiota compositions of 
elderly subjects which appear to be dependent on residence cohort, geographical 
location and detection methods used (Mueller et al., 2006; Tiihonen et al., 2010). The 
large inter-individual variation in the microbiota composition continues into old age 
(Claesson et al., 2011) and the process of ageing coincides with decreasing microbiota 
diversity (Biagi et al., 2010). Researchers are continually striving to elucidate the 
composition of the intestinal microbiota of the elderly but as yet no specific ‘common 
core’ has been identified. However, some of the fundamental changes that occur include 
a decrease in total number and species diversity of bifidobacteria and bacteroides as 
well as a reduction in amylolytic activity and the availability of total short chain fatty 
acids (SCFA). There is a concurrent increase in facultative anaerobes, fusobacteria, 
clostridia and eubacteria as well as an increase in proteolytic activity (Cusack & 
O'Toole, 2010; Woodmansey, 2007). A study by the ELDERMET consortium found 
that the microbial population of elderly Irish subjects is dominated by Bacteroidetes, 
whereas the microbiota of younger subjects is dominated by Firmicutes (Claesson et al., 
2011). However, Biagi et al. (2010) did not find significant differences among the 
Firmicutes/Bacteroidetes ratios of Italian centenarians, elderly and young adults. These 
conflicting results have been attributed to the country-related variation in the gut 
microbiota (Biagi et al., 2012) which was highlighted several years ago (Mueller et al., 
2006) and presumably may be linked to diet. Furthermore, the composition of the gut 
microbiota of the elderly may also vary depending on residence location (Bartosch et 
al., 2004; Claesson et al., 2012), which is a proxy measure for radically different diets 
(see below). 
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3.2 Diet 
Diet is a factor which undoubtedly influences the composition of the intestinal 
microbiota. Diet provides nutrients both for the host and the bacteria in the GIT. Most 
of the enzymes needed to break down the structural polysaccharides in plant material 
are not encoded by mammalian genomes. The intestinal microbiota produces a larger 
collection of degradative enzymes and exhibits a broader range of metabolic capabilities 
(Flint et al., 2012). It is estimated that 20-60g of dietary carbohydrates reaches the colon 
on a daily basis (Flint et al., 2012) including resistant starch, non-starch polysaccharides 
(NSP), plant cell wall polysaccharides and non-digestible oligosaccharides (Flint et al., 
2012; Fuller, 1991; Scott et al., 2008). Some dietary protein (e.g. collagen and elastin) 
as well as various secondary plant metabolites (e.g. polyphenolic substances), can also 
reach the large intestine and may undergo bacterial transformations (Guarner & 
Malagelada, 2003; Louis et al., 2007).  
Alternative substrates can give rise to different products due to fermentation via 
different metabolic processes, while the same substrate can be metabolised by different 
pathways depending on their rate of supply, or the physiology and environment of the 
bacterial cell (Louis et al., 2007). Changes in the composition of the gut microbiota in 
response to dietary intake occur because different bacterial species are better equipped 
(genetically) to utilise different substrates (Scott et al., 2008). Generally, bacteria favour 
carbohydrates as primary energy sources if they are available (Apajalahti, 2005). 
Metagenomic sequencing of the intestinal microbiota identified a large group of 
carbohydrate active enzymes (CAZymes) (Kurokawa et al., 2007). While certain 
species, particularly among the Bacteroidetes, possess large numbers of genes encoding 
CAZymes, which allows them to switch between different energy sources, other groups 
encode fewer CAZymes and are noticeably more specialised (Flint et al., 2012). Dietary 
supplementation with prebiotics such as inulin and fructo-oligosaccharide can promote 
specific groups of bacteria, including bifidobacteria (Flint et al., 2007; Gibson, 1999; 
Roberfroid, 2007).  A recent study demonstrated rapid and reversible changes in the 
relative abundance of specific dominant bacterial groups after changes in the major type 
of non-digestible carbohydrate (i.e. resistant starch, NSP or reduced carbohydrate diet). 
There were profound inter-individual differences in the response of the microbial 
community to dietary change due to the inter-individual differences in the initial 
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microbiota composition; this suggests that dietary advice on the consumption of non-
digestible carbohydrates may need to be personalised in the future (Walker et al., 2010).  
Saccharolytic bacterial fermentation mainly takes place in the proximal colon (due to 
greater fermentable carbohydrate availability) (Hamer et al., 2008) and may result in the 
production of short-chain-fatty acids (SCFAs) (Guarner & Malagelada, 2003), the type 
and levels of which depend on the source and quantity of carbohydrate available, and 
the microbiota present (Scott et al., 2008). SCFAs are energy sources for the colonic 
epithelium, and butyrate in particular exerts important effects on cell differentiation and 
gut health (Hamer et al., 2008). Proteolytic fermentation generally takes place in the 
distal colon (where fermentable carbohydrates become depleted) (Hamer et al., 2008) 
and results in the production of SCFAs in addition to ammonia, amines, phenols, thiols 
and indoles (Guarner & Malagelada, 2003).  
Early studies comparing dietary patterns (e.g. ‘Japanese’ versus ‘Western’) or 
examining the impact of changing the proportions of food categories on the intestinal 
microbiota found only moderate effects involving a few genera (Drasar et al., 1973; 
Drasar et al., 1976; Finegold et al., 1974). These studies relied on culture-based 
techniques and were therefore limited in their ability to detect changes in the fine detail 
of gut microbiota composition. More recent studies have employed culture-independent 
approaches and have further elucidated the role of diet in determining the composition 
of the intestinal microbiota in humans (Table 1).  
In a landmark study, De Filippo et al. (2010) compared the faecal microbiota of 
European children (EU) (consuming a ‘Western’ diet) with that of children in the 
African state of Burkina Faso (BF) (consuming a plant-rich, ‘rural’ diet, high in fibre 
content). The BF children had a lower abundance of phylum Firmicutes and a higher 
abundance of phylum Bacteroidetes (mainly Prevotella and Xylanibacter) in their faecal 
microbiota compared to the EU children, who had higher levels of Enterobacteriaceae. 
Prevotella and Xylanibacter, which contain genes for cellulose and xylan hydrolysis, 
were associated with increased faecal SCFAs. The authors postulated that the gut 
microbiota co-evolved with the plant-rich diet of the BF children, allowing them to 
maximise energy extraction from dietary fibre, while also protecting these children from 
inflammation and non-infectious intestinal disease.  
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Similar dietary associations were found in a study linking dietary patterns of American 
adults with gut microbial enterotypes, dominated by Bacteroides or Prevotella. Wu et 
al. (2011) found that the Bacteroides enterotype was positively associated with protein 
and animal fat, whereas the Prevotella enterotype was associated with a diet high in 
carbohydrates and low in meat and dairy.  
Vegetarianism has also been shown to alter the intestinal microbiota (Hayashi et al., 
2002a; Kabeerdoss et al., 2011; Liszt et al., 2009). The higher intakes of carbohydrate 
and fibre associated with this dietary practice, result in SCFA production by microbes 
which lowers the intestinal pH, preventing growth of potentially pathogenic bacteria 
such as E. coli and other members of Enterobacteriaceae (Zimmer et al., 2011). Indeed, 
Zimmer et al. (2011) demonstrated that subjects consuming a vegan or vegetarian diet 
had lower stool pH than controls and total counts of culturable Bacteroides spp., 
Bifidobacterium spp., E. coli and Enterobacteriaceae spp. were significantly lower in 
vegan samples than in controls. A vegetarian diet has also been shown to decrease the 
amount and change the diversity of Clostridium cluster IV and Clostridium rRNA 
clusters XIVa and XVII (Hayashi et al., 2002a; Liszt et al., 2009). 
It was recently reported that diverse dietary patterns are responsible for the gut 
microbiota variation seen between community-dwelling elderly subjects and subjects in 
long-term residential care. The diet of community-dwelling individuals was typically 
more diverse with low to moderate fat and high fibre intake, whereas that of subjects in 
long term residential care was less diverse with moderate to high fat and low to 
moderate fibre intake. Those in long-term care had a less diverse microbiota with a 
higher proportion of the phylum Bacteroidetes, while the microbiota of community 
subjects was more diverse with a higher proportion of phylum Firmicutes. Community-
dwelling subjects had a higher abundance of bacteria from the genus Prevotella, 
supporting the association between Prevotella and a diet high in carbohydrates as 
observed in the BF children and American adults. Coprococcus and Roseburia were 
also more abundant in the faecal microbiota of community subjects, whereas 
Parabacteroides, Eubacterium, Anaerotruncas, Lactonifactor and Coprobacillus were 
more abundant in subjects in long-term care. For subjects in long-term care, both the 
faecal microbiota and the diet were associated with the duration of stay, with subjects’ 
resident for more than a year having a diet and microbiota that was furthest separated 
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from community-dwelling subjects compared to recently admitted subjects. 
Interestingly, the major trends in the microbiota that separated the community-dwelling 
elderly from the elderly in long-term care were associated with changes in frailty, 
inflammation and other clinical markers and hence indicate a role for diet-driven 
microbiota alterations in health among the elderly (Claesson et al., 2012).  
Changes in the gut microbiota of (humanised germ-free) mice have been analysed after 
the mice were switched from a diet low in fat and rich in plant polysaccharides to a 
‘Western’ diet high in fat and sugar and low in plant polysaccharides. After just a single 
day, mice on a ‘Western’ diet displayed an increased abundance of bacteria of the 
Firmicutes phylum and a decrease of those of the Bacteroidetes phylum (Turnbaugh et 
al., 2009b). Hildebrandt et al. (2009) also found distinctive changes in the gut 
microbiota of mice following a switch from a standard chow to a high fat diet, which 
was associated with a proportional decrease in phylum Bacteroidetes and an increase in 
both Firmicutes and Proteobacteria. 
Faith et al. (2011) developed a statistical model for predicting how a change in diet 
would alter the abundance of particular species of the gut microbiota. A model 
community of 10 genome-sequenced human intestinal bacteria (including Bacteroides 
thetaiotaomicron, Bacteroides ovatus, Bacteroides caccae, Escherichia. coli, 
Desulfovibrio. piger, Collinsella. aerofaciens, Clostridium symbiosum, Blautia 
hydrogenotrophica, Eubacterium rectale and Marvinbryantia formatexigens) was 
introduced into germ-free mice and the composition of the intestinal community as the 
mice consumed different proportions of protein (casein), fat (corn oil), polysaccharide 
(corn-starch) and sugar (sucrose) was monitored. Each mouse was fed a randomly 
selected diet with diet switches occurring every two weeks. Steady-state levels of 
community members were achieved within 4 days of a diet change. Notably, the total 
DNA yield per faecal pellet increased as the amount of casein in the host diet increased. 
In addition, changes in species abundance as a function of changes in the concentration 
of casein in the host diet were apparent for all ten species; the abundances of seven 
species were positively correlated with casein concentration, whereas the remaining 
three species (E. rectale, M. formatexigens and D. piger) were negatively correlated 
with casein concentration. Indeed, inspection of the most highly expressed genes of E. 
rectale and M. formatexigens suggested they focused on carbohydrate catabolism 
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whereas D. piger can use only a restricted number of substrates (e.g. lactate, H2, 
succinate). In a follow-up experiment, involving diets containing various mixtures of 
pureed human baby foods (i.e. foods more typically consumed in human diets), changes 
in species abundance that were a function of diet ingredients (e.g. apple, beef, chicken, 
oat, pea, peach, rice and sweet potato) were found. For example, B. ovatus increased in 
absolute abundance with increased concentration of oats in the diet, whereas most of the 
bacterial species responded to multiple ingredients.  
Although these results from animal studies are interesting, it can be difficult to apply 
these findings to humans due to the artificial nature of these experiments compared to 
natural human microbiota and food consumption patterns. Only a limited number of 
human clinical trials have assessed the effects of dietary pattern changes on the 
intestinal microbiota (De Palma et al., 2009; Muegge et al., 2011; Walker et al., 2010; 
Wu et al., 2011). In a controlled-feeding study with 10 individuals (Bacteroides 
enterotype), Wu et al. (2011) found that the microbiome composition changed detect-
ably within 24 h of initiating a high-fat/low-fibre or low-fat/high-fibre diet, showing the 
rapid effect that diet can have on the intestinal microbiota. However, enterotype identity 
remained constant, with no stable changes to the Prevotella enterotype indicating that 
alternative enterotype states are associated with long-term diet.  
In overweight men, supplementation of the diet with resistant starch increased faecal 
levels of Eubacterium rectale and Ruminococcus bromii, which correlates with fibre 
fermentation. However, the inter-individual variation in microbiota response to resistant 
starch indicates that dietary interventions may need to be personalised (Walker et al., 
2010).  
In another study, a gluten free diet (GFD) intervention which featured a reduction in 
overall polysaccharide intake, led to reductions in gut bacteria populations such as 
Bifidobacterium, Clostridium lituseburense and Faecalibacterium prausnitzii and 
proportional increases in E. coli and total Enterobacteriaceae in healthy volunteers (De 
Palma et al., 2009; Sanz, 2010).  
Based on the available data, differences in the composition of GI microbiota are 
demonstrable between groups of people living on different diets. These diet-associated 
changes in the composition can lead to changes in metabolic activity of the intestinal 
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microbiota which may in turn provoke changes in inflammatory and immune responses. 
Although attempts to change the composition of the intestinal microbiota by varying the 
diet have been successful in mice, there is a relative paucity of human dietary 
intervention studies and those available are small in sample size and took place over a 
short period of time. Moreover, mechanisms that link dietary changes to microbiota 
alterations remain poorly defined and need to be further investigated. Large, well-
controlled trials are also required to determine the impact of altering long-term dietary 
patterns on the human intestinal microbiota and to elucidate the implications of the key 
population changes for health and disease.  
3.3 Antibiotics 
Antibiotic treatment has been shown (Claesson et al., 2011; De La Cochetiere et al., 
2008; Woodmansey et al., 2004; Young & Schmidt, 2004) to dramatically disturb the 
composition of the faecal microbiota in humans. Palmer et al. (2007) reported changes 
in the density or composition of the intestinal microbiota in infants following antibiotic 
treatment. Striking changes were found in some cases, even to a point where the faecal 
microbiota was undetectable. As there is considerable inter-individual variability in the 
composition of the microbiota among humans (Claesson et al., 2011), it has been 
suggested that the impact of antibiotics is best assessed on an individual basis (Jernberg 
et al., 2010). In general, antibiotic treatment leads to a decrease in the diversity of the 
microbiota (Jernberg et al., 2007). Nonetheless, the community is quite resilient and can 
resemble the pre-treatment state in a matter of days or weeks (Claesson et al., 2011; De 
La Cochetiere et al., 2005; Dethlefsen et al., 2008) However, a number of other studies 
have shown that the microbiota alterations following antibiotic administration can often 
persist for a long time following withdrawal of treatment, with some members of the 
microbial community failing to return to pre-treatment levels and these may even be lost 
from the community indefinitely (Croswell et al., 2009; Dethlefsen et al., 2008; 
Dethlefsen and Relman, 2011; Jakobsson et al., 2010; Jernberg et al., 2010). Microbiota 
disruption by antibiotics can also affect the metabolic activity of the bacterial 
community in the gut. Antibiotic treatment in mice was shown to drastically alter the 
intestinal metabolome by affecting host metabolic pathways such as sugar, nucleotide 
and fatty acid metabolism as well as bile acid, eicosanoid, and steroid hormone 
synthesis coding capacity (Antunes et al., 2011).  
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The effect of antibiotics on the intestinal microbiota in infancy is of particular concern. 
Recent reports demonstrated that short-term parenteral antibiotic treatment of neonates 
caused significant alternations in the gut microbiota including a disturbance of the 
expected colonisation pattern of bifidobacteria (Fouhy et al., 2012; Hussey et al., 2011). 
Colonisation of the intestine early in life has an important role in directing immune 
system development, and antibiotic use may increase the risk of atopy and allergic 
asthma by reducing the protective effect of microbial exposure (Foliaki et al., 2009; 
Russell et al., 2012). In a large, multi-centre study, Foliaki et al. (2009) reported an 
association between antibiotic use in the first year of life and symptoms of asthma, 
rhinoconjunctivitis and eczema in children 6 and 7 years old.  
The impact of antibiotic use on the intestinal bacteria of the elderly is also of interest 
since, compared with younger adults, cohorts of elderly populations are typically 
administered a complex array of medications, including antibiotics. Antibiotic treatment 
in hospitalised elderly subjects was shown to increase the intestinal abundance of 
proteolytic bacteria (Woodmansey et al., 2004), to reduce overall bacterial numbers, 
and in some subjects, to completely eliminate certain bacterial communities (Bartosch et 
al., 2004). A more recent study found that antibiotic treatment led to a decrease in the 
taxonomic richness, diversity, and evenness of the intestinal community in elderly 
subjects, although the magnitude of the changes and the taxa affected were different 
between subjects. Moreover, the overall community structure was restored within 4 
weeks post-treatment (Claesson et al., 2011).  
One of the best known complications arising following antibiotic therapy is antibiotic-
associated diarrhoea (AAD) (Sekirov et al., 2010). A number of mechanisms underlie 
the development of AAD. Antibiotic therapy can disturb the natural microbiota in the 
GIT, which may result in pathological overgrowth of Cl. difficile and it may also disturb 
the metabolism of carbohydrates, giving rise to maladsorption of osmotically active 
particles (Vanderhoof et al., 1999; Young & Schmidt, 2004). Young & Schmidt (2004) 
found that, in a patient who developed AAD, antibiotic administration was associated 
with distinct changes in the diversity of the gut microbiota, including a decrease in the 
prevalence of butyrate-producing bacteria. Following discontinuation of the antibiotic, 
resolution of diarrhoea was accompanied by a reversal of these changes. This provided 
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evidence linking changes in the community structure of the gastrointestinal bacteria 
with the development of AAD.  
The impact of antibiotic use in the short and long-term needs to be further investigated. 
Longitudinal type studies rather than cross sectional studies will allow more direct 
testing of questions regarding the influence of antibiotic use on the development of 
allergy and gastrointestinal disease, particularly in early life. 
3.4 Disease 
3.4.1 Inflammatory Bowel Disease  
Inflammatory Bowel Diseases (IBDs), including Crohn’s disease (CD) and ulcerative 
colitis (UC), are chronic intestinal disorders whose aetiology is unclear. However, an 
abnormal immune response against luminal antigens, such as dietary factors and/or 
bacteria may be involved (Isaacs & Herfarth, 2008; Ojetti et al., 2009). CD can affect 
any part of the GIT, although the lower ileum and colon are most commonly involved 
(Reiff & Kelly, 2010). It is characterised by discontinuous inflammation of the 
epithelial lining and deep ulcers. UC affects only the colon and the rectum and is 
characterised by continuous mucosal inflammation and superficial ulcers (Gerritsen et 
al., 2011). Clinical symptoms of IBD include abdominal pain, diarrhoea, rectal 
bleeding, malaise and weight loss (Reiff & Kelly, 2010). 
Numerous studies have compared the intestinal microbiota composition of IBD patients 
and healthy individuals and it appears that the dominant microbiota differs between the 
two groups (reviewed in: Dicksved & Willing, 2011; Gerritsen et al., 2011; Ojetti et al., 
2009; Shanahan, 2010a). Similarly, the dominant microbiota in patients with UC differs 
from those with CD (Gerritsen et al., 2011; Ojetti et al., 2009). Some changes in the 
microbiota composition are however shared between UC and CD patients (Dicksved & 
Willing, 2011).  
Although the phylum level changes observed in IBD patients have not always been 
consistent, in general an overall decrease in microbial diversity and stability of the 
intestinal microbiota has been observed in IBD patients (Dicksved & Willing, 2011; 
Gerritsen et al., 2011). A decrease in the abundance of specific members of the 
Firmicutes has been reported, which in some cases coincided with an increase in 
Chapter 1 
 
15 
 
Bacteroidetes abundance and that of facultative anaerobes such as Enterobacteriaceae 
(Gerritsen et al., 2011). Moreover, increased numbers of E. coli, some of which may be 
pathogenic have been observed in IBD patients (Dicksved & Willing, 2011). Increased 
detection of Cl. difficile in relapse and remission of both forms of IBD has been 
observed (Shanahan, 2010a). Other reports described alterations in abundance of 
Bacteroidetes spp., proteobacteria, bifidobacteria and lactobacilli but results have been 
inconsistent (Dicksved & Willing, 2011).  
As regards CD, a number of consistent observations have been reported (Shanahan, 
2010a). These include increased mucosal bacterial counts, detection of increased levels 
of adherent-invasive E. coli (AIEC), and increased levels of Mycobacterium avium 
subsp. paratuberculosis (MAP). Furthermore, a reduced number of bacteria in the 
Clostridium leptum group, including Faecalibacterium prausnitzii, have been observed 
in CD patients (Sokol et al., 2008). In fact, F. prausnitzii was even proposed as a 
potential probiotic for counterbalancing dysbiosis in CD (Sokol et al., 2008). As for 
UC, a reduced presence of the Clostridium coccoides group has been described but no 
specific members of this group have been correlated with the disease as yet (Dicksved 
& Willing, 2011). 
Although marked alterations occur in the gut microbiota composition of IBD patients, it 
is unclear whether these shifts cause the disease or whether they arise due to the 
changes in the gut environment that result from the disease. Indeed most of the studies 
carried out to date have made associations between the microbiota and IBD only after 
the IBD phenotype has emerged which doesn’t allow one to answer the important 
question of what came first – IBD or a change in the microbiome. More long-term 
longitudinal studies are needed to examine the disease progression and to typify the 
taxonomic and functional composition changes of the microbiome that lead to, or may 
even define IBD. 
3.4.2 Irritable Bowel Syndrome 
Irritable Bowel Syndrome (IBS) is a common, debilitating gastrointestinal disorder 
characterised by abdominal pain, bloating and disturbances in bowel function (Jeffery et 
al., 2011; Madden, 2004; Malinen et al., 2005).  IBS can present as diarrhoea-
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predominant IBS (D-IBS), constipation-predominant IBS, or mixed-bowel-habit IBS 
(Carroll et al., 2011). 
IBS can be difficult to diagnose due to a lack of a biological or pathogenic marker 
(Madden, 2004; Malinen et al., 2005). Although the pathophysiology of IBS is still not 
well understood, several factors are thought to play a role. These include: mal-
fermentation of food ingredients; an altered microbiota; intestinal motor and sensory 
dysfunction; immune mechanisms; psychological factors and brain-gut axis 
dysregulation (Andresen & Baumgart, 2006; Madden, 2004; Quigley, 2007). 
Considerable evidence suggests that factors that disturb the gut microbiota, such as 
gastroenteritis, may contribute to the development of IBS (Thabane et al., 2007).   
The differences in the intestinal microbiota between IBS patients and healthy controls 
(HCs) have mostly been studied using faecal material. Mättö et al. (2005), using culture 
based techniques, observed slightly higher numbers of culturable coliforms and an 
increased aerobe:anaerobe ratio in IBS subjects relative to healthy controls. Moreover, 
PCR-DGGE revealed more temporal instability in the predominant bacterial population 
of IBS subjects than in controls and IBS subjects had more Clostridium spp. and less 
Eubacterium spp. amplicons. However, the researchers did not control for antibiotic 
use, which may have contributed to the apparent temporal instability observed (Mättö et 
al., 2005). In a subsequent study, which targeted the clostridial groups in IBS, it was 
reported that a similar instability existed (Maukonen et al., 2006). In addition, a study 
employing DGGE techniques found that there was significantly more variation in the 
gut microbiota of healthy volunteers than that of IBS patients (Codling et al., 2010).   
Jeffery et al. (2011) described detailed analysis of the faecal microbiota in a cohort of 
well characterised IBS patients and control subjects and found no uniform change in the 
microbiota in IBS. However, analysis of the microbial populations revealed distinct 
clusters, one of which showed normal-like microbiota composition compared with 
healthy controls. The other IBS samples were characterised by an increase of 
Firmicutes-related taxa and a decrease of Bacteroidetes-related taxa. In addition, 
analysis of the IBS microbiota and separate analyses of the two subgroups showed 
microbial associations with colonic transit time, satiety, bloating, rectal pain threshold 
and depression (Jeffery et al., 2011). Significantly, the IBS subjects with a microbiota 
similar to that of the matched healthy controls displayed higher anxiety and depression 
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scores, suggesting a non-intestinal or at least a non-microbiota aetiology for IBS in this 
sub-group. 
A more recent study showed intestinal dysbiosis in diarrhoea-predominant IBS patients 
compared to healthy controls. A significant increase in the abundance of unclassified 
Enterobacteriaceae and significant reductions in members of the Faecalibacterium 
genus were found in IBS patients compared to controls. Furthermore, Enterococcus, 
Fusobacterium, Pediococcus, unclassified Lactobacillaceae and Veilonella species were 
found in IBS patients but were below detection limits in the healthy controls (Carroll et 
al., 2012). 
The studies described above demonstrate that the intestinal microbiota of patients with 
IBS can differ from that of healthy individuals. Nonetheless, it is not yet possible to be 
certain (as in IBD above) whether the alterations in the intestinal microflora seen in IBS 
patients are the cause of IBS, or are simply a result of the disrupted gut motility or other 
physiological features of IBS. More studies are needed to clarify whether the microbiota 
have a causal role in the initiation and/or progression of IBS. 
3.4.3 Obesity  
Some of the earliest evidence showing the role of the gut microbiota in the regulation of 
fat storage was demonstrated in animal models. A pioneering study by Bäckhed et al. 
(2004) found that germ-free (GF) mice were leaner than their conventional counterparts 
and colonisation with an intestinal microbiota resulted in a significant increase in body 
fat content despite lower food consumption in the colonised animals. A subsequent 
study found that GF mice were protected against obesity following consumption of a 
western style, high fat, sugar rich diet (Bäckhed et al., 2007). In addition, colonisation 
of GF mice with an ‘obese microbiota’ (i.e. from an obese animal) led to greater 
increases in total body fat compared to GF mice colonised with a ‘lean microbiota’ 
(Turnbaugh et al., 2006), indicating that the obese microbiota had an increased capacity 
to harvest energy from the diet.  
 It has been suggested that inflammation (Cani et al., 2007) and alterations in host gene 
expression (Bäckhed et al., 2007) are other mechanisms by which gut microbiota may 
influence the host. Obesity and its related metabolic disorder, type 2 diabetes, are 
generally associated with chronic low-grade inflammation (Wellen & Hotamisligil, 
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2005). The highly proinflammatory component, lipopolysaccharide (LPS) is a possible 
initiator of metabolic impairment (Cani et al., 2007). Plasma LPS levels increase with 
higher fat intake in both mice (Cani et al., 2007) and humans (Erridge et al., 2007) and 
the direct infusion of LPS mimics the physiological effects of the high fat diet in mice 
(Cani et al., 2007). It has been hypothesised that LPS is taken up with dietary fats in 
chylomicrons (Ghoshal et al., 2009) or that LPS reaches the circulation because the gut 
is more permeable in obese mice due to disruption of tight junction proteins (Brun et al., 
2007; Cani et al., 2009). A review on this topic has been described recently (Sommer & 
Bäckhed, 2013). 
Studies have also linked alterations in the intestinal microbiota composition to obesity 
(Duncan et al., 2008; Ley et al., 2005; Ley et al., 2006; Zhang et al., 2009). An 
increased ratio of Firmicutes to Bacteroidetes has been observed in genetically obese 
mice (ob/ob) (Ley et al., 2005) as well as obese humans (Ley et al., 2006; Turnbaugh et 
al., 2009a). However, a number of other studies have failed to confirm these findings 
and have shown variable patterns in the phylum level changes measured in the 
microbiota composition of obese humans (Duncan et al., 2007; Duncan et al., 2008; 
Schwiertz et al., 2010).  
Although it is clear from the studies described above that the gut microbiota are likely 
to play some role in obesity and metabolic disease, it is difficult to draw definite 
conclusions on the importance of particular bacterial groups. Further well-designed, 
large clinical studies will be required to identify microbiota-related biomarkers of risk 
for obesity and metabolic dysregulation.  
4.0  Manipulation of intestinal microbiota  
4.1 Probiotics 
The term ‘probiotic’, a word derived from the Greek and meaning ‘for life’ (Quigley, 
2007), has been defined as ‘live microorganisms which when administered in adequate 
amount confer a health benefit on the host’ (FAO/WHO, 2002). Some probiotic 
products contain a single strain while others contain a mixture of several species of 
bacteria or fungi. The most studied and commonly used organisms in probiotic 
preparations are lactobacilli and bifidobacteria.  
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One of the original concepts associated with probiotics was that their consumption 
would alter the composition of the intestinal microbiota from a possibly harmful one 
towards a microbiota that would benefit the host (i.e. replace ‘bad’ bacteria with ‘good’ 
bacteria) (Metchnikoff, 1908). This was a rather simplistic theory, and it was not based 
on a full understanding of the complexity of the intestinal microbiota anyway. It has 
since been suggested (Ouwehand et al., 2002) that too much emphasis should not be 
placed on the potential change in microbiota composition but rather the inherent health 
benefits conferred by the probiotics themselves. Indeed for some probiotic effects (e.g. 
immune modulation) it may not be necessary to achieve a measurable modification of 
the intestinal microbiota composition. In recent times two main motives have emerged 
for the use of probiotics. The first one is the use of probiotics by healthy subjects in 
order to maintain a healthy state and decrease the risk of illness. The second is the use 
of probiotics as a treatment/therapeutic modality targeted at particular diseases.  
There is a variety of proposed health effects (both direct and indirect) for probiotics 
which have been extensively reviewed (Goldin, 2011; Parvez et al., 2006; Vanderhoof 
& Young, 2008). However, the subtleties of the positive effects of probiotics can only 
be fully appreciated following meta-analysis. Some of the most robust clinical data are 
confined to the preventative and therapeutic effects of probiotic strains against 
diarrhoeal illnesses (Allen et al., 2011; Bernaola Aponte et al., 2010; Hempel et al., 
2012; Videlock & Cremonini, 2012). A number of beneficial effects of probiotics 
dealing with intestinal health have been evaluated in Cochrane reviews (AlFaleh et al., 
2010; Allen et al., 2011; Bernaola Aponte et al., 2010; Johnston et al., 2007). These and 
other meta-analyses have demonstrated the efficacy of probiotics in the prevention and 
treatment of antibiotic-associated diarrhoea (Hempel et al., 2012; Johnston et al., 2007; 
Videlock & Cremonini, 2012), acute infectious diarrhoea (Allen et al., 2011) and 
persistent diarrhoea in children (Bernaola Aponte et al., 2010). Evidence is also 
accumulating from well-conducted clinical studies on the efficacy of probiotics in 
preventing and reducing the severity of necrotizing enterocolitis (NEC) in premature 
infants and those with very low birth weight (AlFaleh et al., 2010; Barclay et al., 2007; 
Wang et al., 2012). Probiotics have also yielded promising improvements in the 
prevention and treatment of Inflammatory Bowel Diseases (IBD; Ulcerative Colitis and 
Crohn’s Disease) (Isaacs & Herfarth, 2008) and Irritable Bowel Syndrome (IBS) 
(Quigley, 2007). However, it must be noted that these meta-analyses have their own 
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limitations. The clinical and methodological heterogeneity between studies as well as 
the differences in probiotic type, delivery method (yoghurt vs. capsule) and dosage 
make comparisons difficult. Indeed no two different probiotics are likely to be 
functionally the exact same and therefore performing meta-analyses based on studies 
involving different strains, species and even genera is inherently questionable. Different 
strains may have vastly different effects and hence no ideal probiotic strain for any of 
the above conditions has been identified, despite continuing advances in this area.  
Although there is no single mechanism of action for probiotics, there are a number of 
common mechanisms by which probiotics might influence the intestinal microbiota 
(Fig. 2) (O'Toole & Cooney, 2008). It is likely however, that the mechanism of action of 
probiotics is multi-factorial and strain specific (Tuohy et al., 2003).  
While there are extensive scientific and clinical portfolios associated with (specific 
strains of) probiotics, the European Food Safety Authority (EFSA) has yet to approve 
health claims for a single probiotic (there have been 120 negative opinions on probiotic 
claims through February 2011) (Sanders et al., 2011). Indeed, the regulators are 
applying almost pharmaceutical standards to the use of probiotics. As already 
mentioned, there are two main uses for probiotics: 1) probiotics as a ‘food for health’ 
product or 2) probiotics as a therapeutic modality for illness. The first example is clearly 
one where the food industry is focussing its resources – that is, keeping healthy people 
healthy. One may ask if it is appropriate for the regulators to apply pharmaceutical 
industry standards of proof for probiotics which are largely intended to be given to 
healthy people? Moreover, unlike pharmaceutical drugs with a single active entity, 
probiotics encompass hundreds of different strains and hundreds of different surface 
molecules and possibly metabolites which may be responsible for the ‘probiotic’ effect. 
Certainly this is a regulatory challenge that is yet to be resolved. As a scientist 
interested in exploring probiotic function, one has to be in favour of stringent regulation 
and the challenge is now firmly with commercial probiotic purveyors to generate high 
quality scientific data that will allow them to make health claims. However, one can 
also conclude that trying to apply the same concepts and standards as employed for 
pharmaceuticals may not be appropriate for probiotics. The scientists, companies and 
regulators need to address these issues. Otherwise, credibility with the consumer, 
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interest by the food industry and ultimately scientific research will be seriously 
damaged.  
There has been recent interest in faecal transplantation as an alternative approach for the 
manipulation of the intestinal microbiota. Indeed, evidence for its use as a treatment for 
gastrointestinal illness (including pseudomembranous colitis, Cl. difficile-associated 
diarrhoea; antibiotic associated diarrhoea, IBS and IBD) is rapidly accumulating and has 
been reviewed recently (Anderson et al., 2012; Guo et al., 2012; Landy et al., 2011). 
Faecal transplantation as a treatment modality remains a controversial and the available 
evidence for its efficacy is limited. Nonetheless this therapy holds great promise and 
further studies are necessary to explore this potential.  
4.1.1 Probiotics: dead or alive? 
It has been proposed that the minimum therapeutic dose for probiotics is 108-109 viable 
cells per day (Kailasapathy & Chin, 2000).  However, live cells in probiotic products 
will inevitably lose viability and the actual products will contain varying proportions of 
populations of viable to non-viable/dead cells (Shah et al., 1995). There may be further 
losses of viability of the organisms on passage through the relatively hostile 
environment of the stomach and small intestine (Adams, 2010). Concerns have also 
been raised that the administration of live microorganisms may not be appropriate for 
some population groups (e.g. premature infants and immunocompromised individuals) 
as they may translocate to the locally draining tissues, thereby causing bacteraemia and 
sepsis (Kataria et al., 2009; Lopez et al., 2008). 
An area of related on-going debate is therefore whether or not non-viable forms of 
beneficial bacterial strains have a role in conferring benefits to the host. Indeed, a 
considerable amount of published scientific evidence indicates that inactivated microbes 
may positively affect health by influencing the host immune system (reviewed in: 
Adams, 2010; Kataria et al., 2009; Taverniti and Guglielmetti, 2011). The ability of 
bacterial cells to potentially interact with the host, independent of viability, is based on 
the capacity of human cells to recognise specific bacterial components or products, 
leading to responses that commonly involve the mucosa-associated lymphoid tissue, and 
therefore, the immune system (Adams, 2010). Some studies have proposed that the 
immunomoddulatory effects exerted by non-viable probiotics may be due to their 
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immunostimulatory DNA, cell wall components, peptidoglycan, intra- and extra-cellular 
polysaccharide products and cell-free extracts (Dalpke et al., 2002; Hosono et al., 1997; 
Lammers et al., 2003; Rachmilewitz et al., 2004).  
A number of studies have evaluated the immunomodulatory effect of probiotic L. 
rhamnosus GG (LGG), in both live and dead (inactivated) form. Heat-killed or ultra-
violet inactivated LGG may reduce inflammation by decreasing experimentally induced 
IL-8 production by epithelial Caco-2 cells (Lopez et al., 2008; Zhang et al., 2005). In 
the absence of induction, high doses of live LGG actually induce production of IL-8, 
while the heat-killed agent causes only a slight increase in IL-8 meaning it had a lower 
potential to cause inflammation itself (Zhang et al., 2005), thus indicating the heat-
killed agent may be a safer alternative. A similar response was demonstrated in an 
animal model, in which both live and heat-killed LGG reduced LPS-induced pro-
inflammatory mediators and up-regulated anti-inflammatory mediators in intestinal 
tissue in rats (Li et al., 2009). Similarly, heat-killed Lactobacillus strains were found to 
induce secretion of TNF-α from mouse splenic mononuclear cells, to various degrees 
(Matsuguchi et al., 2003). Furthermore, the purified surface glycolipid, lipoteichoic acid 
(LTA), which is a major component of the cell wall of lactobacilli, activated 
macrophages through TLR2, in a strain specific manner. It has even been suggested that 
the immense structural diversity in the LTAs derived from different bacteria may induce 
a variety of immunoregulatory properties (Ciszek‐Lenda et al., 2011). 
The immunoregulatory potential of exopolysaccharide (EPS) has also been investigated 
(Arena et al., 2006; Ciszek‐Lenda et al., 2011; Hidalgo-Cantabrana et al., 2012; López 
et al., 2012; Wu et al., 2010). It has been shown that in vitro levels of pro-inflammatory 
cytokines are highly elevated upon exposure of mouse splenocytes to cells of EPS-
deficient Bifidobacterium breve co-cultures, whereas exposure to an EPS-producing 
strain markedly reduced these cytokine levels. Moreover, treatment of mice with EPS+ 
B. breve elicited reduced levels of pro-inflammatory immune cells compared with EPS- 
strains (Fanning et al., 2012). A recent study described the stimulatory effects of a 
Lactobacillus-derived EPS on the release of inflammatory mediators by mouse 
peritoneal macrophages in vitro (Ciszek‐Lenda et al., 2011). EPS effectively induced 
the production of mediators and cytokines by macrophages, especially TNF-α, IL-6 and 
IL-12. Interestingly, EPS induced higher levels of TNF-α and IL-6 than IL-10, 
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suggesting a net pro-inflammatory potential. However, its stimulatory effect was 
significantly lower than LPS or whole, killed bacterial cells. Moreover, whole cells 
were stronger inducers of anti-inflammatory IL-10 than EPS alone, suggesting that 
intact bacteria and EPS may have an opposing effect on macrophage polarisation 
(Ciszek‐Lenda et al., 2011). Similarly, Wu et al. (2010) investigated the effect of heat-
killed B. longum and its isolated EPS fraction on the activities of a murine macrophage 
cell line, including IL-10 and TNF-α induction. EPS exposure stimulated growth and 
induced IL-10 secretion in the macrophage cells as well as inducing lower levels of 
TNF-α secretion. LPS on the other hand induced high levels of TNF-α secretion and 
EPS pre-treatment prevented LPS-induced release of TNF-α. As EPS and LPS are both 
surface macromolecules with oligosaccharide moieties, the authors concluded that EPS 
may act as an LPS blocker. Although EPS may play a role in immune regulation, 
information about the molecular mechanisms by which EPS interacts with the immune 
system is scarce (Hidalgo-Cantabrana et al., 2012). It has also proved difficult to define 
the common biological properties of EPS because of its enormous structural diversity 
(Ciszek‐Lenda et al., 2011).  
Some studies have found that bacterial DNA may be partly responsible for the 
immunomodulatory effect of probiotics. Administration of non-viable, irradiated 
probiotics (VSL#3) but not heat-killed probiotics was shown to effectively ameliorate 
experimental colitis in mice mediated by a TLR-9-probiotic DNA interaction 
(Rachmilewitz et al., 2004). Similarly, Bifidobacterium genomic DNA induced 
secretion of the anti-inflammatory IL-10 by human peripheral blood mononuclear cells 
(Lammers et al., 2003). 
Immune-active components of probiotic bacteria may not be limited to cell wall 
structures and DNA. There have been reports concerning a soluble immunomodulator 
from bifidobacteria. The immunomodulating activity of Bifidobacterium adolescentis 
increases after disruption of the cells by sonication and the immunopotentiating activity 
appeared in the soluble fraction following centrifugation, indicating the existence of an 
intracellular soluble immunomodulator (Hosono et al., 1997). Bifidobacterium 
pseudocatenulatum components also have immunomodulatory effects which appear to 
be dependent on the method of preparation (Hiramatsu et al., 2007). Compared to heat-
treated and untreated cells, sonicated Bifidobacterium was the most potent inducer of 
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innate immune responses in Peyer’s patch (PP) cells in vitro and in vivo (following a 
single-shot oral administration to mice). However, heat-treated Bifidobacterium showed 
the greatest immunomodulatory activity following repeated oral administration (for 7 
consecutive days) to mice. The researchers concluded that the immunomodulatory 
effect of Bifidobacterium is dependent upon the bacterial conformation and condition 
(Hiramatsu et al., 2007).  
Although there is substantial evidence from in vitro and animal studies that inactivated 
probiotics can act as biological response modifiers, there is a relative paucity of 
information on the effect of dead probiotics in vivo in human clinical trials. However, a 
number of basic human consumption studies have been carried out with Lacteol Fort 
(Lb. acidophilus LB which is heat-killed and freeze dried in the presence of its 
fermented culture medium) (Halpern et al., 1996; Xiao et al., 2002). Lacteol Fort was 
shown to improve clinical symptoms (by decreasing bowel movement, abdominal pain 
and distension and by improving stool consistency and the feeling of incomplete 
evacuation) of chronic diarrhoea (Xiao et al., 2002), possibly through a mechanism 
involving competitive exclusion (Chauvière et al., 1992).  
To conclude, while a number of studies have proposed that the viability of probiotics is 
not essential to exert an immunomodulatory effect, this is not a uniform feature of all 
probiotics tested to date, as different in vitro studies have also reported that a viable 
probiotic is essential to exert an immunomodulatory effect (Arribas et al., 2011; Ma et 
al., 2004). In addition, the method of preparation may play a significant role as the 
immunodulatory effect may be dependent on the bacterial conformation and condition, 
as has been described above (Hiramatsu et al., 2007; Rachmilewitz et al., 2004). Further 
study is essential to elucidate whether inactivated probiotic bacteria or their products are 
able to provide similar beneficial effects as live bacteria in vivo. Work on the specific 
mechanisms is also required to explain what is actually being triggered by the dead 
agents and whether this is similar to the mechanisms of live agents (Li et al., 2009). 
Biological products based on dead cells might be relatively easy to produce, 
commercialise, and standardise and would have the added benefit of having a much 
longer shelf life. In addition, use of dead probiotics may be, in some circumstances, 
safer than using live probiotics. Resolution of this debate might also require 
participation of relevant stakeholders in re-examining the definition of a probiotic, 
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which is currently restricted to live cells (FAO/WHO, 2002). It must be noted that while 
probiotic viability may not be necessary to exert an immunomodulatory effect, a 
number of mechanisms mediating probiotic health benefits do require viability, such as 
metabolism of non-digestible polysaccharides and production of metabolites (e.g. 
SCFAs). Hence, one should be cautious in applying the term ‘probiotic’ to these dead 
cell preparations. 
5.0  Conclusion  
The intestinal microbiota is undoubtedly an important factor in determining health 
status of the host and has been implicated in both gastrointestinal and extra-intestinal 
disorders. The studies described in this review raise the question of whether it is now 
possible to deduce the composition of a ‘healthy’ normal microbiota. Indeed, limited 
accessibility of the different parts of the GIT (including the colonic mucosa) as well as 
the individual-specific, complex composition of the GIT microbiota makes our 
understanding of this community somewhat incomplete (Zoetendal et al., 2008). It is 
also essential to bear in mind the influence of different dietary patterns on the activity 
and composition on the microbiota and the potential implications for host health. 
Although several large international studies are striving to improve our knowledge of 
the composition of the gut biota, an overwhelming majority of microbes that compose 
these microbial communities are not yet characterised to any great level of detail 
(Ehrlich, 2010). Comparing data from different studies is difficult as sample processing 
and analysis methods vary between research groups. Moreover, our apparent inability to 
culture all members of the microbiota makes it currently impossible to create 
hypotheses regarding the role of these uncultured microbes in health and disease 
(Zoetendal et al., 2008). As we are still unable to completely define the microbiota of a 
healthy intestinal tract, it is similarly difficult to define the microbiota associated with 
an intestinal disorder. However, major advances in human metagenomics have now 
provided a catalogue of 3.3 million non-redundant genes (Ehrlich, 2010; Qin et al., 
2010). This catalogue will enable the development of the gene profiling approaches 
which aim to detect associations of bacterial genes and phenotypes. These developments 
should lead to rapid advances in diagnostic and prognostic tools as well as paving the 
way to rational approaches to the manipulation of an individual’s intestinal microbiota 
in order to promote health.  
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The improvement or maintenance of health through the use of probiotics has been the 
focus of extensive research. Indeed, the probiotic market has expanded rapidly in recent 
years and a large variety of probiotic products are available. However, the efficacy of 
probiotics is strain and dose dependent and the clinical and methodological differences 
(strain, dose, formulation) between studies make comparisons difficult. Hence, there is 
presently strong evidence to support their use in only a few conditions. It is also 
acknowledged that in most cases the exact mechanisms of the beneficial effects are not 
fully understood. Although many studies have provided several possible modes of 
action, it has not been possible to identify definite cause-effect relationships. Stringent 
requirements imposed by regulatory authorities such as EFSA require more solid 
scientific evidence to support any health claims associated with probiotic products. 
Future research requires well designed, large, randomised double-blind placebo 
controlled clinical trials along with more mechanistic studies in cell and animal models 
in order to strengthen our evidence base. Indeed the development of novel in vitro 
models of the human intestinal epithelium (e.g. bioreactors and organoids) will increase 
our understanding of the molecular mechanisms of host-microbe interaction and is 
paving the way for future ventures aimed at bioengineering human intestine (Bermudez-
Brito et al., 2013). Further investigation into the health benefits of ingesting dead 
organisms in vivo is also required. Indeed the potential health effect of these non-viable 
bacteria depends on whether the mechanism of the probiotic health effect is dependent 
on viability and hence each probiotic strain should be assessed on a case-by-case basis. 
Furthermore, as the term ‘probiotic’ fails to account for the use of dead organisms, it 
has been suggested that the term ‘pharmabiotic’ would be more inclusive (Shanahan, 
2010b).  
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Table 1.  Associations of the human intestinal microbiota with habitual dietary patterns or interventions 
Authors Methods Study design Subjects Diets/nutrients Microbiota response 
Claesson et al. (2012) 16s rDNA 
sequencing  
Cross-
sectional  
178 elderly subjects (64-102 
yrs) - community, day-
hospital, rehabilitation and 
long stay subjects 
‘Community’ diet – 
diverse with low-
moderate fat/high 
fibre 
↑diversity 
↑ Firmicutes 
↑ Coprococcus, 
Roseburia 
        ‘Long-Stay’ diet – 
reduced diversity 
with moderate-high 
fat/low-moderate 
fibre 
↓ diversity 
↑ Bacteroidetes 
↑Parabacteroides, 
Eubacterium, 
Anaerotruncas,    
Lactonifactor and 
Coprobacillus 
  
 
   De Filippo et al. (2010) 16s rDNA 
sequencing & 
biochemical 
analysis 
Cross-
sectional  
29 children (1-6 yrs) - 
African children from 
Burkina Faso (n=14) and 
European children from 
Florence, Italy (n=15)  
‘Western’ diet – 
high 
fat/protein/sugar 
and low fibre 
↑Firmicutes 
↑ Enterobacteriaceae 
    ‘Rural’ diet – low 
fat/protein and high 
fibre 
↑ Bacteroidetes 
 exclusively 
present:Prevotella, 
Xylanibacter, 
Butyrivibrio and 
Treponema  
↑ SCFAs 
      De Palma et al. (2009) FISH & qPCR Feeding  (1 
mo) 
10 healthy subjects (mean 
age 30.3 yrs) 
Gluten-free diet 
(reduced 
polysaccharide) 
↓ Bifidobacterium, 
Lactobacillus, 
Clostridium 
lituseburense and 
Faecalibacterium 
prausnitzii 
↑ Enterobacteriaceae 
and E. coli 
      Kabeerdoss et al. (2011) qPCR Cross sectional  56 healthy female subjects 
(18-27 yrs) 32 vegetarian, 24 
omnivore 
Vegetarian diet ↓Clostridium cluster 
XIVa 
↓ Roseburia - 
Eubacterium rectale 
↓ butyrl-CoA CoA-
transferase gene 
      Liszt et al. (2009) qPCR & PCR-
DGGE 
Cross sectional  29 healthy subjects (19-34 
yrs) - 15 vegetarians and 14 
omnivores 
Vegetarian diet ↑ bacterial DNA 
 tendency for ↓ 
Clostridium cluster IV 
and ↑ Bacteroides (but 
not significant) 
      Muegge et al. (2011) 16s rDNA 
sequencing & 
shotgun 
metagenomics 
Cross-
sectional  
18 lean subjects (mean age 
59.6 yrs) - members of a 
Calorie Restriction Society 
proteins associated with KEGG 
orthology groups 
    insoluble dietary 
fibre 
associated with bacterial 
OTU content 
      Walker et al. (2010) 16s rDNA 
sequencing & 
qPCR 
Randomised 
cross over   
(3 wk 
intervention) 
14 overweight male subjects 
(27-73 yrs) 
Diet high in 
resistant starch 
(type III) 
↔ phylum level  
↑Ruminococci bromii 
and E. rectale 
↑ Ruminococcaceae  
↑ Oscillibacter 
valericigenes 
↑ Firmicutes bacteria 
related to Roseburia and 
E. rectale  
        Reduced 
carbohydrate diet 
(weight loss diet) 
↔ phylum level  
↓Collinsella aerofaciens 
↑ Oscillibacter 
valericigenes 
↓ Firmicutes bacteria 
related to Roseburia and 
E. rectale  
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Wu et al. (2011) 16s rDNA 
sequencing & 
shotgun 
metagenomics 
Cross-
sectional  
98 healthy subjects (18-40 
yrs) 
Fat ↑ Bacteroidetes, 
Actinobacteria 
↓Firmicutes, 
Proteobacteria  
    Fibre ↓Bacteroidetes, 
Actinobacteria 
↑ Firmicutes, 
Proteobacteria  
    Animal fat & 
protein 
positively associated 
with Bacteroides 
enterotype 
    Carbohydrates  positively associated 
with Prevotella 
enterotype 
      Wu et al. (2011) 16s rDNA 
sequencing & 
shotgun 
metagenomics 
Controlled 
feeding  (10 d 
intervention) 
10 subjects in Bacteroides 
enterotype (high fat/protein)  
low fat/high fibre 
diet or high fat/low 
fibre 
changes in microbiome 
composition detectable 
within 24 h  of initiating 
diet; 
no stable switch in 
enterotype after 10 days 
      Zimmer et al. (2011) culture-based 
methods 
Cross sectional 295 healthy subjects - 144 
vegetarians, 105 vegans, 46 
controls 
Vegetarian diet ↓ stool pH 
    Vegan diet ↓ stool pH 
↓ Bacteroides spp., 
Bifidobacterium spp., E. 
coli and 
Enterobacteriaceae spp. 
SCFA, short chain fatty acid; FISH, fluorescent in situ hybridization; qPCR, quantitative real time polymerase chain reaction;  DGGE, denaturing 
gradient gel electrophoresis; KEGG, Kyoto Encyclopedia of Genes and Genomes; OTU, operational taxonomic unit;; ↑, increased; ↓, decreased; ↔, no 
change 
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Figure 1.  A) Variations in microbial numbers across the length of the GIT B) Selected features affecting microbiota establishment and maintenance and factors influencing 
microbial composition.  Microorganisms are listed where their abundance is related to a particular environmental factor (Arumugam et al., 2011; Cusack & O'Toole, 2010; 
Dominguez-Bello et al., 2010; Isolauri et al., 2004; Marques et al., 2010; Morelli, 2008; Qin et al., 2010; Tap et al., 2009; Tiihonen et al., 2010). 
 
 
 30 
 
Figure 2.  Schematic diagram illustrating selected mechanisms by which probiotic bacteria may influence the intestinal microbiota and/or induce beneficial host responses: 1) 
production of antimicrobial compounds (e.g. bacteriocins); 2) reduction of luminal pH through production of short-chain fatty acids (SCFA); 3) competition with pathogens 
for nutrients and prebiotics; 4) competitive exclusion of pathogens for adhesion to epithelial cells; 5) production of growth substrates (e.g. vitamins, SCFAs and 
exopolysaccharide); 6) enhanced intestinal barrier function (e.g. increased mucus and β-defensin secretion and/or modulation of cytoskeletal and tight junctional protein 
phosphorylation and; 7) modulation of immune response. IEC: intestinal epithelium cells; DC: dendritic cell; TJ: tight junction (modified from O'Toole & Cooney, 2008) 
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1.0  Abstract 
The relatively recent discovery that changes in the composition and metabolic activity 
of the gut microbiota are associated with obesity and related disorders has led to an 
explosion of interest in this now distinct research field. In the following chapter, we 
discuss the current evidence related to how the modulation of gut microbial populations 
might have beneficial effects with respect to controlling obesity. A number of studies in 
both animals and humans have shown that the composition of the gut microbiota is 
significantly altered in obesity and diabetes. Strategies including specific functional 
foods, probiotics and prebiotics have the potential to favourably influence host 
metabolism by targeting the gut microbiota. Indeed, probiotics appear to be a promising 
approach to alter the host metabolic alterations linked to the changes in the gut 
microbiota. However, the mechanisms by which probiotics may impact on the 
development of obesity and metabolic health remain unclear and require further 
investigation. 
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2.0  Introduction 
The prevalence of obesity and its associated metabolic disorders has increased 
substantially over recent decades to a point where they have reached epidemic levels 
worldwide. As such, obesity is a major public health issue and is associated with an 
increased risk of cardiovascular disease (CVD), type 2 diabetes mellitus (T2D), 
atherosclerosis, non-alcoholic fatty liver disease (NAFLD) and certain cancers. Obesity 
is a complex condition that results from an imbalance between energy intake and 
expenditure and appears to be influenced by a combination of genetic, lifestyle and 
environmental factors. In this chapter the current evidence linking gut microbiota with 
the development of obesity and obesity-related metabolic diseases and the effects of 
interventions, and probiotics, in particular, on the management and prevention of 
obesity will be discussed. 
3.0  Gut microbiota and obesity 
3.1 Animal Studies 
The availability of animal models and the advent of new molecular, culture-independent 
techniques have together greatly enhanced our ability to study the gut microbiota and its 
relationship to obesity. Mice, in particular, offer a suitable model for conducting such 
experiments as their gut microbiota, by virtue of a predominance of Firmicutes (60-
80%) and Bacteroidetes (20-40%), exhibits an overall pattern that is similar to that of 
humans (Ley et al., 2005). Furthermore, germ-free (GF) mice are particularly useful for 
understanding the role of the gut microbiota in health and disease and the mechanisms 
underlying microbiota-associated alterations in host physiology. A landmark study by 
Bäckhed et al. (2004) found that GF mice were leaner than their conventional (CONV) 
counterparts, even though they consumed more food. In addition, colonisation of GF 
mice with the gut microbiota harvested from CONV mice led to an increase in total 
body fat despite a related decrease in food intake. GF mice have also been shown to be 
protected against obesity while consuming a western-style, high-fat diet (Bäckhed et al., 
2007; Fleissner et al., 2010) but the source and type of fat and carbohydrate may be an 
important factor (Fleissner et al., 2010). Indeed, Fleissner et al. (2010) observed that GF 
mice fed a high-fat diet lacking sucrose, were no longer protected against the 
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development of diet-induced obesity, illustrating the complexity of the interactions 
between diet, microbes and host adiposity. 
There is mounting evidence that it is not simply the presence, but also the relative 
proportions of the major microbial divisions, within the microbiota that are associated 
with obesity. The development of obesity is associated with an increase in the 
Firmicutes to Bacteroidetes ratio in both diet-induced obese (DIO) (Turnbaugh et al., 
2008; Turnbaugh et al., 2009b) and genetically obese (ob/ob) mice (Ley et al., 2005; 
Turnbaugh et al., 2006). Furthermore, a recent study showed that feeding a high-fat diet 
determined the composition of the gut microbiota independent of obesity, in mice 
(Hildebrandt et al., 2009). In this study, Hildebrandt et al. (2009) showed, using the 
resistin-like molecule β (RELM-β)-knockout mice (which are resistant to diet-induced 
obesity), that the high-fat diet itself, and not the obese state, mainly accounted for the 
observed changes in the gut microbiota composition. Other work showed that switching 
from a low-fat to a high-fat diet resulted in a rapid and dramatic shift in the structure of 
the gut microbiota in mice in a single day (Turnbaugh et al., 2009b). Murphy et al. 
(2010) investigated the effects of a high-fat diet and genetic obesity (the ob/ob mouse 
model) on the gut microbiota over time. While no significant changes in the proportions 
of the different microbial groups were observed in the control lean mice over the 8 week 
period, a progressive increase in Firmicutes in both the high-fat-fed and ob/ob mice was 
reported, reaching statistical significance in the former case only. Moreover, 
Bacteroidetes proportions decreased overtime in all groups but again reached statistical 
significance in only the ob/ob mice. These studies suggest that microbial adaptation to 
diet over time, and perhaps with age, is an important variable in the complex 
relationship between the composition of the microbiota and obesity and should be 
considered in future studies. 
3.2 Human Studies 
In man the relationship between the gut microbiota and obesity is somewhat more 
unclear. The first study examining the qualitative changes of the gut microbiota in 12 
human obese individuals was published by Ley and colleagues in 2006. In agreement 
with results from animal studies, Ley et al. (2006) observed an increased ratio of 
Firmicutes to Bacteroidetes in obese individuals compared to matched lean individuals. 
Interestingly, after weight loss (following a fat-restricted or carbohydrate-restricted low 
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calorie diet), the ratio of Bacteroidetes to Firmicutes approached a lean type profile 
after 52 weeks. Comparison of the faecal microbiota of monozygotic and dizygotic 
twins who were either lean or obese also revealed that obesity was associated with a 
reduced representation of Bacteroidetes, reduced bacterial diversity and increased 
proportions of Actinobacteria. Notably, no significant differences in the proportions of 
Firmicutes were apparent between lean and obese subjects (Turnbaugh et al., 2009a). 
Although a similar reduction of Bacteroidetes in obese subjects has been confirmed in 
another study (Armougom et al., 2009), the concept that Bacteroidetes are reduced in 
obese subjects has been largely contradicted by other studies (Duncan et al., 2008; 
Schwiertz et al., 2010; Zhang et al., 2009; Zupancic et al., 2012). 
Duncan et al. (2008) detected no differences in Bacteroidetes proportions between 
obese and non-obese individuals and no significant changes in the proportions of 
Bacteroidetes were detected in obese subjects following weight loss. Furthermore, 
Schwiertz et al. (2010) reported a decrease in the ratio of Firmicutes to Bacteroidetes in 
obese human adults compared with lean controls. Similarly, Zhang et al. (2009) 
reported that overweight individuals harboured more Bacteroidetes than normal weight 
individuals. They showed that a subgroup of Bacteroidetes (Preveotellaceae) was 
significantly enriched in obese individuals. Moreover, surgical treatment for these 
morbidly obese subjects (gastric bypass) altered the gut microbiota toward an increase 
in Gammaproteobacteria (members of Enterobacteriaceae) and a proportional decrease 
in Firmicutes. More recently, Zupancic et al. (2012) found no association between the 
Bacteroidetes/Firmicutes ratio and any metabolic syndrome trait in an Old Order Amish 
sect. However, 22 bacterial species were found to be either positively or inversely 
correlated with obesity and metabolic syndrome traits, indicating that specific members 
of the gut microbiota may play a role in these metabolic derangements. The conflicting 
results observed in these human studies emphasise the complexity of the relationship 
between gut microbiota and obesity. Further work is required to identify if obesigenic 
components of the gut microbiota exist. Moreover, the potential influence of 
confounding factors such as diet highlights the need for well-controlled large, clinical 
trials to identify specific proximate microbiota-related biomarkers of risk for obesity 
and metabolic dysregulation. 
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3.3 Mechanisms linking the gut microbiota to obesity 
3.3.1 Host factors 
The gut microbiota may be involved in the regulation of fat storage and composition. 
Fiaf (fasting induced adipocyte factor) is involved in regulating fat storage by inhibiting 
lipoprotein lipase, while also promoting fatty acid release by inducing peroxisomal 
proliferator-activated receptor (PPAR) coactivator (Bäckhed et al., 2004). It has been 
suggested that germ-free mice are resistant to obesity through a mechanism involving 
Fiaf in the intestine (Bäckhed et al., 2004). Indeed, germ-free Fiaf knock out (Fiaf -/-) 
mice gained significantly more weight than their germ-free wild type littermates when 
fed a Western diet (Bäckhed et al., 2007) However, a more recent study found that 
while intestinal Fiaf mRNA was increased in germ-free mice, there was no increase in 
plasma protein levels compared to CONV mice (Fleissner et al., 2010) suggesting that 
the Fiaf mechanism may not be universally associated with intestinal microbiota-related 
adiposity. Other work has suggested that the gut microbiota and its products affect host 
energy regulation acting through mechanisms involving adenosine monophosphate-
activated protein kinase (AMPK) (Bäckhed et al., 2007). Furthermore, the microbiota 
may also influence food intake and energy expenditure of the host (Bäckhed et al., 
2004; Fleissner et al., 2010; Rabot et al., 2010). These studies suggest that a number of 
host-related factors may be involved in the regulation of adiposity by the gut 
microbiota. 
3.3.2 Energy harvesting 
Colonisation of germ-free mice with an ‘obese microbiota’ (i.e. microbiota from an 
obese animal) leads to a significantly greater increase in adiposity compared to germ-
free mice colonised with a ‘lean microbiota’ (Turnbaugh et al., 2008; Turnbaugh et al., 
2006). Indeed, the gut microbiota may affect obesity by increasing energy harvesting 
from indigestible polysaccharides. It is estimated that around 20-60g of undigested 
dietary carbohydrates reach the colon on a daily basis (Flint et al., 2012) where they are 
broken down by the gut microbiota to short-chain fatty acids (SCFAs), thereby 
contributing energy to the host (estimated to account for 5- 10% of daily energy intake) 
(McNeil, 1984). Metagenomic analysis of ob/ob caecal microbiota revealed that this 
obese microbiome had an increased capacity to harvest energy from the diet as it was 
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enriched with bacterial genes encoding enzymes for the utilisation and fermentation of 
dietary fibres (Turnbaugh et al., 2006). Moreover, the ob/ob caecum had increased 
concentrations of the major fermentation end-products butyrate and acetate, and ob/ob 
mice had significantly less energy remaining in their faeces relative to their lean 
counterparts. ob/ob mice have also been shown to harbour more methanogenic Archaea, 
which would be expected to increase the efficiency of bacterial fermentation by 
removing one of its end products, H2 (Turnbaugh et al., 2006). Indeed, co-colonisation 
of germ-free mice with Methanobrevibacter smithii (the main methanogenic archaeon in 
the human intestine) and Bacteroides thetaiotaomicron (a major saccharolytic member 
of the human intestine) increased polysaccharide fermentation efficiency and adiposity 
compared with mice colonised with either organism alone (Samuel & Gordon, 2006). 
However, age may be an important factor in determining the potential of the gut 
microbiota to extract energy. Indeed, although ob/ob mice had less faecal energy and 
higher caecal concentrations of SCFAs compared to lean mice at 7 weeks of age, these 
patterns did not persist to the ages of 11 and 15 weeks (Murphy et al., 2010). In 
humans, SCFA levels were shown to be significantly increased and the proportion of 
individual SCFA changed in favour of propionate in obese individuals compared to 
their lean counterparts (Schwiertz et al., 2010). A recent study reported that an altered 
nutrient load induced rapid changes in the composition of the human gut microbiota 
which were directly associated with stool energy loss in lean individuals. In this case, a 
20% increase in Firmicutes and a corresponding decrease in Bacteroidetes were 
associated with an increased energy harvest of approximately 150kcal (Jumpertz et al., 
2011). 
3.3.3 Inflammation 
Recent research has suggested that altered function of the innate immune system may 
promote the development of metabolic syndrome through a mechanism involving the 
gut microbiota. Obesity is generally associated with low grade, chronic, systemic 
inflammation (Wellen & Hotamisligil, 2005). Indeed, in murine models of obesity 
(genetic and diet-induced), the adipose tissue exhibits increased expression and content 
of proinflammatory cytokines (Hotamisligil et al., 1993; Weisberg et al., 2003). Cani et 
al. (2007b) demonstrated that excess dietary fat facilitates the absorption of the highly 
proinflammatory bacterial component lipo-polysaccharide (LPS), a toll-like receptor-4 
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(TLR-4) ligand, from the intestine. Mice fed for four weeks a high-fat diet had plasma 
LPS levels 2 or 3 times higher than normal, which was defined as ‘metabolic 
endotoxemia’. Indeed, the direct infusion of LPS mimicked the physiological effects of 
the high-fat diet. Moreover, the effects of the high-fat diet were ameliorated in mice 
lacking cluster of differentiation 14 (CD14), a component of the TLR-4 receptor 
complex (Cani et al., 2007b). In a follow-up study, the gut microbiota was implicated in 
metabolic endotoxaemia through the use of oral antibiotics which significantly 
decreased the levels of gut bacteria and systemic metabolic endotoxaemia (Cani et al., 
2008). In addition, while plasma LPS concentrations correlated negatively with 
Bifidobacterium spp. (Cani et al., 2008), feeding mice a prebiotic (oligofructose) 
restored the number of bifidobacteria and reduced the impact of high-fat diet-induced 
metabolic endotoxemia (Cani et al., 2007a). This was associated with a reduction in gut 
permeability, improved tight junction integrity and increased expression of glucagon-
like peptide 2 (Glp2) (Cani et al., 2009). 
3.3.4 SCFAs 
In addition to their other physiological roles, recent data suggests that SCFAs can have 
a role as signalling molecules (Samuel et al., 2008) by acting as ligands for at least two 
G protein-coupled receptors (GPR41 and GPR43) on gut enteroendocrine cells (Bjursell 
et al., 2011; Samuel et al., 2008). A recent study has shown that GPR43 knock-out mice 
are protected from high-fat diet-induced obesity and its consequences on glucose and 
lipoprotein metabolism (Bjursell et al., 2011). Moreover, conventional GPR41 knock-
out (GPR41 -/-) mice and germ-free GPR41-/- mice colonised with a model 
fermentative community (B. thetaiotaomicron and M. smithii) were significantly leaner 
than their wild type counterparts, despite similar food intakes. However, there was no 
difference between germ-free wild type and germ-free GPR41-/- mice indicating that 
the effects of GPR41 are dependent on the gut microbiota. Moreover, GPR41 deficiency 
was also associated with reduced expression of peptide YY (PYY), an enteroendocrine 
cell-derived hormone that normally inhibits gut motility, reduces intestinal transit rate 
and increases harvest of energy (SCFAs) from the diet (Samuel et al., 2008). Therefore 
these studies support the theory that intestinal metabolites (SCFAs) may also act as 
metabolic regulators in the host. 
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3.3.5 Flagellum and TLR-5 
TLR-5 is highly expressed in the intestinal mucosa and is involved in arbitrating 
immune responses through recognition of bacterial flagellum. Vijay-Kumar et al. 
(2010) reported that TLR-5–knock-out (T5KO) mice exhibited hyperphagia and 
demonstrated many of the features associated with the metabolic syndrome including 
increased body mass and visceral fat deposition, dyslipidemia, hypertension and insulin 
resistance. Moreover, these metabolic changes correlated with changes in the 
composition of the gut microbiota which were mainly at a species rather than phylum 
level. Indeed, transplantation of the microbiota from T5KO mice to wild-type germ-free 
mice conferred many aspects of the T5KO phenotype including hyperphagia, obesity, 
hyperglycaemia and insulin resistance (Vijay-Kumar et al., 2010). 
In summary, studies suggest that gut microbiota and their metabolic products can 
influence obesity but that the relationship between diet, the gut microbiota and obesity 
is complex. Changes in diet not only leads to obesity by caloric intake per se, but also 
affect the composition of the gut microbiota and which may in turn lead to obesity 
through several mechanisms (e.g. regulation of energy balance and low grade 
inflammation). The question as to whether specific populations are responsible for 
obesity or just indicators (i.e., are these populations a ‘cause’ or an ‘effect’) remain 
unanswered. Taken together, these findings indicate that therapeutic manipulation of the 
microbiota may be a useful strategy in the prevention or management of obesity.  
4.0  Gut microbiota and obesity-related metabolic disease 
The role of the gut microbiota in obesity has been studied in detail and the majority of 
the published literature describes the disparities between gut microbiota in obese 
compared to lean subjects. Type II diabetes, cardiovascular disease and non-alcoholic 
fatty liver disease (NAFLD) are generally considered as consequences of obesity. 
Though relationships between the microbiota and these disorders are less well studied 
than in obesity, per se, inferences regarding the role of the gut microbiota in these 
obesity-related conditions are starting to be made.   
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4.1 Gut microbiota and Type 2 Diabetes 
Low-grade inflammation is a common feature of type II diabetes (T2D) (Wellen & 
Hotamisligil, 2005) and LPS is a possible initiator of metabolic impairment (Cani et al., 
2007b). Indeed subjects with T2D have higher LPS levels than subjects without diabetes 
(Creely et al., 2007; Pussinen et al., 2011) and the infusion of LPS in mice induces low-
grade chronic inflammation and features of early onset of metabolic diseases such as 
visceral fat deposition, glucose intolerance and hepatic insulin resistance (Cani et al., 
2007b). Moreover, the development of T2D in mice was associated with increased 
endotoxaemia along with increased gut permeability and systemic/adipose tissue 
inflammation (Serino et al., 2012). 
However, it has been shown that not all genetically identical mice develop diabetes 
when fed a high-fat, carbohydrate-free diet, indicating that the metabolism of each 
phenotype is different despite identical genetic backgrounds and diets (Burcelin et al., 
2002; Serino et al., 2012). Serino et al. (2012) identified a gut microbial profile specific 
to diabetes-sensitive and diabetes-resistant metabolic phenotypes and found that an 
increased Bacteroidetes to Firmicutes ratio and a reduction in Lachnospiraceae family 
and Oscillibacter genus were associated with the diabetic phenotype. Furthermore, 
modulation of the gut microbiota of these high-fat fed mice with dietary fibres 
prevented the occurrence of the diabetic phenotype and resulted in a specific microbial 
signature (Serino et al., 2012). Similarly, modulation of the gut microbiota with 
antibiotics has been shown to reverse insulin resistance in ob/ob mice independent of 
obesity (Membrez et al., 2008); while it has also been demonstrated that germ-free mice 
are resistant to high-fat, diet-induced insulin resistance (Rabot et al., 2010). 
A small number of human, clinical studies have also reported on the relationship 
between gut microbiota composition and T2D. Indeed, there is increasing evidence 
which suggests that T2D can be associated with the gut microbiota, irrespective of the 
presence of obesity (Larsen et al., 2010; Wu et al., 2010). The proportions of phylum 
Firmicutes and the class Clostridia were shown to be reduced while the class 
Betaproteobacteria was enriched in diabetic subjects compared to non-diabetic controls. 
Interestingly, the ratios of Bacteroidetes to Firmicutes, as well as the ratios of 
Bacteroides-Prevotella group to the Clostridium coccoides-Eubacterium rectale group, 
correlated positively and significantly with plasma glucose concentration but not with 
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body mass index (BMI) (Larsen et al., 2010). Other studies have found increased 
Bacteroides and reduced Prevotella, Bifidobacterium, Bacteroides vulgatus (Wu et al., 
2010) and Faecalibacterium prausnitzii proportions associated with diabetes (Furet et 
al., 2010). Recently, deep shotgun sequencing of the gut microbial DNA from 345 
Chinese individuals identified approximately 60,000 type-2-diabetes-associated 
markers, a decrease in the abundance of some universal butyrate-producing bacteria and 
an increase in various opportunistic pathogens, as well as an enrichment of other 
microbial functions conferring sulphate reduction and oxidative stress resistance. An 
analysis of 23 additional individuals demonstrated that these gut microbial markers 
might be useful for classifying T2D (Qin et al., 2012). Furthermore, a very recent study 
has shown that infusion of the gut microbiota from lean donors to male recipients with 
metabolic syndrome for six weeks resulted in an increased insulin sensitivity of the 
recipients along with increased levels of butyrate-producing gut microbiota (Vrieze et 
al., 2012). These latter two studies highlight the role of SCFA, in particular butyrate in 
the relationship between the gut microbiota and T2D. 
4.2 Gut microbiota and cardiovascular disease 
A link between the gut microbiota and cardiovascular disease (CVD) has recently been 
established following the discovery of a microbial-dependent pathway for the 
metabolism of dietary phospholipids which generates metabolites that are pro-
atherosclerotic after absorption and hepatic metabolism (Wang et al., 2011). The gut 
microbiota metabolises dietary phosphatidylcholine (present in high-fat foods) to 
trimethylamine (TMA), which is then transported to the liver and oxidised to 
trimethylamine-N-oxide (TMAO). Wang et al. (2011) found that increasing levels of 
plasma TMAO, choline and betaine was found to have dose-dependent relationships 
with the presence of CVD in a cohort of 1,876 men and women. Furthermore, dietary 
supplementation of atherosclerosis-prone mice with choline, TMAO or betaine 
promoted up-regulation of multiple macrophage scavenger receptors linked to 
atherosclerosis, and dietary supplementation with choline or TMAO promoted 
atherosclerosis. This study suggests opportunities for the development of novel 
therapeutic strategies for the treatment for atherosclerosis.  
Furthermore, it has been shown that germ-free mice were resistant to high-fat, diet-
induced dyslipidemia and elevated proinflammatory markers compared to their CONV 
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counterparts. Moreover, there were unexpected changes in cholesterol metabolism, 
including reduced hypercholesterolemia, a moderate increase of hepatic cholesterol, an 
increase in cholesterol excretion and an up-regulation of cholesterol biosynthesis gene 
(Rabot et al., 2010).  
Low-grade inflammation is a common feature of CVD (Wellen and Hotamisligil, 2005) 
and metabolic endotoxemia has also been linked to its development. In a 5 year 
prospective study (the Bruneck study) it was demonstrated that subclinical endotoxemia 
constitutes a strong risk factor for the development of carotid atherosclerosis, among 
smokers in particular (Wiedermann et al., 1999).  
The relationship between both the oral and gut microbiota and atherosclerosis has 
recently been investigated. Although no relationship was found between plaque 
microbiota and gut microbiota in affected patients, the abundance of certain bacteria 
(Veillonella and Streptococcus) in atherosclerotic plaque correlated with their 
abundance in the oral cavity (Koren et al., 2011). 
4.3 Gut microbiota and NAFLD 
Although there is a relative paucity of data, the microbiota may also be linked to the 
development and progression of NAFLD and non-alcoholic steato-hepatitis (NASH). It 
has been shown that germ-free mice are resistant to high-fat diet-induced hepatic 
steatosis (Rabot et al., 2010) and colonisation of germ-free mice with the gut microbiota 
harvested from CONV mice increased liver fat and liver triglyceride content (Bäckhed 
et al., 2004). Moreover, NAFLD and NASH have been associated with increased 
intestinal permeability, as well as small intestinal bacterial overgrowth (SIBO) (Miele et 
al., 2009). Several molecular mechanisms relevant to the involvement of the microbiota 
in NAFLD/NASH have been proposed. The increased production of SCFA by the 
microbiota would provide more energy to the liver (Bäckhed et al., 2007; Turnbaugh et 
al., 2006). The microbiota has also been shown to stimulate hepatic triglyceride 
production through suppression of Fiaf (Bäckhed et al., 2004) and its role in choline 
metabolism has also been implicated as one of the mechanisms which contribute to 
NAFLD (Dumas et al., 2006; Wang et al., 2011). As liver disease is associated with a 
state of inflammation, LPS is also likely to be involved in NAFLD/NASH. Indeed, 
increased levels of LPS have been observed in NAFLD patients (Harte et al., 2010). 
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More recently it has been shown that genetic inflammasome deficiency and its related 
dysbiosis result in abnormal accumulation of bacterial products in the portal circulation 
and drive progression of NAFLD/NASH (Henao-Mejia et al., 2012). 
In summary, the gut microbiota represents an important source of metabolic variability 
in the host and may also play a role in the development of metabolic disorders such as 
T2D, NAFLD and cardiovascular disease, perhaps even independently of obesity. 
Increased knowledge of the mechanisms involved in the interactions between the 
microbiota and its host will aid in the development of treatments for metabolic disease. 
5.0  Probiotics: role in obesity and metabolic syndrome 
The demonstration of the possible role of gut microbiota in the pathogenesis of obesity 
and related metabolic diseases has led to the development of different strategies to 
modulate the gut microbiota and hence ameliorate host metabolism. In this respect, 
there are differing approaches to modulate the gut microbiota. Specific bacterial species 
or classes may be reduced by antibiotics. Studies have shown that treatment of both 
ob/ob and DIO mice with broad spectrum antibiotics leads to changes in the 
composition of the gut microbiota, as well as an improvement in metabolic 
abnormalities including improved insulin resistance, fasting glycaemia, glucose 
tolerance and a reduction in both metabolic endotoxaemia and body weight gain (Cani 
et al., 2008; Membrez et al., 2008; Murphy et al., 2012).  
In contrast to reducing specific bacterial species through the use of antibiotics, certain 
beneficial bacteria may be increased either by pre- or probiotics. As discussed 
previously, Cani et al. (2007a) found that the number of caecal Bifidobacterium spp. 
was inversely correlated with the development of fat mass and glucose intolerance as 
well as LPS levels in high-fat diet fed mice. Prebiotics containing oligofructose were 
found to completely restore Bifidobacterium species, normalise plasma endotoxin levels 
as well as leading to improved glucose tolerance and glucose induced insulin secretion 
when administered to high-fat fed mice (Cani et al., 2007a). Similarly, Serino et al. 
(2012) recently showed that the prebiotic, α1-2-gluco-oligosaccharide, reversed most 
aspects of the high-fat induced diabetic phenotype in mice. 
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The application of probiotics as a potential therapy in the management of obesity and its 
associated metabolic disorders has also received particular attention and has been 
explored in a number of studies. 
5.1 Animal Studies 
A number of experimental studies suggest that the probiotic approach can be used to 
alter biomarkers of metabolic disease (summarised in Table 1). Indeed, specific 
Lactobacillus and Bifidobacterium strains have been shown to reduce body weight and 
fat mass (Aronsson et al., 2010; Ji et al., 2012; Kang et al., 2010; Kondo et al., 2010; 
Lee et al., 2006; Lee et al., 2007; Takemura et al., 2010; Tanida et al., 2008) and alter 
lipid profiles (Hamad et al., 2009; Kondo et al., 2010; Martin et al., 2008; Xiao et al., 
2003; Yadav et al., 2007) in murine models, although the effect is likely to be strain 
dependent (Yin et al., 2010). For example, milk products fermented with Lb. gasseri 
SBT2055 were shown to have a possible role in the regulation of adipose tissue growth 
by reducing adipocyte size, serum leptin (Sato et al., 2008), fatty acid absorption 
(Hamad et al., 2009); possibly, through an anti-inflammatory mechanism (Kadooka et 
al., 2011). In contrast, other work has shown an increase in body weight with the 
administration of Lb. fermentum (CIP 102980) to chickens (Khan et al., 2007). Indeed 
there has been recent debate regarding the role of probiotics in metabolic disease, 
prompted a proposal that these ‘friendly’ bacteria may play a role in the development of 
obesity. Raoult (2009) suggested that since probiotics are used as growth promoters in 
the farm industry, there is a possibility that probiotics may also promote weight gain in 
humans. However, this view has largely been rejected by other researchers in the field 
(Delzenne & Reid, 2009). 
Probiotic strains may also be able to modify the fat composition of host tissues. Wall et 
al. (2009) showed that the administration of a conjugated linoleic acid (CLA)-producing 
B. breve strain, in combination with linoleic acid as a substrate, led to a modulation of 
the fatty acid composition of mice and pigs, including significantly elevated 
concentrations of hepatic and adipose tissue content of cis-9, trans-11 CLA, omega-3 
fatty acids, along with reduced levels of the proinflammatory cytokines tumour necrosis 
factor α (TNF-α) and interferon γ (IFN-γ). 
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In rat models of diabetes (high fructose-/streptozotocin–induced diabetes), specific 
Lactobacillus strains can improve such markers of diabetes as hyperinsulinemia, 
hyperglycemia, glucose intolerance, dyslipidemia and oxidative stress (Tabuchi et al., 
2003; Yadav et al., 2007; Yadav et al., 2008). Moreover, the probiotic product VSL#3 
has been shown to improve insulin resistance, hepatic natural killer T cell depletion and 
hepatic steatosis in DIO mice (Ma et al., 2008) while Lb. casei Shirota has been 
demonstrated to improve insulin resistance and glucose intolerance as well as reduce 
endotoxemia (Naito et al., 2011). 
5.2 Human Studies 
Only a limited number of human clinical trials have assessed the effects of probiotic 
intake on metabolic and obesity biomarkers (summarised in Table 2). 
Kadooka et al. (2010) carried out a double-blind, randomised, placebo controlled 
intervention trial among subjects (n=87) with an increased BMI and abdominal visceral 
fat area. Subjects received either a fermented milk product containing Lb. gasseri 
LG2055 or the same product without LG2055 over a period of 12 weeks. Abdominal fat 
area was determined by computed tomography. In subjects receiving the probiotic, 
abdominal visceral and subcutaneous fat areas decreased significantly from baseline (by 
an average of 4.6 and 3.3%, respectively). Body weight, BMI, hip and waist measures 
also decreased significantly while none of those parameters changed significantly in the 
control group (Kadooka et al., 2010). 
A large study by Laitinen et al. (2009) showed that the combination of dietary 
counselling and a probiotic intervention led to consistently improved glucose 
metabolism and insulin sensitivity in a cohort (n=256) of healthy, normoglycaemic 
pregnant women. Moreover, the probiotics were shown to provide a greater glucose-
lowering effect than dietary counselling alone. In a double-blind RCT, Andreasen et al. 
(2010) allocated male subjects (n=45) with T2D, impaired or normal glucose tolerance 
to a 4 week treatment with either Lb. acidophilus NFCM or placebo. Insulin sensitivity 
was preserved in the Lb. acidophilus-fed group whereas it decreased in the placebo 
group. However, there was no change in inflammatory markers over the four week 
period indicating that this effect was not linked to the immune system. 
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A number of studies have also investigated the cholesterol lowering effects of probiotic 
strains. Bukowska et al. (1998) investigated the role of ‘Pro viva’ (a food product 
containing a fermentable oat fraction and the probiotic Lb. plantarum299v) 
supplementation on the atherogenic markers low density lipoprotein (LDL)-cholesterol 
and fibrinogen in a double blind cross-over study among 30 male subjects. Six weeks of 
treatment resulted in a reduction in levels of both markers (Bukowska et al., 1998). In a 
subsequent study, Naruszewicz et al. (2002) investigated the influence of Lb. plantarum 
in a double-blind RCT involving 36 smokers and found that the 6 week treatment 
reduced systolic blood pressure along with several pro-atherogenic markers, including 
plasma concentrations of fibrinogen, IL-6 and F2-isoprostanes (markers of lipid oxidant 
stress). Moreover, Lb. plantarum administration markedly decreased the adherence of 
monocytes to native and tumor necrosis factor–activated endothelial cells (Naruszewicz 
et al., 2002). Similarly, Kullissar et al. (2003) investigated the effect of a probiotic 
product (goats milk fermented with Lb. fermentum ME-3) on oxidative stress markers 
(including pro-atherogenic markers) in 21 healthy subjects. Consumption of the 
fermented goats’ milk altered both the prevalence and proportion of lactic acid bacteria 
species in the gut microbiota, and exhibited antioxidative and anti-atherogenic effects in 
the healthy subjects. Furthermore, Kiessling et al. (2002) demonstrated in a cross-over 
type study including 29 women that daily consumption of a yogurt supplemented with 
Lb. acidophilus 145, B. longum 913 and oligofructose increased serum concentration of 
high-density lipoprotein (HDL)-cholesterol and led to the desired improvement of the 
LDL/HDL cholesterol ratio compared with a control yoghurt. Xiao et al. (2003) 
investigated the effect of consuming a low-fat yoghurt containing B. longum BL-2 on 
the lipid profiles of 32 healthy males and showed a decline in serum total cholesterol 
after 4 weeks, particularly among subjects with moderate hypercholesterolemia. 
Although many of these reports demonstrate a cholesterol-lowering effect, a number of 
studies have failed to show such an effect in humans. For example, Lewis & Burmeister 
conducted a cross-over type study in eighty healthy volunteers with elevated cholesterol 
and found that supplementation with Lb. acidophilus had no significant effect on plasma 
total-, LDL- and HDL-cholesterol and triglycerides (Lewis & Burmeister, 2005). 
Simons et al. (2006) also demonstrated that the consumption of Lb. fermentum did not 
contribute to any significant lipid profile changes after its administration to healthy 
subjects with elevated cholesterol levels for 10 weeks (Simons et al., 2006). Similarly, 
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the administration of a synbiotic product (Lb.acidophilus, B. longum and oligofructose) 
for approximately 2 months had no significant effect on plasma cholesterol or 
triglyderides in normocholesteraemic volunteers (Greany et al., 2007). These 
contradictory findings are probably due to differences in experimental design and study 
population as well as variations in probiotic strain and dosage. 
Many questions still remain regarding the role of probiotic bacteria in obesity and 
metabolic disease and current evidence is derived mainly from animal studies. Although 
these results from animal studies are interesting, the underlying mechanisms are 
unclear. Only a minority of human studies have examined the benefits of probiotic 
bacteria on biomarkers of metabolic disorders and these have shown conflicting results. 
In addition, the majority of these trials have been relatively small-sized (< 50 subjects) 
and of short duration (<10 weeks). The differences between studies may arise due to the 
use different bacterial strains. Indeed, the results from one probiotic strain cannot be 
extrapolated to another. Moreover, quite often different delivery systems (e.g. fermented 
dairy product v freeze dried bacteria); different population groups (e.g. 
normocholesterolaemic v hypercholesterolaemic) as well as different administration 
dosages have been employed, rendering comparisons difficult. 
6.0  Conclusions 
Obesity and associated metabolic diseases are increasing in prevalence worldwide. Both 
experimental and clinical data have demonstrated that obesity is associated with 
changes in the gut microbiota. Nonetheless, many unanswered questions still remain. 
Researchers have yet to conclusively identify ‘obesigenic’ bacterial groups. Moreover, 
the question still remains whether the differences in the microbiota between lean and 
obese groups are the cause or the consequence of obesity or perhaps a combination of 
both. Future research is therefore challenged with the task of identifying beneficial 
bacteria which are capable of controlling adiposity and related metabolic disorders and 
also with investigating possible dietary approaches to promote these bacteria in order to 
improve metabolic health. Indeed, data is accumulating which suggest that manipulation 
of the microbiome using prebiotics or probiotics may reduce insulin resistance and fat 
accumulation. Although a number of animal studies have revealed promising results, it 
is difficult to apply these findings to man. Only a limited number of small-sized clinical 
trials have demonstrated the promise for specific probiotic strains in beneficially 
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modulating biomarkers of metabolic disease in humans. However, the potential 
implications of this advancing field are promising. 
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Table 1.  Effects of probiotic consumption on biomarkers of metabolic disease in animal models 
Author Probiotic Model Duration Outcome 
Aronsson et al. (2010) Lb. paracasei ssp. 
paracasei F-19 
 (2 x 109 CFU/g feed) 
Male C57BL/6J 
mice-high-fat diet 
10 wk ↓ body fat 
↑ circulating Fiaf 
Hamad et al. (2009) Skim milk fermented with 
Lb. gasseri SBT2055  
(6 x 107 CFU/g diet) 
Lean and obese 
Zucker rats 
4 wk ↓ serum total and HDL cholesterol 
↑ excretion of faecal fatty acids and total 
neutral faecal sterols 
Lean rats: 
↓ mesenteric adipose tissue weight 
↓ adipocyte sizes  
↓serum leptin 
Obese rats: 
↑ no. of smaller adipocytes in the 
subcutaneous adipose tissue  
 Skim milk fermented with 
Lb. gasseri SBT2055 
 (6 x 107 CFU/g) 
Male Sprague-
Dawley rats  
(with permanent 
cannulation of 
thoracic duct) 
1 wk ↓maximum transport rate of TG and 
phospholipids 
Ji et al. (2012) Lb. rhamnosus GG 
 (1 x 108 CFU/day) or Lb. 
sakei NR28 (1 x108 CFU/d) 
Male C57BL/6J 
mice  
3 wk ↓epididymal fat  
↓obesity related biomarkers such as FAS, 
ACC and SCD-1 from the liver 
Kadooka et al .(2011) Yoghurt containing Lb. 
gasseri SBT2055 (5 x 108 
CFU/g) 
Male Sprague 
Dawley rats 
4 wk inhibition of enlargement of visceral 
adipocytes prevention of up-regulation of 
sICAM-1 (inflammatory marker that is 
elevated in obesity) 
Kang et al. (2010) Lb. gasseri BNR17  
(109 CFU/0.5mL - 
administered twice daily) 
Male Sprague 
Dawley rats - high 
carbohydrate diet 
12 wk ↓ weight gain 
↓ fat pad mass 
↔ serum total, HDL and LDL  
cholesterol 
↔ TG 
Kondo et al. (2010) Bifidobacteriumbreve B-3 
(108 or 109 CFU/d) 
Male C57BL/6J 
mice - High-fat 
DIO 
8 wk ↓ body weight and epididymal fat 
↓ serum levels of total cholesterol, fasting 
glucose and insulin 
↑ expression of genes related to fat 
metabolism and insulin sensitivity in gut 
and epididymal fat tissue 
Lee et al. (2006) Lb. rhamnosus PL60  
(1 x 107 CFU/d or 1 x 109 
CFU/d) 
Male C57BL/6J 
mice - High-fat 
DIO 
8 wk ↓weight gain 
↓ white adipose tissue (epididymal and 
perirenal) 
↑ apoptotic signals and UCP-2 levels in 
adipose tissue 
Lee et al. (2007) Lb. planatarum PL62  
(1 x 107 CFU/d or 1 x 109 
CFU/d) 
Male C57BL/6J 
mice - High-fat 
DIO 
8 wk ↓ weight of epididymal, inguinal, 
mesenteric and perirenal white adipose 
tissue 
↓ blood levels of glucose 
↓ body weight 
Ma et al. (2008) VSL#3 probiotics (mixture 
of bifidobacteria, 
lactobacilli and 
Streptococcus 
thermophilus)  
(1.5 x 109 CFU/d) 
Male C57BL/6J 
mice - High-fat, 
diet induced 
hepatic steatosis 
and insulin 
resistance 
4 wk ↑ hepatic natural killer T (NKT) cell 
depletion.  
↓ weight 
 improved insulin resistance 
improved steatosis 
Martin et al. (2008) Lb. paracasei NCC2461 or 
Lb. rhamnosus NCC4007  
(1 x 108 CFU/d) 
Female germ-free 
C3H mice - 
colonised with 
human baby flora 
2 wk ↓caecal acetate and butyrate 
↑caecal isobutyrate and isovalerate with 
Lb. paracasei 
↓plasma LDL- and VLDL cholesterol 
↑TG 
Naito et al. (2011) Lb.casei strain ShirotaYIT 
9029 (heat-killed) 
Male C57BL/6J 
mice - High-fat 
DIO 
4 wk improves insulin resistance and glucose 
intolerance. ↓endotoxaemia 
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Sato et al. (2008) Skim milk fermented with 
Lb. gasseri SBT2055 (6 x 
107 CFU/g diet) 
Male Sprague-
Dawley rats  
4 wk ↓adipocyte size in mesenteric white 
adipose tissue 
↑no. of small adipocytes from mesenteric 
and retroperitoneal adipose tissues 
↓ serum leptin 
Tabuchi et al. (2003) Lb. rhamnosus GG Male Wistar rats 
(streptozotocin 
induced diabetes) 
9 wk ↓glycosylated haemoglobin  
improved glucose tolerance  
Takemura et al . (2010) Lb. plantarum LP14 (1 x 
108 CFU/mouse- 
administered 
intragastrically) 
Female C57BL/6 
mice - high-fat 
diet 
11 wk ↓ adipocyte size 
↓ white adipose tissue weight 
↓ serum total cholesterol 
↓ serum leptin 
 
Tanida et al. (2008) Lb. paracasei ST11  (1 x 
109 CFU/2mL water) 
Male Wistar rats - 
High-fat DIO 
11 wk ↓ weight gain 
↓abdominal fat tissue weight 
Wall et al. (2009) B. breve NCIMB 702258 
(109  microorganisms per 
day) + linoleic acid  
Healthy BALB/c 
mice, SCID mice 
and weaning pigs 
8 wk ↑ hepatic and  adipose tissue content of 
cis-9, trans- 11 CLA, DHA and EPA  
↓ splenocytes production of TNF-α, IL-6 
and IFN-γ 
Xiao et al. (2003) Milk product fermented 
with B. longum BL-1 
(approx 4 x 108 CFU/g) 
Male Sprague 
Dawley rats 
3 wk ↓ serum total and LDL cholesterol  
↓TG 
Yadav et al. (2007) Dahi product containing Lb. 
acidophilus and Lb. casei 
Male Wistar rats 
(high-fructose 
induced diabetes) 
8 wk ↓ plasma glucose, glycosylated 
haemoglobin and insulin and liver 
glycogen 
 ↓ total, LDL and VLDL cholesterol 
↓TG and free fatty acids  
↓thiobarbituric acid-reactive substances  
↑reduced glutathione in liver and pancreas 
Yadav et al. (2008) Dahi product containing Lb. 
acidophilus and L. casei(7.3 
x 109 CFU/g - 15g/day/rat) 
Male Wistar rats 
(streptozotocin 
induced diabetes) 
4 wk ↓ oxidative damage in pancreatic tissues 
by inhibiting the lipid peroxidation and 
formation of nitric oxide  
preserved antioxidant pool such as 
glutathione content and activities of super 
oxide dismutase, catalase and glutathione 
peroxidase 
Yin et al. (2010) Bifidobacteria strains - 
L66-5, L75-4, M13-4 and 
FS31-12 
Male Sprague 
Dawley rats-high-
fat diet 
6 wk the response to energy metabolism was 
strain dependent: 
M13-4 ↑body weight gain 
 L66-5  ↓body weight gain 
 all 4 strains ↓ serum and liver TG 
ACC, acetyl CoA carboxylase; CFU, colony forming units;  CLA, conjugated  linoleic acid; DHA, docosahexanoic acid; DIO, diet 
induced obesity; EPA, eicosapentanoic acid; FAS, fatty acid synthase; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; IL-6, interleukin 6 ;IFN-γ, interferon-γ; SCD-1,  stearoyl-CoA desaturase-1; SCID, severe combined  immunodeficient; 
sICAM-1,soluble intercellular adhesion molecule-1; TG, triglycerides; UCP-2, uncoupling protein-2; VLDL, very low density 
lipoprotein 
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Table 2.  Effects of probiotic consumption on biomarkers of metabolic disease in human subjects 
Author Probiotic  Experimental 
design 
Subjects (mean age) Duration Outcome 
Andreasen et 
al. (2010) 
Lb. 
acidophilus 
NCFM (1 x 
1010 CFU/d) 
Double-blind 
RCT - 2 arms  
1) probiotic 
2) placebo 
45 males T2D, impaired 
or normal glucose 
tolerance (mean age 55.6 
yrs) 
4 wk Insulin sensitivity was 
preserved in the 
probiotic group but ↓ in 
the placebo group 
↔ inflammatory 
markers or systemic 
immune response in 
either group. 
Bukowska et 
al. (1998) 
Pro viva – a 
food product 
containing  
fermentable  
oatmeal with 
Lb. plantarum  
299v (~ 5 x 
107 CFU/mL - 
200mL 
administered 
daily) 
Double-blind 
RCT -2 arms  
1) Pro viva 
product 
2) Rose-hip drink 
(control) 
30 healthy males with 
moderately elevated 
serum cholesterol (mean 
age 42.6 yrs) 
6 wk ↓ total and LDL-
cholesterol 
↓fibrinogen  
↔ Triglycerides, HDL-
cholesterol, glucose 
levels and BMI 
Greany et al. 
(2007) 
L. acidophilus 
DDS-1, B. 
longum 
UABL-14 (109 
CFU) and 
oligofructose 
(10-15g) per 
capsule - 
administered 3 
times a day 
Single-blind 
RCT- 2 arms 1) 
probiotic 2) 
placebo 
55 normacholesterolemic 
males and females (age 
range18-36 yrs) 
2 months 
(males) or 2 
menstrual 
cycles 
(females) 
↔  plasma 
concentrations of total 
cholesterol, HDL 
cholesterol, LDL-
cholesterol and 
triglycerides 
Kadooka et al. 
(2010) 
Fermented 
milk 
containing Lb. 
gasseri 
SBT2055  
Double-blind 
RCT -2 arms  
1) fermented 
milk + probiotic 
 2) fermented 
milk 
87 subjects with an 
increased BMI (24.2-
30.7 kg/m2) and 
abdominal visceral fat 
area (81.2-178.5 cm2).   
12 wk ↓abdominal visceral 
and subcutaneous fat 
areas 
↓ body weight, BMI, 
hip and waist 
measurements 
Kiessling et al. 
(2002) 
Yoghurt 
containing  
L. acidophilus 
145 (106-108 
CFU/g), B. 
longum913 (>  
105 CFU/g) 
and 1% 
oligofructose - 
300g 
administered 
daily) 
Cross-over study  
(7 week period 
each) 1) control 
(for all women)  
2) & 3) control 
or probiotic  
29 healthy females –
including 
normacholesterolemic 
and 
hypercholesterolemic 
subjects (mean age 34 
yrs) 
7 wk ↑ HDL cholesterol 
↓ LDL/HDL 
cholesterol ratio. 
↔ total cholesterol and 
LDL-cholesterol 
Kullisar et al. 
(2003) 
Goats milk 
fermented with 
Lb. fermentum 
ME-3 (3 x 1011 
CFU/d) 
CT – 2 arms 
1)Goats milk + 
probiotic (n=16)  
2) Goats milk 
(control; n=5) 
21 healthy males and 
females (mean age 50 
yrs) 
3 wk enhanced total 
antioxidative activity 
prolonged resistance of 
the lipoprotein fraction  
to oxidation 
↓ levels of peroxidised 
lipoproteins, oxidised 
LDL and 8-
isoprostanes 
↓glutathione redox 
ratio 
Laitinen et al. 
(2009) 
Lb. rhamnosus 
GG and B. 
lactisBb12  
(1 x 1010 
CFU/d each) 
Double-blind 
RCT - 3 arms  
1) 
Diet/Probiotics 
2)Diet/Placebo  
3) 
Control/placebo 
 256 healthy pregnant 
females (mean age 30 
yrs) 
from1st 
trimester to 
the end of 
exclusive 
breastfeedin
g 
 
fasting plasma glucose, 
serum insulin and 
HOMA were lowest in 
the diet/probiotic group 
during 3rd trimester of 
pregnancy and  12 
month post partum 
Lewis et al. 
(2005) 
L. acidophilus 
LA-1 (6 x 1010 
CFU - 3 times 
a day) 
Cross-over study 
(6 week period 
each) - 1) 
probiotic 2) 
control 
80 healthy males and 
females with elevated 
cholesterol (mean age 47 
yrs)  
6 wk ↔ plasma lipids 
Chapter 2 
68 
 
Naruszewicz et 
al. (2002) 
Rose-hip drink 
containing Lb. 
plantarum299v 
(5 x 107 
CFU/mL - 
400mL 
administered 
daily) 
Double-blind 
RCT - 2 arms  
1) Rose-hip drink 
+ probiotic 
 2)Rose-hip drink 
36 healthy male and 
female smokers (mean 
age 42.3 yrs)  
6 wk ↓systolic BP and 
fibrinogen 
↓ F2-isoprostanes and 
IL-6 
isolated monocytes 
showed significantly 
reduced adhesion to 
native and stimulated 
endothelial cells 
Simons et al. 
(2006) 
PCC® Lb. 
fermentum(2 x 
109 
CFU/capsule - 
2 capsules 
administered 
twice daily) 
Double-blind 
RCT - 2 arms 
 1) PCC® Lb. 
fermentum 
2) placebo 
46 healthy males and 
females with elevated 
serum cholesterol (mean 
age 51.5 yrs) 
10 wk LDL cholesterol 
showed a modest 
downward trend for 
both probiotic and 
placebo 
no significant 
difference in other 
measurements between 
treatment arms (total 
cholesterol, HDL 
cholesterol, 
triglycerides 
Xiao et al. 
(2003) 
Low-fat 
yoghurt 
containing B. 
longum BL-1 
(approx 108 
CFU/mL - 
300mL 
administered 
daily) 
Single-blind 
RCT - 2 arms 
 1) Low fat- 
yoghurt + 
probiotic  
2) Low-fat 
yoghurt  
32 healthy males with 
serum cholesterol 
ranging from 220-280 
mg/dl (mean age 43.8 
yrs) 
4 wk ↓serum cholesterol in 
half of subjects, 
particularly among 
subjects with moderate 
hypercholesterolemia 
(serum total cholesterol 
>240mg/dl) 
BMI, body mass index; BP, blood pressure; CFU, colony forming units; CT, controlled trial; HDL, high-density lipoprotein; 
HOMA, homeostatic model assessment(method used to quantify insulin resistance and beta-cell function ); LDL, low-density 
lipoprotein; RCT, randomised controlled trial; T2D, type 2 diabetes mellitus; ↓, decreased; ↑, increased; ↔, unchanged 
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1.0  Abstract 
The global proportion of older persons is increasing rapidly. Poor dietary habits and 
inadequate nutrient intakes are of particular concern in this population group and may 
influence quality of life and health outcomes. The aim of the present study was to assess 
the dietary intakes of Irish community-dwelling elderly individuals, participating in the 
ELDERMET project. Two hundred and eight (94 males, 114 females) subjects aged 64-
93 yrs were analysed. Dietary intake was assessed using a validated semi-quantitative 
food frequency questionnaire (FFQ). A high rate of overweight/obesity was observed in 
this population group. Consumption of energy-dense, low-nutrient foods was excessive. 
Older elderly subjects (≥75 yrs) consumed significantly (P<0.01) more desserts/sweets 
than younger elderly (64-74 yrs). Intakes of dietary fat and saturated fat were high while 
dairy food consumption was inadequate in both males and females. Elderly females 
typically had a more nutrient dense diet than males. A considerable proportion of 
subjects, particularly males, had inadequate intakes of calcium, magnesium, vitamin D, 
folate, zinc and vitamin C. The data indicate that the diet of Irish community-dwelling 
elderly individuals is sub-optimal with respect to nutrient intake, and excessive in terms 
of fat intake, with implications for the health status of this population group. Reductions 
in dietary fat and increased low fat dairy food intakes are recommended for the 
prevention of diet-related disease in older persons. In addition, strategies to improve a 
number of sub-optimal micronutrient intakes need to be developed and implemented, 
particularly among elderly Irish males. 
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2.0  Introduction 
Older persons represent an increasing proportion of world populations. In the period 
2010-2050, the number of people aged 65 yrs or over is projected to increase from 8% 
to 16% of the world population (World Health Organisation/National Institute of 
Health, 2011). In 2011, approximately 12% of the inhabitants of the Republic of Ireland 
were aged 65 years or over (Central Statistics Office, 2012), a figure that is predicted to 
rise to 22% by the year 2041 (McGill, 2010). This dramatic increase in the proportion of 
older citizens can partly be attributed to the improved living conditions and health 
services of modern society (Department of Health, 2012; McGill, 2010). An 
increasingly elderly population poses a major challenge to public healthcare systems 
and to exchequer funds due to an increased prevalence of age-related chronic diseases 
(Christensen et al., 2009; Gariballa & Sinclair, 1998) but also due to an increased 
demand for long-term care services (Health Service Executive, 2009; World Health 
Organisation/National Institute of Health, 2011; Wren et al., 2012). Evidence suggests 
that several age-onset chronic diseases including cardiovascular disease, cancer and 
osteoporosis are influenced by diet (World Health Organisation, 2003; Fontana, 2009). 
Improving dietary intakes among the elderly would undoubtedly improve health, quality 
of life and reduce mortality (Anderson et al., 2011; Bamia et al., 2007; Iimuro et al., 
2012).  
A number of key factors contribute to malnutrition in the elderly including inadequate 
dietary intakes, increased metabolic demands or malabsorption of nutrients (Chen et al., 
2008; Corish & Kennedy, 2000). In addition, a decrease in olfactory functioning 
including decreased perception of taste and smell, dental condition, disease, 
medications, anorexia, disability and reduced physical activity, depression, 
bereavement, economic instability and dementia (Brownie, 2006; Mila et al., 2012) can 
all have a negative impact on dietary intakes among elderly individuals. Malnutrition is 
frequently associated with several adverse health outcomes associated with ageing, 
impaired quality of life and increased morbidity and mortality (Chen et al., 2008; 
Lundin et al., 2012). Nevertheless the prevalence of overweight and obesity is 
increasing in all population groups (James et al., 2001), including the elderly 
(Andreyeva et al., 2007) and is strongly associated with chronic disease risk and poor 
health outcomes. Older persons have much lower energy requirements than younger 
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subjects which can be attributed to changes in body composition (decrease in lean body 
mass and increase in body fat) and reduced physical activity (Brownie, 2006; Chernoff, 
2005; Elmadfa & Meyer, 2008). Despite a reduction in energy requirements, 
micronutrient requirements for most vitamins and minerals remain similar to those 
recommended for adult populations (Elmadfa & Meyer, 2008) with requirements for 
some micronutrients (e.g. calcium) increased (Institute of Medicine, 2011). Good food 
choices and a high quality, varied diet therefore become extremely important 
determinants of optimal health with advancing years (Brownie, 2006). 
The vast majority (94%) of elderly subjects in Ireland are currently living in the 
community (Central Statistics Office, 2012). Although life expectancy in Ireland has 
increased significantly over recent decades, a lower proportion of these years are spent 
disability-free in comparison to other European countries such as Sweden, Malta and 
Bulgaria (European Joint Action on Healthy Life Years, 2012). Because inadequate 
nutritional status can be an obstacle to healthy ageing (Amarantos et al., 2001; Ferry & 
Roussel, 2011) and nutritional adequacy may prevent adverse health outcomes and 
significantly delay the need for long-term residential care, it is important to identify 
individuals who are at risk of over- or under- consumption of specific nutrients.  
The ELDERMET consortium (http://eldermet.ucc.ie) was established in 2007 to 
investigate how the intestinal bacteria influence, and are influenced by, diet, health and 
lifestyle in 500 older Irish people, across a range of health profiles and including those 
living in the community, day-hospital attendees, rehabilitation patients and long-term 
care residents. This project has previously elucidated links between microbiota 
composition, diet, health and frailty status in the elderly (Claesson et al., 2011; Claesson 
et al., 2012). The present study was based on the hypothesis that different subgroups 
within the community-dwelling elderly population may be at nutritional risk.  The aim 
of this study was therefore to assess dietary intakes among an Irish community-dwelling 
elderly population group who participated in the ELDERMET project and to establish 
their compliance with macro- and micronutrient recommendations.  
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 3.0  Materials and Methods 
3.1 Subject Recruitment 
The present study investigates dietary intakes among a sub-set of self-selected, 
community-dwelling ELDERMET participants (n 208; 94 males, 114 females; 64-93 
years), who responded to advertising in local health-care and general practice centres, 
active retirement groups and events, information sessions and local media from the 
Cork city and county region of southern Ireland. Community-dwelling, day-hospital 
attendees, were also included in the present study. Eligible candidates were community-
dwellers (i.e. not in residential care such as nursing homes/long-term care facilities), 
aged 64 years and older and in any stage of health. Exclusion criteria included history of 
alcoholism, participation in investigational medication trials in the previous month and 
advanced organic disease (precluding longitudinal follow-up). Two subjects were 
excluded from the analyses due to unrealistic reported values for daily energy intakes 
(>4000 kcal).  
3.2 Ethical Considerations 
Written informed consent was obtained from all subjects in accordance with local 
Clinical Research Ethics Committee of the Cork Teaching Hospitals. This study 
complies with the guidelines set out in the Declaration of Helsinki and those of the Cork 
Research Ethics Committee, Ireland.  
3.3 Data Collection 
Height and weight were recorded by the research nursing personnel. Height was 
predicted from forearm (ulna) length (Mitchell & Lipschitz, 1982) which was measured 
to the nearest 0.5 centimetre using a tape measure. Weight was measured in light 
clothing to the nearest 0.1kg. All subjects were able to complete the measurements (step 
on scale, keep body straight, etc.). Body Mass Index (BMI) was calculated as weight 
(kg)/height (m2); subjects were classified into four BMI categories according to World 
Health Organisation (WHO) recommendations (World Health Organisation, 2013). The 
Mini Nutritional Assessment (MNA) was used as a screening tool to identify subjects at 
risk of malnutrition (Cuervo et al., 2008; Vellas et al., 1999). Information on smoking 
status was also collected.  
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3.4 Dietary data 
Dietary data were collected by means of a semi-quantitative food frequency 
questionnaire (FFQ) administered by trained research nursing personnel. The FFQ was 
an amended version of that used by the European Prospective Investigation into Cancer 
(EPIC) study (Riboli & Kaaks, 1997) and validated for use in the Irish population 
(Harrington et al., 2008). The questionnaire assessed habitual dietary intakes of 147 
single food items/beverages. The frequency of intake was measured using ten categories 
ranging from ‘never’ to ‘six times a day or more’. In order to estimate the number of 
servings from each food group consumed on a daily basis, each frequency option in the 
FFQ was converted to a single daily serving (i.e. 0 for ‘never’, 0.01 for ‘less than once a 
month’, 0.03 for ‘once a month’, 0.14 for ‘once a week’, 0.29 for ‘twice a week’, etc.). 
Recently derived, population-based, gender-specific portion sizes for community-
dwelling elderly subjects (65-75 yrs and ≥75 yrs) were applied to each FFQ item 
(Wrieden & Barton, 2006). Food and beverage items in the questionnaire were 
aggregated into 30 mutually exclusive food groups based on nutrient profiles, as 
described elsewhere (Leite et al., 2003; Pryer et al., 2001a; Pryer et al., 2001b; Villegas 
et al., 2004). Information on vitamin/mineral supplement use (including. supplement 
type, brand and formulations) was also collected as part of the FFQ. 
To evaluate food group intakes, we took as reference the recommended number of daily 
servings for adults (aged 51+ yrs) from the recently revised Food Safety Authority of 
Ireland (FSAI) Irish food-based dietary guidelines (FBDG) (Flynn et al., 2012). The 
number of servings of each food group consumed daily was calculated by adding the 
daily value of each relevant food item. The revised recommendations for the bread, 
cereal and potato group vary according to physical activity levels. For example, 
sedentary males and females aged ≥51 yrs are recommended to consume 4 and 3 
servings per day, respectively while moderately active males and females are advised to 
consume 4-5 and 3-4 servings from this food group, respectively (Flynn et al., 2012). 
Because information on physical activity levels were not recorded as part of the present 
study, males and females who consumed at least 4 and 3 servings, respectively were 
considered compliant with dietary recommendations for this food group.  
3.5 Nutrient Intakes  
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A nutrient composition database was established for the ELDERMET FFQ using 
information compiled from the UK Food Standards Agency (FSA) nutrient databank 
(Food Standards Agency, 2002), with additional information from the Irish Food 
Consumption database (Black et al., 2011) and manufacturers’ information. The FSA 
food compositional databank was the primary nutrient data source used. For food items 
with several variations (e.g. different cuts of meat) prepared by different cooking 
methods, a range of appropriate foods were selected from the food compositional 
database and the average nutrient composition of that item calculated. Supplement 
intakes were included in the estimation of the nutrient intakes where appropriate. 
The FSA nutrient databank (Food Standards Agency, 2002) provides two values for 
dietary fibre based on different measurement methods: the Englyst method (including 
non-starch polysaccharide (NSP) values) and the AOAC method (including lignin and 
resistant starch, in addition to NSP). Because values for a more comprehensive range of 
foods was available using the Englyst method, this dietary fibre value was used in our 
analysis, and intakes compared to the UK Department of Health recommendations for 
NSP (Department of Health, 1991). 
Daily micronutrient intakes were compared to the dietary reference intakes, using the 
estimated average requirements (EAR) where available or adequate intakes (AI) for 
nutrients where no recommended daily allowance has been established (Flynn et al., 
2011; Institute of Medicine, 2011).  
3.6 Micronutrient density 
Variance in body size often determines gender-specific differences in energy and 
micronutrient intakes. For this reason, micronutrient intakes were adjusted for energy 
intakes. In line with other studies (Hannon et al., 2001; O'Brien et al., 2001), 
micronutrient density was calculated by dividing absolute nutrient intake by total energy 
intake (KJ) and amounts expressed per 10 MJ.  
3.7 Statistical Methods 
Statistical analyses were performed using PASWTM version 18 statistical package. 
Statistical comparisons were made between males and females and between different 
age groups (64-74 yrs and ≥ 75 yrs). Differences between means were evaluated using 
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the Independent-samples t-test or Mann Whitney test, as appropriate. Differences 
between categorical distributions were evaluated using chi-square test or Fisher’s exact 
test. A P value of <0.01 was considered as statistically significant. 
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4.0  Results 
4.1 Demographic and Anthropometric Data 
Selected baseline demographic and anthropometric characteristics are shown in Table 1. 
Mean age of study participants was 75 years. The majority of subjects had an adequate 
nutritional status (according to the MNA score ≥24). The mean BMI was 28.5 for males 
and 27.6 for females. The majority of subjects were classified as either overweight 
(45% of males, 34% of females) or obese (36% of males, 32% of females). A 
significantly larger proportion of females consumed dietary supplements compared to 
males (60% vs. 39%). The most commonly consumed supplements were minerals 
(23%), fish oil/fatty acids (23%), vitamins (16%) and multivitamin/multimineral 
(MVMM) preparations (11%). Over twice as many females used mineral supplements 
as males (32% vs. 13%), with calcium and calcium/vitamin D combination supplements 
being the most widely consumed supplement in this category. 
4.2 Food consumption 
Median daily food consumption data are presented in Table 2. Bread was consumed 
once to twice daily while wholegrain breakfast cereals and potatoes were consumed on 
average, once daily. Dairy foods, particularly milk and yoghurt were consumed once 
daily while eggs were consumed twice weekly. Two to three servings of fruit and 
approximately three servings of vegetables were consumed daily. Meat was consumed 
four to five times per week while fish and poultry were consumed one to two times per 
week. On average, four cups of hot beverages and two to three servings of 
desserts/sweets were consumed daily. Males consumed alcohol on average twice 
weekly while female consumption was limited to once per month. Food groups which 
were rarely/never consumed included pasta, rice, french fries, refined grain breakfast 
cereals, savoury snacks and soft drinks. Among the younger age category examined (64-
74 yrs), females consumed significantly more wholegrain breakfast cereals, probiotics 
(P<0.01) and chicken/poultry (P<0.001), and significantly less meat, fish products, 
miscellaneous foods (sauces, ketchup, jams, preserves etc.), alcoholic drinks (P<0.01) 
and processed soups (P<0.001) than males of similar age. In the older age bracket (≥75 
yrs), gender specific dietary choices were also apparent, with greater amounts of meat, 
chicken/poultry, potatoes and alcohol drinks being consumed by males compared with 
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females (P<0.01). Older participants (≥75 yrs) consumed significantly more 
desserts/sweets than the younger age group (64-74 yrs) for both genders (P<0.01).  
4.3 Compliance with Dietary Recommendations 
The Irish food-based dietary guidelines (FBDG) indicate the number of servings 
recommended for each of the four main food groups, in addition to guidelines for 
consumption of foods high in fat and/or sugar (Table 3). Daily food group consumption 
and compliance was measured with respect to recommendations for each food group. 
The median daily consumption of foods from the bread, cereal and potato food group 
was adequate (4.7 and 4.5 servings/day for males and females, respectively) with the 
majority of subjects (73.4% of males and 82.5% of females) compliant with the 
recommendations. Approximately half of subjects (47.9% of males and 57.9% of 
females) complied with recommendations to consume at least five servings of fruit and 
vegetables daily. Consumption of foods from the milk, cheese and yoghurt group was 
low among both genders with only 2.1% of males and 9.7% of females compliant with 
recommendations to consume 3 servings daily. On further analysis it was found that 
26.6% of males and 25.4% of females consumed more than the recommended 3 
servings daily, while 71.3% of males and 64.9% of females consumed less than the 
recommendation. Less than half of subjects (39.4% and 43.0%, males and females, 
respectively) consumed the recommended 2 servings of meat, fish and alternatives per 
day. Approximately 34.0% of males and 22.8% of females consumed more than the 
recommended amounts while 26.6% of males and 34.2% of females consumed less than 
the recommended 2 daily servings. Over half of those surveyed complied with 
guidelines to consume fish twice weekly (50% of males and 57% of females). 
Compliance with recommendations to consume foods high in fat and/or sugar sparingly 
(<3 servings/day) was low (10.6% and 19.3% males and females, respectively) with 
males consuming, on average 6.6 servings and females consuming 6.2 servings daily. 
Although no significant differences in compliance levels between gender and age 
groups were found, it is noteworthy that females from both age categories showed 
higher compliance rates than males with the dietary guidelines for all food groups. 
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4.4 Nutrient intakes 
The median daily energy and macronutrient intakes from all sources and percentage 
energy contribution according to age group and gender are shown in Table 4. In general, 
elderly males had higher energy (P<0.001), protein and carbohydrates (P<0.01) intakes 
than females. Overall, the contribution to energy intakes from protein, carbohydrate and 
fat did not differ between males and females. Females had a significantly higher 
proportion of energy from total sugars than males (24.7% vs. 22.4%, P<0.01) while 
males consumed a significantly higher proportion of energy from alcohol (1.5% vs. 
0.2%, P<0.001). Median daily alcohol intake for men was greater than that for women 
(P<0.01). Comparative analysis of energy and macronutrient intakes between genders 
aged 64-74 yrs showed no significant differences. Significant differences were found 
among the older age group (≥75 yrs) with males consuming significantly more energy, 
protein, carbohydrates (P<0.001) and fat (P<0.01) than females. Older males (≥75 y) 
had significantly higher energy and carbohydrate intakes (P<0.01) compared to younger 
males (64-74 yrs), with no such differences observed among females.  
The percentage contribution of food groups to energy and macronutrient intakes were 
also investigated (data not shown). Food groups contributing the highest proportion to 
energy intakes were breads (16.7%), desserts/sweets (13.6%) and meat/poultry (10.2%). 
The main sources of protein were meat/poultry (26.4%), dairy foods (14.2%) and breads 
(14.2%) while fats/oils, including butter, spreads, salad dressings (19.7%), meat/poultry 
(15.7%) and desserts/sweets (13.4%) were the main contributors to fat intakes. The 
main dietary sources of carbohydrate were breads (24.1%), desserts/sweets (17.1%) and 
fruit (13.4%). 
The median daily intake of vitamins and minerals from all sources, stratified by age and 
gender are shown in Table 5. In general, males had significantly higher intakes of 
thiamine, niacin, iron (P<0.001) and zinc (P<0.01) while females had significantly 
higher intakes of vitamin C (P<0.01). Older males (≥75 yrs) had significantly higher 
intakes of calcium and phosphorous (P<0.01) compared to those in the 64-74 age 
category. In contrast, older females (≥75 yrs) had significantly lower intakes of calcium 
and vitamin B6 than their younger counterparts (P<0.01).  
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The proportional contribution of food groups and nutritional supplements to key 
micronutrient (i.e. vitamin A, vitamin C, vitamin D, folate, calcium and iron) intakes 
were also investigated (data not shown). The contribution of dietary supplements to 
micronutrient intakes varied. Overall, the contribution of dietary supplements to 
micronutrient intakes was less than 9% with the exception of vitamin C and vitamin D. 
Fruit, vegetables and potatoes contributed 30.6%, 26.9% and 13.4%, respectively of the 
daily vitamin C intake while supplements contributed a further 10.1% to intakes. 
Dietary supplements were the main contributor to vitamin D intakes in this elderly 
group (28.5%), followed by fats/oils (12.2%) and fish (11.2%). Vegetables, soups and 
meat/poultry were the main contributors to vitamin A intakes (36.7%, 10.9% and 10.0% 
respectively), while the predominant contributors to folate intakes were vegetables 
(17.0%), breads (10.9%), potatoes (10.8%) and breakfast cereals (10.5%). The main 
dietary sources of iron were breads (22.1%), breakfast cereals (16.7%) and meat/poultry 
(11.3%), while the main sources of calcium were dairy foods (27.9%), breads (14.7%), 
breakfast cereals (13.5%) and dietary supplements (8.8%). 
4.5 Micronutrient density 
Daily intakes of vitamins and minerals were expressed per 10 MJ of energy and 
stratified by age and gender (Table 6). Dietary intake was generally more nutrient dense 
among females for most micronutrients and significantly for some including: vitamin A, 
vitamin B12, biotin, pantothenate, vitamin C, calcium, magnesium phosphorous and 
copper (P<0.01). Among older subjects (≥75 yrs), less disparity in nutrient density was 
found between genders with only a higher intake of vitamin C in females compared to 
males (P<0.001). This may be due to the fact that there was a significant reduction in 
micronutrient density between younger and older females for a number of 
micronutrients including several B vitamins, calcium and magnesium (P<0.01). There 
was no significant difference in micronutrient density between younger (64-74 yrs) and 
older (≥75 yrs) males. 
4.6 Recommended Nutrient Intake Adequacy 
The contribution of protein and carbohydrate to total energy intakes were within the 
target ranges (10-35% and 45-65%, respectively) (Flynn et al., 2011). The percent of 
energy derived from total fat was at the upper limit of the target range (20-35%) (Flynn 
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et al., 2011), providing 34% and 35% of total energy for males and females, 
respectively, while the energy contribution from saturated fat was above the 
recommended target (<10%) (Flynn et al., 2011), providing 14% and 15% of total 
energy for males and females, respectively. Non-starch polysaccharide (NSP) intakes 
were just below the UK recommendations (>18g/d) (Department of Health, 1991) for 
elderly females (16.4g/d), while elderly males consumed adequate NSP (18.0g/d). A 
NSP intake of 18g has been shown to equate to a dietary fibre intake of approximately 
25g based on population food intakes in the North/South Ireland Food Consumption 
Survey (Galvin et al., 2001).  
The proportions of the surveyed Irish, community-dwelling elderly subjects with 
micronutrient intakes below the estimated average requirements (EAR) are shown in 
Table 7. In general, adequate intakes were reported for vitamin E, thiamine, riboflavin, 
niacin, vitamin B6, vitamin B12 intakes, while a large proportion of male (81.9%) and 
female subjects (71.9%) had sub-optimal vitamin D intakes. Over one third of subjects 
(36.2% of males and 42.1% of females) did not meet the requirements for folate and a 
significantly higher proportion of males had vitamin C intakes below the EAR, 
compared to females (27.7% vs. 7% P<0.01). Approximately one third of subjects did 
not meet the average requirement for calcium intake (39.4% males and 36.0% females) 
while a significantly larger proportion of elderly males had inadequate intakes for 
magnesium compared to females (61.7% vs. 32.5%; P<0.001). 
5.0  Discussion 
In this cross-sectional study of 208 community-dwelling elderly subjects, food 
consumption, nutrient intakes and nutritional status was assessed. In accordance with 
previous reports (Corish & Kennedy, 2003; Guigoz, 2006; Romero-Ortuno et al., 2011), 
none of the study participants were classified as malnourished, and a low proportion of 
subjects had a BMI less than 18.5 kg/m2, indicative of being underweight. In addition, 
and consistent with previous findings (Andreyeva et al., 2007; Corish and Kennedy, 
2003; Irish Universities Nutrition Alliance, 2011), a large proportion of the study 
participants were classified as overweight or obese. However, the definition of the 
optimal BMI among the elderly remains controversial as the relevance of a high BMI 
becomes less pronounced with ageing (Corrada et al., 2006; de Hollander et al., 2012). 
Epidemiological findings on the relationship between BMI and mortality suggest an 
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increased mortality risk for elderly with BMI values < 25 (Corrada et al., 2006; Dey et 
al., 2001; Landi et al., 2000). It has also been shown that BMI classification of 
overweight in the elderly did not increase the risk of all-cause mortality, and obesity 
(BMI >30 kg/m2) increased the risk only modestly (de Hollander et al., 2012). Evidence 
also indicates that excessive weight in old age may serve a protective function against 
osteoporosis (Albala et al., 1996; Barrera et al., 2004) and it has been suggested that the 
World Health Organisation (WHO) cut-off of 25 kg/m2 for overweight may not be 
appropriate for older persons (de Hollander et al., 2012). 
The primary objective of the ELDERMET study was to determine the gut microbiota 
profile of elderly population groups. Because of the population group involved, the use 
of weighed food intakes and food diaries was not appropriate. The dietary assessment 
method employed was not therefore designed to capture dietary information at the 
micronutrient level. However, FFQs have been shown to be an appropriate tool for 
conducting dietary assessment in elderly populations (Klipstein-Grobusch et al., 1998) 
and use of the recently published UK portion size database, applicable for elderly, 
community-dwelling individuals (Wrieden & Barton, 2006) increased the accuracy of 
estimating nutrient intake in this population cohort. Some potential limitations of our 
findings must, however, be taken into account. FFQs inherently rely on a number of 
assumptions when estimating nutrient intakes; they contain broad food descriptions (e.g. 
lamb) rather than specific foods and cooking methods (e.g. grilled lamb chops) and 
therefore an average nutrient composition is assigned to each FFQ item based on the 
mean of a range of appropriate foods. Furthermore, in the present study, standard 
portion sizes for community-dwelling elderly subjects were used to determine daily 
nutrient intakes. Although these methods infer a number of assumptions, they are 
currently the most accurate and appropriate methods for this population group.  The 
problem of assessing adequacy of micronutrient intakes at a population level is a long 
standing one (Carriquiry, 1999; Román-Viñas et al., 2009) with comparison to 
Recommended Daily Allowance (RDA) values leading to an overestimation of nutrient 
inadequacy (Carriquiry, 1999). In this study, the prevalence of inadequate micronutrient 
intakes was estimated from the percentage of the population with median daily intake 
levels below the estimated average requirement (EAR; the average daily intake 
estimated to meet the requirement of fifty percent of healthy individuals in a particular 
age or gender group) as recommended (De Lauzon et al., 2005). The present study 
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lacked information on physical activity, therefore comparisons to reference energy 
recommendations and estimations of underreporting were not performed for this 
population group. It is well acknowledged that dietary surveys are affected by varying 
degrees of underreporting (Goldberg & Black, 1998). However, the validity of methods 
to determine underreporting in elderly populations has not been thoroughly evaluated. 
As the prevalence of underreporting was not established in the present study cohort, 
results should be interpreted with caution. Finally, as the study population was self 
selected, it is possible that our study participants had better mental and physical health. 
Consequently, our study results cannot be generalised to the entire Irish community-
dwelling elderly population.   
Previous studies of food consumption report different eating patterns among older 
populations compared with their younger counterparts. In general, older persons 
traditionally consume three meals a day (Shahar et al., 2003) with a decline in food 
quantity (Wakimoto & Block, 2001; Zhu et al., 2010) and dietary variety (Fanelli and 
Stevenhagen, 1985; Kwon et al., 2005) and an increase in dietary supplement usage 
with age (Irish Universities Nutrition Alliance, 2011; Radimer et al., 2004). In line with 
other studies, approximately half of those surveyed in the present study consumed some 
form of dietary supplement (Bailey et al., 2011; Irish Universities Nutrition Alliance, 
2011; Johnson et al., 2000; Schwarzpaul et al., 2006). 
Although a high level of fruit and vegetable consumption was evident in the cohort 
analysed, over one third of elderly subjects did not meet the recommended EAR for 
folate intake. Inadequate folate intakes, common amongst older populations (Elmadfa, 
2009; Volkert et al., 2004; Zhu et al., 2010) are associated with increased plasma levels 
of homocysteine, an independent risk factor for heart disease and stroke (Zhu et al., 
2010). Additional supplementation of this important nutrient may be required to address 
nutritional inadequacy among elderly populations. 
Despite relatively good compliance with guidelines for certain food groups, and in 
contrast to previous findings for elderly Irish subjects (Harrington et al., 2008) the 
majority of subjects failed to meet the recommended guidelines for dairy foods with 
intakes among both genders. Avoidance of dairy products in older adults may be due to 
actual or perceived lactose intolerance (Lichtenstein et al., 2008; Russell et al., 1999) or 
misperceptions linking milk product consumption to weight gain or poor lipid profiles 
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(Eddy et al., 1999; Horwath et al., 1995). One third of participants in this study had 
calcium intakes below the EAR. In addition, vitamin D intakes were sub-optimal among 
both males and females with over two-thirds of subjects reporting intakes below the 
EAR. Not only is vitamin D vital for adequate intestinal calcium absorption (Cashman 
et al., 2012), deficiency has been associated with several chronic conditions including 
cardiovascular disease, autoimmune disease, cancer (Souberbielle et al., 2010) and 
mortality (Holick, 2007). However, inadequacy is widespread among elderly population 
groups (Elmadfa, 2009; Irish Universities Nutrition Alliance, 2011). The level of dietary 
supplementation reported in the present study is in line with estimates from the recent 
National Adult Nutrition Survey (Irish Universities Nutrition Alliance, 2011), 
contributing to over one quarter of dietary vitamin D intakes. Dietary supplements also 
played a significant contribution to calcium intakes (8.8%) in this population group. 
However, despite the high contribution of supplement use to both vitamin D and 
calcium intakes, the rationale for poor dietary intakes of such vital nutrients needs to be 
investigated and potentially more targeted, food-based strategies, such as food 
fortification of selected relevant foods are required to address this issue. 
Excessive consumption of foods high in fat and/or sugar was prevalent among this 
elderly cohort and has been reported previously (Harrington et al., 2008). 
Desserts/sweets were one of the main contributors to energy and fat in the elderly diet. 
High consumption of desserts/sweets and soft drinks is of particular concern as 
excessive intakes of high fat and/or sugar foods may contribute to the development of 
chronic health problems including type 2 diabetes and overweight/obesity. Energy 
dense foods tend to possess little nutritional value and frequent consumption of these 
foods often displace more nutrient-dense foods from the diet (Kant, 2003; van Dam & 
Seidell, 2007). 
In line with findings from similar cohort studies (Elmadfa, 2009; Irish Universities 
Nutrition Alliance, 2011; Department of Health/Food Standards Agency, 2012), fat 
intakes were high in this elderly population group. In addition, intakes of saturated fat 
were excessive and may contribute to high BMI values, raised blood cholesterol and 
increase the risk of heart disease (Flynn et al., 2011). Reports of high intakes of 
saturated fat are commonplace among Northern European population groups (Elmadfa, 
2009; Pryer et al., 2001b), while saturated fat intakes are lower among Southern 
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European elders (Moreiras et al., 1991; Tur et al., 2005), potentially due to high 
consumption of mono- and polyunsaturated fats. 
Gender differences in food consumption among older populations have previously been 
reported. While females tend to have healthier dietary patterns than their male 
counterparts (Anderson et al., 2011; Bamia et al., 2005; Bates et al., 1999; Prättälä et 
al., 2007), males tend to consume more meat, potatoes, bread and alcohol and less 
fruits, vegetables, fish, chicken, cheese and sweets than women (Prättälä et al., 2007). In 
general, females tend to consume more dietary supplements than males (Bailey et al., 
2011; Irish Universities Nutrition Alliance, 2011; Johnson et al., 2000; Schwarzpaul et 
al., 2006) and female food behaviours tends to be more in accordance with the dietary 
guidelines (Roos et al., 1998). In the current study, use of dietary supplements was 
more common among females than males. In addition, the observed gender differences 
in food group intakes are consistent with those previously reported (Arganini et al., 
2012; Bates et al., 1999). It has been shown that when making food choices, males rank 
health as a lower priority to other considerations such as taste and convenience (Donkin 
et al., 1998; Steptoe et al., 2002; Wardle & Griffith, 2001). Older males (55-64 yrs) also 
tend to have poorer knowledge about current dietary recommendations with fewer men 
aware of the links between diet, health and disease (Baker and Wardle, 2003). 
Furthermore, gender differences in food consumption may be related to social norms 
and cultural beliefs (Prättälä et al., 2007) with elderly women often maintaining the 
traditional role of choosing, preparing and cooking food (Arganini et al., 2012; Donkin 
et al., 1998; Prättälä et al., 2007).  
Dietary intakes of elderly females were more nutrient-dense than those of elderly males, 
as shown previously (Pryer et al., 2001b; Volkert et al., 2004). In addition, the 
prevalence of inadequate micronutrient intakes was higher among males than females 
and may reflect the observed differences in food consumption and dietary supplements 
usage. A higher proportion of elderly males consumed inadequate amounts of vitamin C 
compared to elderly females, a trend evident in both younger and older age categories. 
Higher vitamin C intakes have previously been reported in the UK among elderly 
females compared to males (65-75 yrs) and have been attributed to increased 
consumption of ‘vitamin C-rich’ foods such as fruit and vegetables (Bates et al., 1999). 
Although not significantly different, females consumed more fruit than elderly males in 
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the current study. Age-related decreases in antioxidant enzyme activity, reported to 
contribute to increases oxidative damage and age related degeneration (Chernoff, 2005; 
Elmadfa & Meyer, 2008) highlight the requirement for a continuous supply of key 
antioxidant nutrients, including vitamin C. The occurrence of inadequate zinc and 
magnesium intakes were particularly high among males and may have negative health 
implications in this group. Therefore, older adults, particularly elderly men, should be 
encouraged to eat rich dietary sources, such as shellfish, legumes, nuts/seeds and whole-
grain cereals.  
For the majority of food groups studies there was no significant difference in intakes 
between the younger (64-74 yrs) and older (≥75 yrs) elderly participants, with the 
exception of desserts/sweets where there was a marked increase in consumption with 
age. Similarly, a study examining dietary intakes over a ten year follow-up in a group of 
elderly Italians found a significant increase in sweet-eating with age (Toffanello et al., 
2010). Altered olfactory function including a reduced sense of taste associated with 
ageing may be responsible for this preference for softer, sweeter, more palatable foods 
(Toffanello et al., 2010). Indeed, elderly women with olfactory dysfunction have a 
higher intake of sweets than those without dysfunction (Duffy et al., 1995). This 
increased consumption of desserts/sweets with age may displace more nutrient-dense 
foods from the diet and increase the risk of obesity-induced chronic disease disorders, 
including type 2 diabetes. In the present study, the female diet appeared to deteriorate 
with advancing age: older females (≥75 yrs) had a lower micronutrient-dense diet than 
younger females (64-74 yrs).  
To conclude, this study highlights the main foods contributing to nutrient intakes among 
older Irish persons and points to several inadequacies among this vulnerable population 
group. Our results highlight the need to improve awareness among elderly populations 
regarding the importance of nutritious dietary choices for long-term health. 
Interventions to improve dairy consumption, and reduce dietary fat (particularly 
saturated fat) intakes among elderly population groups may also be warranted. In 
addition, specific micronutrient supplementation may be necessary, particularly among 
elderly males, to ensure adequate micronutrient intakes. Dietary recommendations 
specific to the nutritional needs and health concerns associated with ageing are required 
as improvement of nutritional status may lead to reduced ill-health, help maintain a 
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better quality of life and promote longer independent living (Harris & Haboubi, 2005). 
In addition, the association between diet and the intestinal microbiota outlined in a 
previous study by the ELDERMET project (Claesson et al., 2012) highlights the 
importance of promoting healthy ageing by nutritional interventions which target the 
gut microbiota. Our findings present both challenges and opportunities to the food 
industry and healthcare policy makers: to identify dietary vehicles suitable for 
fortification and to devise age-specific, dietary recommendations to address the 
nutritional concerns of elderly males and females.  
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Table 1.  Selected descriptive characteristics of Irish community-dwelling elderly subjects  (n 208) stratified by age group and gender 
 
All ages   64-74 years   ≥75 years 
Characteristicsa Males (n 94) 
 
Females (n 114) 
 
Males (n 45) 
 
Females (n 57) 
  
Males (n 49) 
 
Females (n 57) 
 
Mean SD   Mean SD   Mean SD  Mean SD  Mean SD  Mean SD 
Age (yrs) 75.4 6.5  74.8 6.7  69.9†† 2.6  69.1†† 2.9 
 
80.4 4.7  80.5 3.9 
Smoking status (%) 
 
  
 
             
Never  42   52   36   55   47   48  
Former smoker  53   42   54   43   53   41  
Current   5   6   10   2   0   11  
Weight (kg) 83.2 14.3  69.3** 15.1  87.5 15.6  70.8** 14.6  79.4† 11.9  67.9** 15.6 
Height (cm) 170.4 7.2  158.5** 5.1  172.3 7.2  159.0** 5.9  168.7† 6.7  158.1** 4.2 
BMIb (kg/m2) 28.5 4.1  27.6 6.1  29.2 4.2  28.1 5.9  27.9 4.0  27.1 6.4 
BMI, kg/m2  categories (%) 
 
  
 
             
Underweight (<18.5) 1   2   0   0   2   4  
Normal (18.5-24.9) 18   32   13   32   22   32  
Overweight (25-29.9) 45   34   44   36   45   32  
Obese (≥30) 36   32   42   32   31   32  
MNAc score (0, 30) 26.0 2.0  25.8 2.2  25.9 2.0  26.2 2.0  26.1 2.1  25.4 2.3 
Nutritional status (%) 
 
  
 
             
Normal Nutritional Status (MNA ≥24) 90   87   91   11   90   84  
At risk of malnutrition (MNA 17-23.5) 10   13   9   89   10   16  
Malnourished (MNA<17) 0   0   0   0   0   0  
Dietary Supplement Users (%) 39*   60   31**   68   47   51  
MVMMd Supplements (%) 6   15   9   21   4   9  
Vitamin Supplement (%) 17   15   16   18   8   12  
Mineral Supplements (%) 13*   32   9**   40   16   23  
Fish Oil/Fatty acids (%) 18   27   22   33   14   21  
Amino acids (%) 3   3   4   5   2   0  
Glucosamine (%) 3   10   4   14   2   5  
Food Supplement (%) 1   3   0   0   2   5  
Herbal Supplements (%) 4   8   7   14   2   2  
aValues represent mean and standard deviation (SD) or percentages (%) 
bBody Mass Index cMini-Nutritional Assessment: Score out of a total of 30.  Higher scores indicate a higher degree of nourishment 
dMultivitamin/Multimineral supplements 
*P≤ 0.01; **P ≤ 0.001: comparisons between males and females (Independent-samples t test or chi-square test). 
†P≤ 0.01; ††P≤0.001: comparisons between age groups within each gender category (Independent-samples t test) 
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Table 2.  Median daily intake (g/d) of food groups among Irish community-dwelling elderly subjects stratified by age group and gender 
  All ages   64-74 years   ≥75 years 
 
Males (n 94) 
 
Females (n 114) 
 
Males (n 45) 
 
Females (n 57) 
  
Males (n 49) 
 
Females (n 57) 
Food groups (g/d) Median IQR   Median IQR   Median IQR   Median IQR   Median IQR   Median IQR 
Brown breads  78 27-117 
 
58 19-103 
 
66 25-135 
 
62 19-106 
 
107 23-113 
 
54 17-99 
White breads 33 6-107 
 
14* 2-50 
 
30 3-109 
 
8 2-49 
 
36 7-108 
 
14 2-53 
Wholegrain breakfast cereals 53 4-225 
 
161 31-219 
 
42* 0-200 
 
185 29-219 
 
87 30-225 
 
122†† 25-161 
Refined grain breakfast 
cereals  0 0-1  0 0-0  0 0-1  0 0-0  0 0-0  0 0-0 
Pasta/rice 2 0-17 
 
4 0-24 
 
2 0-18 
 
4 0-30 
 
2 0-17 
 
4 0-18 
Potatoes  153 98-172 
 
131** 80-146 
 
144 97-173 
 
140 81-148 
 
156 120-168 
 
127** 73-137 
French fries  4 1-18 
 
3* 1-16 
 
4 1-18 
 
3 1-16 
 
15 1-17 
 
3 1-15 
Fruit  178 96-313 
 
223 153-349 
 
184 112-276 
 
246 125-384 
 
171 82-379 
 
223 159-315 
Vegetables  150 109-222 
 
155 117-236 
 
151 108-229 
 
156 118-273 
 
145 110-215 
 
153 105-226 
High fat dairy 30 5-129 
 
63 9-135 
 
25 8-128 
 
57 4-150 
 
66 4-129 
 
69 14-133 
Low fat dairy 1 0-119 
 
4 0-101 
 
1 0-85 
 
9 0-118 
 
1 0-188 
 
0 0-96 
Meat  52 39-73 
 
41** 22-56 
 
51 34-68 
 
36* 17-56 
 
58 39-76 
 
47* 30-56 
Meat products 11 2-22 
 
7* 2-12 
 
10 2-22 
 
8 2-11 
 
12 2-23 
 
7 2-15 
Fish  19 7-31 
 
20 6-38 
 
19 5-31 
 
29 12-41 
 
19 12-30 
 
19 6-34 
Fish products 1 0-17 
 
0* 0-6 
 
1 0-18 
 
0* 0-3 
 
1 0-17 
 
1 0-15 
Poultry  12 12-24 
 
12 11-26 
 
12** 12-25 
 
26 12-26 
 
12 12-24 
 
11*†† 11-23 
Poultry products 0 0-1 
 
0 0-0 
 
0 0-4 
 
0 0-0 
 
0 0-1 
 
0 0-0 
 Eggs  21 10-52 
 
20 11-22 
 
24 9-59 
 
20 13-22 
 
21 10-52 
 
20 10-23 
Salad dressings  0 0-4 
 
2 0-4 
 
0 0-4 
 
3 0-4 
 
0 0-4 
 
2 0-4 
Butter  0 0-20 
 
1 0-20 
 
2 0-20 
 
0 0-18 
 
0 0-20 
 
1 0-20 
Spreads 10 0-22 
 
7 0-20 
 
8 0-22 
 
9 0-18 
 
20 0-20 
 
2 0-20 
Fresh soups 8 0-79 
 
30 0-67 
 
6 0-64 
 
35 2-67 
 
9 0-95 
 
6 0-63 
Processed soups 6 0-35 
 
0 0-39 
 
6 0-33 
 
0**† 0-4 
 
4 0-60 
 
4 0-62 
Desserts/sweets 77 39-135 
 
61 37-101 
 
59† 24-108 
 
50† 25-83 
 
97 52-157 
 
80 46-110 
Savoury snacks 0 0-1 
 
0 0-1 
 
0 0-1 
 
0 0-1 
 
0 0-0 
 
0 0-0 
Soft drinks 1 0-39 
 
0 0-45 
 
3 0-41 
 
0 0-10 
 
1 0-39 
 
3 0-47 
Hot beverages 776 557-1070 
 
764 559-1018 
 
776 394-1079 
 
849 575-1139 
 
760 579-1094 
 
679 485-1017 
Alcoholic drinks 38 1-126 
 
4** 0-37 
 
83 3-160 
 
15* 1-45 
 
18 0-115 
 
1*†† 0-17 
Probiotics 0* 0-29 
 
9 0-100 
 
0* 0-50 
 
29 0-100 
 
0 0-22 
 
0 0-100 
Miscellaneous  31 17-58   22** 9-36   26 17-60   17* 7-33   34 20-58   26 11-43 
Values represent median and interquartile ranges (IQR) 
*P≤ 0.01; **P≤0.001: comparisons between males and females within each age category and both age categories combined (Mann-Whitney test) 
†P≤ 0.01; ††P≤0.001: comparisons between age groups within each gender category (Mann-Whitney test) 
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Table 3.  Median daily intake (servings/d) of food  groups among Irish community-dwelling elderly subjects compared to recommended dietary guidelines for elderly 
individuals stratified by age group and gender 
Food groups (servings/d) Recommended 
All ages 
 
64-74 years 
 
≥75 years 
Males (n 94) 
 
Females (n 114) 
 
Males (n 45) 
 
Females (n 57) 
  
Males (n 49) 
 
Females (n 57) 
Median IQR 
 
Median IQR 
 
Median IQR 
 
Median IQR 
 
Median IQR 
 
Median IQR 
Bread,  Cereals & Potatoes  4+ (3+) 4.7 3.8 -6.3 
 
4.5 3.3-5.5 
 
4.4 3.4-5.3 
 
4.2 3.2-5.3 
 
5.0 4.2-6.6 
 
4.6 3.4-5.7 
Fruit & Vegetables 5+ 4.9 3.2-7.1 
 
5.8 4.1-8.5 
 
4.9 3-2-7.1 
 
6.4 4.2-8.7 
 
4.8 3.1-7.4 
 
5.4 3.9-7.4 
Milk, Yogurt and Cheese  3 1.4 0.7-4.2 
 
1.4 0.7-3.6 
 
1.3 0.7-2.3 
 
1.4 0.7-4.1 
 
1.6 1.0-5.0 
 
1.3 0.7-3.5 
Meat, Fish and Alternatives  2 2.1 1.6-2.8 
 
1.8 1.5-2.3 
 
1.9 1.2-2.5 
 
1.7 1.5-2.2 
 
2.1 1.7-2.8 
 
1.9 1.5-2.4 
Foods high in fat and/or 
sugar Sparingly <3 6.6 4.4-9.4 
 
6.2 3.8-8.6 
 
6.2 3.6-9.0 
 
5.2 2.9-7.9 
 
6.9 5.0-10.8 
 
6.5 4.0-8.6 
Values in parentheses for females 
                 Values represent medians and interquartile ranges (IQR)  
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Table 4.  Median daily intakes of macronutrients and alcohol from all sources (including dietary supplements) among Irish community-dwelling elderly subjects stratified by age group 
and gender 
  
All ages   64-74 years   ≥75 years 
Males (n 94) 
 
Females (n 114) 
 
Males (n 45) 
 
Females (n 57) 
  
Males (n 49) 
 
Females (n 57) 
Median IQR   Median IQR   Median IQR   Median IQR   Median IQR   Median IQR 
Energy (kJ) 8440 6981-9725 
 
6991** 5859-8725 
 
7932† 6646-9196 
 
7144 5446-9009 
 
9231 7639-10024 
 
6988** 6023-8508 
Energy (kcal) 2008 1661-2315 
 
1668** 1396-2068 
 
1883† 1580-2187 
 
1701 1288-2139 
 
2194 1815-2389 
 
1666** 1433-2025 
Protein (g) 79.2 67.8-92.7 
 
67.7** 57.6-85.3 
 
77.5 61.5-86.1 
 
67.3 58.6-89.1 
 
83.9 74.6-97.2 
 
68.1** 54.5-80.9 
Fat (g) 77.2 59.4-94.3 
 
64.0 49.4-88.9 
 
70.6 54.8-91.2 
 
63.9 46.5-94.5 
 
80.8 65.1-98.8 
 
64.0* 51.5-81.9 
Saturated fat (g) 30.3 24.4-39.1 
 
25.6 20.2-40.0 
 
27.5 21.9-35.2 
 
25.8 19.1-42.5 
 
33.9 25.6-40.4 
 
25.6* 21.1-38.0 
Carbohydrate (g) 246.4 203.9-293.7 
 
203.6* 174.2-277.0 
 
233.0† 190.8-264.4 
 
200.4 162.7-282.3 
 
265.5 224.1-323.8 
 
211.3** 182.1-263.7 
Total sugar (g) 104.6 80.9-143.7 
 
104.7 77.2-137.5 
 
96.1 73.3-121.3 
 
105.3 77.0-144.0 
 
113.2 89.7-162.5 
 
101.6 75.9-131.7 
NSP ( g) 18.0 13.7-22.6 
 
16.4 12.9-20.4 
 
16.7 12.8-20.2 
 
16.6 14.1-21.2 
 
19.6 14.4-24.0 
 
15.8 11.9-20.4 
Alcohol (g)  3.7 0.2-11.0 
 
0.4** 0.1-3.4 
 
4.4 0.4-13.0 
 
1.6* 0.1-4.2 
 
1.7 0.2-10.8 
 
0.2* 0.1-2.6 
Protein (%TE) 16.0 14.4-17.7 
 
16.2 14.3-18.2 
 
16.0 14.3-18.5 
 
16.9 14.2-18.5 
 
15.7 14.5-17.4 
 
15.7 14.2-17.7 
Fat (%TE) 34.0 31.6-38.1 
 
35.1 31.8-38.9 
 
33.9 31.3-38.2 
 
35.0 31.3-38.8 
 
34.7 31.8-37.7 
 
35.4 32.5-39.0 
Saturated fat (%TE) 14.0 11.9-16.0 
 
15.0 12.3-17.4 
 
12.9 11.9-16.1 
 
14.9 12.0-17.9 
 
14.4 11.6-16.1 
 
15.1 12.5-17.0 
Carbohydrate (%TE) 49.9  45.8-53.9 
 
50.1 47.2-54.3 
 
49.7 45.0-53.6 
 
49.5 47.0-54.3 
 
50.4 46.9-54.5 
 
50.4 47.8-54.3 
Total sugar (%TE) 22.4* 17.2-26.0 
 
24.7 21.6-27.9 
 
21.4* 16.8-25.5 
 
24.7 21.5-28.8 
 
23.5 18.0-26.4 
 
24.7 21.7-27.3 
Alcohol (%TE) 1.5 0.1-4.0   0.2** 0.0-1.6   2.1 0.1-4.9   0.6 0.1-1.9   0.5 0.0-3.8   0.1 0.0-1.0 
NSP, Non-starch polysaccharide (Englyst method); TE, Total Energy 
Values represent medians and interquartile ranges (IQR)  
*P≤ 0.01; **P≤0.001: comparisons between males and females within each age category and both age categories combined (Mann-Whitney test) 
†P≤ 0.01; ††P≤0.001: comparisons between age groups within each gender category (Mann-Whitney test) 
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Table 5.  Median daily intakes of micronutrients from all sources (including dietary supplements) among Irish community-dwelling elderly subjects stratified by age group and gender 
  
 All ages   64-74 years   ≥75 years 
 
Target 
Males (n 94) 
 
Females (n 114) 
 
Males (n 45) 
 
Females (n 57) 
  
Males (n 49) 
 
Females (n 57) 
Median IQR   Median IQR   Median IQR   Median IQR   Median IQR   Median IQR 
Vitamins:  
                 
Vitamin A (µg RE) a 625 (500) 1208.5 801.8-1739.2 
 
1308.6 807.2-1958.7  1105.5 
788.0-
1645.6  1302.8 802.2-1893.7  1324.8 936.3-1839.0  1327.6 759.5-1971.6 
Vitamin D (µg) a 10 5.1 2.8-7.3 
 
4.8 3.0-11.4 
 
5.0 2.8-7.1 
 
5.5 3.4-13.1 
 
5.3 2.8-8.4 
 
4.0 2.6-10.2 
Vitamin E (mg) a 12 29.7 21.8-36.6 
 
28.4 20.9-35.9 
 
29.5 20.5-38.0 
 
29.1 23.0-39.5 
 
30.8 22.2-36.3 
 
26.1 19.7-33.7 
Thiamin (mg) a 1.0 (0.9)  1.9 1.6-2.4 
 
1.7** 1.3-2.2 
 
1.9 1.6-2.2 
 
1.7 1.4-2.3 
 
2.0 1.7-2.5 
 
1.6** 1.2-2.0 
Riboflavin (mg) a 1.1 (0.9)  2.0 1.5-2.8 
 
1.8 1.4-2.9 
 
2.0 1.3-2.4 
 
2.2 1.6-3.2 
 
2.3 1.7-3.1 
 
1.7* 1.4-2.7 
Niacin (mg NE) a 12 (11)  36.4 30.7-42.9 
 
30.7** 25.0-39.6 
 
33.9 30.3-41.7 
 
33.4 25.3-40.7 
 
36.8 31.0-44.3 
 
30.6** 23.4-35.4 
Vitamin B6 (mg) a 1.4 (1.3)  2.7 2.2-3.5 
 
2.6 2.0-3.4 
 
2.6 2.2-3.5 
 
3.0 2.1-4.1 
 
2.7 2.1-3.4 
 
2.4† 1.8-3.0 
Vitamin B12 (µg) a 2.0  6.9 4.5-9.1 
 
6.7 4.7-9.6 
 
6.4 3.8-8.5 
 
7.8 5.2-10.7 
 
7.1 4.6-9.5 
 
6.0 4.0-8.8 
Folate (µg) a 320  375.2 282.5-527.9 
 
358.0 266.7-485.8  363.8 
273.8-
521.2  406.9 297.0-540.5  377.3 290.5-538.0  324.1 253.5-438.6 
Biotin (µg)b 30  49.3 40.0-63.2 
 
45.3 35.0-65.3 
 
47.4 39.0-58.7 
 
47.2 37.9-82.4 
 
50.6 40.5-64.3 
 
44.3 30.2-56.7 
Pantothenate (mg)b 5  7.2 5.8-9.8 
 
6.7 5.2-9.2 
 
7.0 5.2-8.3 
 
7.3 5.8-10.1 
 
7.3 6.1-10.2 
 
6.3* 5.1-8.6 
Vitamin C (mg) a 75 (60)  95.5* 72.1-139.7 
 
115.2 84.3-175.0  92.5 
70.5-
135.5  129.2 87.2-188.6  98.0 72.5-141.5  108.7 84.0-154.7 
Minerals:  
                 
Calcium (mg) a 800/1000
d 
(1000)  1056.2 829.7-1437.0  1272.2 
796.7-
1640.7  900.4**† 
704.7-
1296.9  1415.7 922.5-1747.3  1193.5 945.5-1582.5  1020.9† 774.9-1440.5 
Magnesium (mg) a 350 (265)  318.7 267.7-394.5 
 
305.3 251.6-397.8  307.6 
255.6-
373.8  307.7 255.4-428.8  331.2 280.1-419.0  297.8 223.6-353.6 
Phosphorous (mg) a 580 1461.7 1231.2-1738.2 
 
1336.1 1051.3-1732.5  1365.7† 
1120.9-
1683.6  1331.0 
1099.9-
1786.6  1523.7 1311.2-1803.5  1338.5* 1021.7-1627.2 
Iron (mg)c 7 (6)  13.3 11.7-15.5 
 
11.1** 8.8-14.6 
 
12.6 11.0-15.2 
 
11.6 9.3-15.2 
 
13.9 12.2-16.2 
 
10.9** 8.7-14.3 
Copper (mg) a 0.7 1.3 1.1-1.5 
 
1.1 0.9-1.6 
 
1.2 1.0-1.4 
 
1.2 1.0-1.6 
 
1.3 1.1-1.6 
 
1.1 0.9-1.6 
Zinc (mg) a 9.4 (6.8) 10.5 9.1-13.1   8.9* 7.6-11.9   10.4 7.9-12.8   9.7 7.9-12.3   10.6 9.4-13.4   8.6** 7.5-11.4 
 RE, retinol equivalents; NE, Niacin Equivalents; values in parentheses are for women. a Estimated Average Requirement (EAR) from Institute of Medicine (Institute of Medicine, 2011); b Adequate Intake (AI) from Institute of Medicine (Institute of Medicine, 
2011)  
c
 Estimated Average Requirement (EAR) from Food Safety Authority of Ireland (Flynn et al., 2011); d 800 mg (males  51-70 y); 1000 mg (males  >70 y). Values represent medians and interquartile ranges (IQR) 
*P≤ 0.01; **P≤0.001: comparisons between males and females within each age category and both age categories combined (Mann-Whitney test) 
†P≤ 0.01; ††P≤0.001: comparisons between age groups within each gender category (Mann-Whitney test) 
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Table 6. Median daily intakes of micronutrients per 10 MJ total energy among Irish community-dwelling elderly subjects stratified by age group and gender 
  All ages   64-74 years   ≥ 75 years 
 Males (n 94) 
 
Females (n 114) 
 
Males (n 45) 
 
Females (n 57) 
  
Males (n 49) 
 
Females (n 57) 
Median IQR   Median IQR   Median IQR   Median IQR   Median IQR   Median IQR 
Vitamins:                  
Vitamin A (µg RE) 1416.7* 1071.9-2110.2  1700.9 1217.6-
2448.5 
 1425.4 1094.7-
2197.7 
 1659 1207.8-
2526.4 
 1409.2 998.9-2020.9  1793.7 1259.5-2362.4 
Vitamin D (µg) 5.4 3.6-8.7  6.4 3.9-14.7  5.7 3.7-8.5  6.6 5.2-17.6  5.0 3.6-9.8  5.7 3.7-11.7 
Vitamin E (mg) 33.8 26.3-44.1  37.6 28.8-48.0  38.9 26.1-47.2  39.9 31.2-54.2  33.3 26.2-38.7  35.4 24.3-45.7 
Thiamin (mg) 2.3 2.0-2.7  2.3 2.0-2.7  2.2 2.0-2.7  2.5 2.1-2.9  2.3 2.0-2.6  2.2† 2.0-2.6 
Riboflavin (mg) 2.4 2.0-3.0  2.7 2.2-3.4  2.3* 2.0-2.7  2.9 2.4-4.0  2.5 2.1-3.2  2.5† 2.1-3.2 
Niacin (mg NE) 42.5 37.9-48.8  43.4 37.4-49.4  44.0 39.0-51.3  44.3 40.7-51.5  42.1 37.2-47.1  41.1 36.4-46.5 
Vitamin B6 (mg) 3.3 2.5-4.2  3.6 2.9-4.7  3.5 2.8-4.4  4.2 3.4-5.3  3.1 2.3-3.7  3.1†† 2.6-4.1 
Vitamin B12 (µg) 7.9* 5.9-9.8  9.3 6.9-12.1  8.3* 5.9-10.0  10.8 8.0-13.6  7.8 5.9-9.6  8.2† 6.2-11.2 
Folate (µg) 430.7 357.9-636.8  480.3 372.7-680.2  452.6 361.6-672.9  560.3 446.0-740.0  408.5 352.3-607.1  413.0† 358.2-588.7 
Biotin (µg) 58.1* 49.7-67.2  62.8 54.7-75.8  57.5* 51.6-67.9  70 57.7-89.4  58.5 48.0-66.9  59.9†† 52.1-67.2 
Pantothenate (mg) 8.8* 7.5-10.0  9.6 8.0-11.4  8.8** 7.4-10.0  10.4 8.9-12.5  8.8 7.3-10.1  8.6† 7.7-10.2 
Vitamin C (mg) 116.4** 82.5-164.6  157.5 123.5-244.4  126.7* 82.0-187.3  160.9 121.5-274.4  110.2** 77.8-157.7  151.9 125.1-193.0 
Minerals: 
Calcium (mg) 1241.4** 994.8-1731.5  1580.8 1153.0-
2075.4 
 1142.4** 943.7-1576.8  1831.1 1308.7-
2260.3 
 1325.5 1110.1-1859.2  1359.6† 1064.0-1770.1 
Magnesium (mg) 383.1* 342.7-454.2  426.1 355.0-489.3  373.1* 348.9-458.9  455.6 376.8-516.7  391.5 323.7-451.4  400† 353.1-459.7 
Phosphorous (mg) 1728.1* 1537.7-1960.2  1883.2 1638.0-
2108.9 
 1724.2** 1518.2-
1957.0 
 1982.4 1736.5-
2216.9 
 1759.4 1562.5-1969.2  1764.7 1601.7-2063.5 
Iron (mg) 15.7 14.0-17.8  15.6 13.7-18.4  15.7 14.1-17.3  16.6 14.4-18.5  15.6 14.0-18.5  15.2 13.2-18.1 
Copper (mg) 14.5** 13.4-16.6  16.3 14.2-19.0  14.4* 13.5-15.9  17 14.6-19.3  14.6 12.7-17.0  15.6 13.8-18.5 
Zinc (mg) 12.8 11.1-14.2   12.6 11.3-14.9   13.0 11.3-14.9   13.2 11.8-15.4   12.3 11.1-13.8   12.3 11.0-14.1 
 RE, retinol equivalents; NE, Niacin Equivalents 
Values represent medians and interquartile ranges (IQR)  
*P≤ 0.01; **P≤0.001: comparisons between males and females within each age category and both age categories combined (Mann-Whitney test) 
†P≤ 0.01; ††P≤0.001: comparisons between  age groups within each gender category (Mann-Whitney test) 
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Table 7.  Percentage of Irish community-dwelling elderly subjects with daily micronutrient intakes below the Estimated Average Requirements (EAR), stratified 
by age group and gender 
    All ages   64-74 years   ≥ 75 years 
  Target Males (n 94) Females (n 114)   Males  (n 45) Females (n 57)   Males (n 49) Females (n 57) 
Vitamins: 
         
Vitamin A (RE)a 625 (500) µg 13.8 5.3 
 
11.1 1.8 
 
16.3 8.8 
Vitamin D a 10 µg 81.9 71.9 
 
86.7 70.2 
 
77.6 73.7 
Vitamin E a 12 mg 1.1 5.3 
 
2.2 3.5 
 
0 7.0 
Thiamin a 1.0 (0.9) mg 2.1 0.9 
 
2.2 0 
 
2.0 1.8 
Riboflavin a 1.1 (0.9) mg 5.3 3.5 
 
8.9 1.8 
 
2.0 5.3 
Niacin (NE)a 12 (11) mg 0 0 
 
0 0 
 
0 0 
Vitamin B6 a 1.4 (1.3) mg 1.1 3.5 
 
2.2 0 
 
0 7.0 
Vitamin B12 a 2.0 µg 1.1 1.8 
 
2.2 0 
 
0 3.5 
Folate a 320 µg 36.2 42.1 
 
40.0 35.1 
 
32.7 49.1 
Vitamin C a 75 (60) mg 27.7 7** 
 
28.9 7* 
 
26.5 7.0* 
Minerals: 
         
Calcium a 800/1000c (1000) mg 39.4 36 
 
48.9 26.3 
 
30.6 45.6 
Magnesium a 350 (265) mg 61.7 32.5** 
 
66.7 28.1** 
 
57.1 36.8 
Phosphorous a 580 mg 0 1.8 
 
0 0 
 
0 3.5 
Iron b 7 (6) mg 1.1 2.6 
 
2.2 3.5 
 
0 1.8 
Copper a 0.7 mg 0 0 
 
0 0 
 
0 0 
Zinc a 9.4 (6.8) mg 31.9 14.9* 
 
37.8 8.8** 
 
26.5 21.1 
Values in parentheses are for women; RE, retinol equivalents 
a
 Estimated Average Requirement (EAR) from Institute of Medicine (Institute of Medicine, 2011) 
b
 Estimated Average Requirement (EAR) from Food Safety Authority of Ireland (Flynn et al., 2011) 
c
 800 mg (males  51-70 y); 1000 mg (males  >70 y) 
*P ≤ 0.01; **P ≤ 0.001:  comparisons between males and females within each age category and both age categories combined (Fisher's exact test) 
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1.0  Abstract 
The proportion of elderly people and the average lifespan are both increasing 
worldwide. Ageing is associated with loss of cognitive function and an increased risk of 
dementia which is expected to place growing demands on health and long-term care 
providers. Among multiple causative factors, evidence suggests that cognitive 
impairment in older subjects may be influenced by diet. The objective of this study was 
to examine the association between dietary patterns, dietary glycaemic index (GI) and 
glycaemic load (GL), and cognition in older Irish adults. Two hundred and eight 
community-dwelling subjects (94 males and 114 females; aged 64-93 years) were 
analysed. Dietary intake was assessed using a validated semi-quantitative food 
frequency questionnaire (FFQ). Cognitive capacity was tested using the Mini-Mental 
State Examination (MMSE). Hierarchical clustering was conducted on FFQs to derive 
patterns of dietary intake. Regression models were used to examine the relationship 
between dietary GI and GL, and MMSE score and adjusted for confounding variables. 
Results: Elderly subjects consuming ‘prudent’ dietary patterns (high in fruit, vegetables, 
fish, low-fat dairy, salad dressings and low in red meat and white bread) had higher 
MMSE scores than those consuming ‘Western’ dietary patterns (high in red meat, white 
bread and low in fruit and vegetables; P<0.05). Logistic and Poisson regression 
analyses both indicated that MMSE score was inversely associated with the GI and the 
GL of the diet (P<0.05) even after adjusting for age, gender, diabetes, hypertension, 
healthy food diversity and nutritional status. In conclusion, consumption of a high 
glycaemic diet is associated with poorer cognitive performance in this community-
dwelling elderly Irish cohort. 
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2.0  Introduction 
Recent decades have witnessed a dramatic increase in the life expectancy of elderly 
people worldwide (World Health Organisation/National Institute of Health, 2011). 
However, the number of years an individual can expect to live a healthy life has not 
kept pace (European Joint Action on Healthy Life Years, 2012). This has resulted in an 
increasing proportion of people living with age-related disabilities such as sarcopenia, 
depression and cognitive decline, placing growing demands on health and long-term 
care providers (World Health Organisation/National Institute of Health, 2011). In 2010, 
there were an estimated 35.6 million people over 60 years of age with dementia 
worldwide and estimates suggest that these figures will almost double every 20 years to 
65.7 million by 2030 and 115.4 million by 2050 (Prince et al., 2013).  
Cognitive impairment can lead to significant loss of functional independence and plays 
a major role in overall age-related deterioration (McGuire et al., 2006). Therefore 
maintenance of cognitive function with aging is a current and growing concern. It has 
been proposed that diet may play a fundamental role in slowing the progression of age-
related decline (Allès et al., 2012; Parrott & Greenwood, 2007). Traditionally, studies 
have investigated the effect of single nutrients or foods (e.g. fish, polyunsaturated fatty 
acids, antioxidant micronutrients, and folate) on cognition (Smith & Blumenthal, 2010). 
More recently, much attention has focussed on the associations between dietary patterns 
(which represent a combination of foods) and cognition (Allès et al., 2012).  
Dietary patterns are increasingly used in current nutrition epidemiology. This approach 
is mainly justified by the fact that theoretically, people do not eat isolated nutrients, but 
rather meals composed of a variety of foods, with complex combinations of nutrients 
which may interact (Villegas et al., 2004). There has been a relatively rapid global shift 
in dietary patterns from diets high in complex carbohydrates and fibre, to what has been 
labelled the ‘Western diet’, characterised by high proportion of fat and refined sugars, 
with reduced fruit, vegetable and fibre consumption (Francis & Stevenson, 2013). High 
saturated fat and refined sugar intakes, typical of the modern Western diet, have been 
associated with a number of adverse health conditions, most notably obesity and type 2 
diabetes (T2D) (Kanoski & Davidson, 2011; Steyn et al., 2004; van Dam et al., 2002). 
It has also been proposed that the Western diet may be associated with cognitive 
impairment (Francis & Stevenson, 2013; Kanoski & Davidson, 2011; Torres et al., 
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2012), while a number of studies have shown that healthful dietary patterns 
characterised by high consumption of wholegrain cereals, fruit, vegetables and fresh 
fish may help attenuate age-related cognitive decline in older populations (Akbaraly et 
al., 2009a; Wengreen et al., 2009).  
Recently, much interest has focussed on the effect of dietary glycaemic index (GI) and 
glycaemic load (GL) on health (Brand-Miller et al., 2009). The GI is a measure of the 
quality of dietary carbohydrate and how quickly it is absorbed into the bloodstream 
following consumption. Carbohydrates with a high GI are associated with greater 
fluctuations in blood glucose and insulin concentrations than those with a low GI 
(Foster-Powell et al., 2002). GL reflects both the quality and quantity of the 
carbohydrate and provides a summary measure of the relative glycaemic impact of a 
typical serving of a particular food. Foods with a high GL elicit larger glycaemic and 
insulinemic responses (Barclay et al., 2005).  
High-GI/GL diets have been proposed to contribute to insulin resistance and diabetes 
development by rapidly increasing postprandial glucose and insulin concentrations 
(Dong et al., 2011; Sluijs et al., 2013). In addition, diabetes and insulin resistance have 
been associated with an increased risk of cognitive impairment (Kalmijn et al., 1995; 
Reijmer et al., 2010; Watson & Craft, 2010). However, there is a paucity of research 
investigating the long-term effect of high GI/GL diets on cognitive function in humans. 
It has been shown that in the short-term, consumption of high GI meals resulted in 
postprandial memory impairment in healthy adults (Nabb & Benton, 2006) and 
diabetics (Greenwood et al., 2003; Papanikolaou et al., 2006). Conversely, Luchsinger 
and colleagues found no relationship between calorie-adjusted GL and the risk of 
Alzheimer’s disease in a cohort of elderly subjects (Luchsinger et al., 2007).  
Mounting evidence indicates a role for nutrition-related factors in lowered loss of 
function decline during brain aging. It is still unknown what, if any, relationships exist 
between dietary GI/GL in the elderly and cognitive function. The present study was 
based on the hypothesis that cognitive decline in non-diabetic elderly subjects is 
associated with a Western dietary pattern and a high glycaemic diet. The objective of 
this study was therefore to examine the association of dietary patterns, dietary GI and 
GL with cognition in an elderly population group.  
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3.0  Materials and Methods 
3.1 Study Participants 
The study population comprised a sub-set of self-selected, community-dwelling 
ELDERMET project participants (n 208; 94 males, 114 females; 64-93 years), who 
responded to advertising in local health-care and general practice centres, active 
retirement groups and events, information sessions and local media from the Cork city 
and county region of southern Ireland. Community-dwelling, day-hospital attendees, 
were also included in the present study. Eligible candidates were community-dwellers 
(i.e. not in residential care such as nursing homes/long-term care facilities), aged 64 
years and older and in any stage of health. Exclusion criteria included history of 
alcoholism, participation in investigational medication trials in the previous month and 
advanced organic disease (precluding longitudinal follow-up). Two subjects were 
excluded from the analyses due to unrealistic reported values for daily energy intakes 
(>4000 kcal).  
3.2 Ethical Considerations 
Written informed consent was obtained from all subjects, in accordance with local 
Clinical Research Ethics Committee of the Cork Teaching Hospitals. This study 
complies with the guidelines set out in the Declaration of Helsinki and those of the Cork 
Research Ethics Committee, Ireland.  
3.3 Data Collection 
The Mini-Mental State Examination (MMSE) (Folstein et al., 1975) was used to assess 
cognitive function. This test covers various aspects of cognitive function, including 
orientation to time and place, naming, repeating, writing, copying, instantaneous recall, 
short-term memory, backward spelling. Demographic characteristics of participants 
including age, gender, body mass index (BMI), diabetes mellitus, hypertension, 
depression and smoking status were used as covariates in this data analysis. BMI was 
calculated as weight (kg)/height (m2). The Mini Nutritional Assessment (MNA) was 
used to identify subjects at risk of malnutrition (Vellas et al., 1999). 
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3.4 Dietary data 
Dietary data were collected by means of a semi-quantitative food frequency 
questionnaire (FFQ) administered by trained research nursing personnel. The FFQ was 
an amended version of that used by the European Prospective Investigation into Cancer 
(EPIC) study (Riboli & Kaaks, 1997) and validated for use in the Irish population 
(Harrington et al., 2008). The questionnaire assessed habitual dietary intakes of 147 
single food items/beverages. The frequency of intake was measured using ten categories 
ranging from ‘never’ to ‘six times a day or more’. In order to estimate the number of 
servings from each food group consumed on a daily basis, each frequency option in the 
FFQ was converted to a single daily serving. Recently derived, population-based, 
gender-specific portion sizes for community-dwelling elderly subjects (65-75 yrs and 
≥75 yrs) were applied to each FFQ item (Wrieden & Barton, 2006). A nutrient 
composition database was established for the ELDERMET FFQ using information 
compiled from the UK Food Standards Agency (FSA) nutrient databank (Food 
Standards Agency, 2002), with additional information from the Irish Food Consumption 
database (Black et al., 2011) and manufacturers’ information. The FSA food 
compositional databank was the primary nutrient data source used. This information 
was used to calculate mean daily nutrient (carbohydrate) intakes.  In order to assess diet 
quality, a healthy food diversity (HFD) index was calculated for each subject as 
outlined previously (Claesson et al., 2012; Drescher et al., 2007). Higher values of a 
HFD reflect a healthier, more diverse diet. 
GI values (glucose referenced) were assigned to all FFQ items from the International 
Table of Glycemic Index (Atkinson et al., 2008). An average GI value was assigned to 
FFQ items consisting of multiple food types (e.g. the ‘white bread’ category, which 
includes rolls, panini and ciabattas) based on the median of a range of appropriate foods.  
In cases where a GI value was not available for a particular food item, values for the 
most similar food type were assigned. Foods with a low carbohydrate content (e.g. 
meats, fish, fats), with no corresponding GI value were assigned a default value of 50, 
as previously described (Flood et al., 2006). The sum total GL of each subject’s daily 
diet was calculated by multiplying the daily carbohydrate intake (g) (from each FFQ 
item) by the GI value. The GI of each individual’s diet was then calculated by dividing 
GL by the total carbohydrate intake, as described previously (Burger et al., 2011).  GI 
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and GL values were adjusted for energy intakes by dividing absolute GI/GL by total 
energy intake (kcal) and amounts expressed per 2000 kcal, as described previously 
(Livesey et al., 2013)  
3.5 Identification of dietary patterns 
Hierarchical clustering with Euclidean distance and Ward’s linkage was conducted 
using the logged number of daily servings reported from each food/beverage item on the 
FFQ. The tree was cut at an appropriate height to provide 5 clusters. 
3.6 Statistical Methods 
Statistical analyses were performed using R (version 2.13.2) and SPSSTM (version 18, 
Chicago, IL, USA) software packages. Differences between means and medians were 
evaluated using the Independent-samples t-test/one-way analysis of variance (ANOVA) 
and the Mann Whitney/Kruskal Wallis test, as appropriate.  Differences between 
categorical distributions were evaluated using chi-square test or Fisher’s exact test.  
Logistic and Poisson regression were used to examine the relation between GI and GL 
with MMSE score. These models included adjustments for age (continuously, in 1 year 
increments), sex (male, female), diabetes mellitus (no, yes; medically diagnosed), 
healthy food diversity (HFD; continuously, in 0.01 point increments), hypertension (no, 
yes; medically diagnosed) smoking (never, former, current), BMI (continuously, in 
1kg/m2 increments) and the Mini Nutritional Assessment (MNA; continuously in 1 
point increments).  For Poisson regression, the number of MMSE errors (30 – x; where 
x is the MMSE score of the patient and 30 is the maximum MMSE score) was used to 
generate a Poisson distribution of increasing cognitive decline. For logistic regression 
analyses, two different cut-off points were used to define cognitive impairment, the 
clinical threshold of less than 24 and the optimal threshold of less than 28, as defined by 
O’Bryant et al. (2008). They showed that the clinical MMSE cut-score of 24 yielded a 
moderate estimate of sensitivity with a high specificity for defining cognitive 
impairment in the clinical setting (O'Bryant et al., 2008). However, the optimal cut-off 
score of 28 was found to yield a much better balance of sensitivity and specificity 
(O'Bryant et al., 2008). For both regression models, a regression coefficient (RC) was 
calculated per one unit increase in standard deviation (SD), where appropriate. For 
logistic regression, the odds ratio associated with each explanatory variable was 
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calculated as the exponential function of the regression coefficient (eRC). For Poisson 
regression, the incidence rate ratio associated with each explanatory variable was 
calculated as the exponential function of the regression coefficient (eRC). A P value of 
<0.05 was considered as statistically significant.  
4.0  Results 
Selected demographic and anthropometric characteristics of study participants are 
shown in Table 1. The mean age of the sample was 75 years. Women had a lower body 
weight and shorter stature than men. The mean BMI was 28 kg/m2 with the majority of 
subjects having a BMI greater than 25. Based on the MNA, the majority of subjects 
were classified as having an adequate nutritional status (MNA≥24). A very low 
proportion (6%) of subjects were current smokers, while just under half (47%) of 
subjects were former smokers. The mean MMSE score was 27 with 8.2% and 39.4% of 
subjects being classified as clinically cognitively impaired (MMSE<24) and mildly 
cognitively impaired (MMSE<28), respectively. Just under half (40%) of subjects had 
hypertension, while 11% of subjects were diagnosed as diabetics.  
We identified 5 groups in this population based on hierarchical cluster analyses (Fig. 1). 
A total of 60 subjects (29%) were in cluster 1, 44 (21 %) in cluster 2, 34 (16%) in 
cluster 3, 51 (25%) in cluster 4 and 19 (9%) in cluster 5. Median food group 
consumption (servings/day) for each cluster is shown in Table 2. Meat products, 
chicken, eggs, potatoes/chips, dairy spreads, alcohol, brown bread and miscellaneous 
food items (jams, sauces etc.) were consumed at similar levels across all five clusters 
(P>0.05). Clusters 1 and 2 were characterised by high intakes of red meat, white bread 
and low intakes of fruit and vegetables, with cluster 2 having the highest intakes of 
desserts/sweets, high fat dairy and soft drinks across all five clusters. As cluster 1 had 
lower intakes of desserts/sweets, high fat dairy and soft drinks relative to cluster 2, these 
clusters were labelled the ‘low-fat Western’ and ‘Western’ dietary patterns, 
respectively. Cluster 3 was characterised by high intakes of red meat, butter, fresh soups 
and moderate-high intakes of fruit and vegetables, salad dressings, desserts/sweets and 
white bread. This cluster was labelled the ‘traditional Irish’ dietary pattern. Clusters 4 
and 5 had the highest intakes of fruit and vegetables, salad dressings, fresh fish, 
probiotics, pasta/rice, low-fat dairy and the lowest intakes of red meat and white bread 
across all five clusters. However, as cluster 4 had lower intakes of butter, salad 
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dressings, desserts/sweets and high fat dairy relative to cluster 5, these clusters were 
labelled the ‘low-fat prudent’ and ‘prudent’ dietary pattern, respectively.  
There was a significant difference in the HFD score, GI and GL across all dietary 
patterns (Fig. 2), with the ‘Western’ dietary patterns having a lower HFD score and a 
higher GI and GL than the ‘prudent’ dietary patterns (P<0.05). There was no significant 
difference in MNA score between the clusters (data not shown; P>0.05). Elderly 
subjects consuming the ‘prudent’ dietary patterns had a higher MMSE score than those 
consuming the ‘Western’ dietary patterns (P<0.05), indicating better cognitive function 
(Fig. 2). 
Results of the multivariable-adjusted Poisson regression models that tested associations 
between GI, GL and cognitive function (number of MMSE errors) are shown in Table 
3. After controlling for potential confounders (age, gender, diabetes, HFD, hypertension 
and MNA), statistically significant associations were observed between GI/GL of the 
diet and the number of MMSE errors (P<0.05), indicative of cognitive decline. Indeed, 
for every one unit increase in glycaemic index, the incident rate for the number of 
MMSE errors increased 1.03 times (by 3%), while for every one unit increase in 
glycaemic load, the incident rate for the number of MMSE errors increased 1.01 times 
(by 1%). Furthermore, age, hypertension and diabetes were also associated with the 
number of MMSE errors (P<0.05), indicative of cognitive decline, while MNA score 
was inversely associated with the number of MMSE errors. Further adjustments for 
body mass index (BMI) and smoking did not effect these results (data not shown). 
Results of the multivariable-adjusted logistic regression models that tested associations 
between GI, GL and mild cognitive impairment, and clinically significant cognitive 
impairment (MMSE <28 and MMSE < 24, respectively) are shown in Table 4 and Table 
5. Using the MMSE score cut-off point of 28, there was a significant association 
between GI (P<0.05) and GL (P<0.01) with mild cognitive impairment (Table 4). 
Increasing the glycaemic index by one unit increased the odds of being cognitively 
impaired by a factor of 1.10 (by 10%), while increasing the glycaemic load by one unit 
increases the odds of being cognitively impaired by a factor of 1.03 (by 3%). Age and 
diabetes were positively associated with cognitive impairment, while MNA score was 
inversely associated with cognitive impairment in this elderly group (P<0.05). Using the 
MMSE cut-off point of 24, there was a significant association between GL (P<0.05) and 
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clinically significant cognitive impairment but other covariates failed to show 
significance, despite known associations (Table 5).  
5.0  Discussion 
In this cross-sectional study of elderly Irish men and women we defined five dietary 
patterns which were associated with divergent food intakes: a ‘Western’ diet, a ‘low-fat 
Western’ diet, a ‘traditional Irish’ diet, a ‘prudent’ diet and a ‘low-fat prudent’ diet. The 
dietary patterns identified in this study show similarity to those identified in other 
elderly cohorts (Hamer et al., 2010; Ledikwe et al., 2004; Pryer et al., 2001) and a 
cohort of middle-aged Irish adults (Villegas et al., 2004). Similar to the ‘traditional 
Irish’ and the ‘Western’ dietary patterns identified in the present study, Villegas et al. 
(2004) identified a ‘traditional’ diet having high intakes of beverages (non-alcoholic), 
white bread and refined cereals, butter, whole milk and dairy products, desserts and 
sweets, and the lowest intakes of fish and alcohol. They also identified a ‘prudent’ diet, 
characterised by high intakes of pasta, rice, brown breads, unrefined cereals, poultry, 
fish, low-fat dairy, salad dressings, fruit and vegetables, and by low intakes of chips, 
white bread, refined cereals, butter, high-fat dairy, meat, meat products and sweets. 
Unlike the findings of Villegas et al. the present study did not identify an ‘alcohol and 
convenience foods’ dietary pattern.   
The ‘Western’ dietary patterns in the present study had a lower HFD score and had a 
higher GI and GL compared to the ‘prudent’ dietary patterns. Moreover, subjects 
consuming the ‘prudent’ dietary pattern had higher MMSE scores, indicating better 
cognitive function compared to subjects consuming a ‘Western’ diet. In agreement with 
the present study, a number of studies have reported that healthy dietary patterns (with 
higher intakes of fruit, vegetables, fish, nuts and legumes and lower intakes of meats, 
high-fat dairy and sweets) are associated with better cognitive function (Akbaraly et al., 
2009b; Gu & Scarmeas, 2011; Scarmeas et al., 2006) while Western dietary patterns 
(with higher intakes of meat, high fat dairy, desserts/sweets, refined cereals and lower 
intakes of fruit and vegetables) are associated with poorer cognitive function (Francis & 
Stevenson, 2013; Kanoski & Davidson, 2011; Torres et al., 2012). Scarmeas et al. 
(2006) reported that higher adherence to the Mediterranean diet (high in fruit, 
vegetables, cereals, legumes, fish, olive oil and low in meat, poultry and saturated fats) 
was associated with a decreased risk of cognitive decline and Alzheimer’s disease in a 
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non-demented, multiethnic cohort of elderly subjects. These results were supported by 
data of Akbaraly et al. (2009b) who showed that a diet rich in fruit, vegetables and fish 
was associated with lower odds of cognitive deficit, while greater odds of cognitive 
deficit were associated with a diet rich in processed meat, chocolate, desserts, fried 
food, refined grains and high fat dairy products in a middle-aged cohort. Similarly, 
Torres et al. (2012) found that a higher intake of processed foods (desserts, biscuits, 
potatoes, refined grains, fried foods, high fat dairy, snacks, high fat takeaway, chocolate 
and sweets, processed meat and fish, sugar beverages and red meat) was associated with 
reduced memory and impaired executive function in a group of older people with mild 
cognitive impairment. 
Initial analysis of the data showed a strong significant association between cognitive 
function and the HFD of the diet (data not shown). However, after further adjustment, 
and when nutritional status was taken into account, the HFD of the diet failed to reach 
significance in all but one statistical model. This result demonstrates the importance of 
adequate nutrition for the maintenance of cognitive health and suggests that the 
association between healthy dietary patterns and cognition may not be as significant as 
previously reported, due to the strong association between nutritional status and 
cognitive function. 
GI and GL were inversely associated with cognitive function in this elderly Irish 
population group; this association remained significant after adjustment for a large 
number of co-factors using both logistic and Poisson regression. To the best of our 
knowledge, this is the first study to directly examine the relationship between GI/GL 
and cognitive function in the elderly. The results of this study are supported by several 
other studies which have found associations between insulin resistance (Neumann et al., 
2008; Zhong et al., 2012), blood glucose levels (Crane et al., 2013; Ravona-Springer et 
al., 2012) impaired glucose tolerance (Lamport et al., 2009) and diabetes (Gregg et al., 
2000; Strachan et al., 2011), and cognitive function in the elderly. A previous 
prospective study found that glycaemic load was not associated with increased risk of 
Alzheimer’s disease (Luchsinger et al., 2007). 
The results of the present study may be explained by a number of hypotheses, including 
hyperglycemia and hyperinsulinemia. It is well established that high GI diets lead to 
increased blood glucose levels (Ludwig, 2002). Crane and colleagues found that higher 
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glucose levels were associated with an increased risk of dementia in populations with 
and without diabetes (Crane et al., 2013). The brain uses glucose, almost exclusively, as 
its source of energy, thus making glucose regulation central to brain function (Kimura, 
2003). A rodent study previously showed a lack of protective adaptation of the blood 
brain barrier to limit glucose transfer into the brain (Jacob et al., 2002). Therefore the 
brain tissue can potentially be exposed to elevated glucose levels, possibly leading to 
tissue damage, including brain lesions (Trone et al., 2009) which have been shown to 
play a role in the development of cognitive impairments in elderly subjects (Frisoni et 
al., 2007). High GI diets are also known to lead to hyperinsulinemia (Ludwig, 2002) 
which is associated with decreased cognitive function and dementia in healthy elderly 
subjects (Kalmijn et al., 1995; Zhong et al., 2012). Insulin secreted by the pancreas can 
cross the blood-brain barrier where it can exert region-specific effects on glucose 
metabolism (Neumann et al., 2008). Results from human and animal studies suggest 
that insulin may also have a direct effect on the brain and cognition (Gispen & Biessels, 
2000; Ott et al., 2012). Neurotransmitter release, neuronal-outgrowth, neuronal survival 
and synaptic plasticity are all directly modulated by insulin and therefore, 
hyperinsulinemia may have a detrimental effect on the function and survival of neurons 
(Neumann et al., 2008).  
In line with previous findings (Gregg et al., 2000; Saka et al., 2010; Strachan et al., 
2011; Waldstein, 2003), this study supports an association between cognitive function 
and other factors, namely age, hypertension, diabetes and nutritional status. The present 
study has several methodological strengths, one of which is the availability of extensive 
adjustment data. Careful control for potential confounders is important in an 
observational setting to limit biases that may arise, since biological and other medical 
characteristics may influence both dietary intake and cognitive function. Indeed the 
association between GI/GL and cognitive function remained significant after controlling 
for age, gender, diabetes, hypertension, HFD, smoking MNA and BMI. Although a 
number of subjects in the present study were classified as cognitively impaired using the 
standard MMSE cut score of 24, a much larger proportion had mild cognitive 
impairment as defined by a MMSE score of 28. While the MMSE cut-score of 24 is 
useful in a clinical setting due to its high specificity, it has a very low sensitivity score. 
A previous study has found that a MMSE cut-off score of 28 has an improved balance 
of specificity and sensitivity (O'Bryant et al., 2008).  
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In conclusion, the present results suggest that the GI/GL of the diet is inversely 
associated with cognitive performance in the elderly and may partly explain the 
relationship between the ‘Western’ dietary pattern and cognitive impairment which has 
been highlighted in this and previous studies (Francis & Stevenson, 2013; Kanoski & 
Davidson, 2011; Torres et al., 2012). The results of this cross-sectional study generate a 
new hypothesis and contribute to a better understanding of the link between nutrition 
and cognition. Additional prospective investigations, intervention and mechanistic 
studies are needed in order to establish a relationship between a low GI/GL diet and 
cognitive decline in the elderly, to elucidate the underlying biological mechanisms. 
Given the prevalence and clinical significance of dementia, associations between the 
GI/GL of the diet and cognitive function could have considerable clinical and public 
health relevance and warrant further investigation.  
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Table 1.  Descriptive characteristics of the study’s participants (n 208) by gender 
Characteristics Males (n 94) 
 
Females (n 114) 
 Mean SD   Mean SD 
Age (yrs) 75.4 6.5  74.8 6.7 
Weight (kg) 83.2 14.3  69.3*** 15.1 
Height (cm) 170.4 7.2  158.5*** 5.1 
BMI (kg/m2) 28.5 4.1  27.6 6.1 
BMI categories (%)      
Underweight (<18.5) 1   2  
Normal (18.5-24.9) 18   32  
Overweight (25-29.9) 45   34  
Obese (≥30) 36   32  
MNA score (0, 30) 26.0 2.0  25.8 2.2 
Nutritional status (%)      
Normal Nutritional Status (MNA ≥24) 90   87  
At risk of malnutrition (MNA 17-23.5) 10   13  
Malnourished (MNA<17) 0   0  
Smoking status (%)      
Never  41   52  
Former smoker  54   42  
Current   5   6  
MMSE score (0, 30) 27.4 2.7  27.5 2.8 
Cognitive Impairment (%)      
MMSE <24 7.5   8.8  
MMSE <28 39.4   39.5  
HFD score  0.41 0.10  0.42 0.09 
Diabetics (%) 15   8  
Insulin-dependent 2.1   0.9  
Non-insulin dependent 12.8   7.0  
Hypertension (%) 43   39  
Glycaemic Index (per 2000kcal) 58.99 4.06  57.04*** 3.72 
Glycaemic Load (per 2000kcal) 146.78 20.15  142.42 18.34 
Values represent mean and standard deviation (SD) or percentages (%) 
BMI, body mass index; HFD, healthy food diversity; MMSE, mini-mental state examination; MNA, mini-nutritional assessment 
 ***P ≤ 0.001: comparisons between males and females (Independent-samples t test). 
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Table 2.  Food group intakes (servings/d) by dietary pattern clusters 
Food group Cluster 1 ‘Low-fat Western’ 
 
Cluster 2 ‘Western’ 
 Cluster 3 ‘Traditional 
Irish’ 
 Cluster 4 ‘Low-fat 
prudent’ 
 
Cluster 5 ‘Prudent 
P value 
  Median IQR  Median IQR  Median IQR  Median IQR  Median IQR 
High consumption foods 
  
 
  
 
  
 
  
 
   
Red meat 0.61 0.44- 0.86  0.70 0.45-0.87  0.70 0.51-1.03  0.43 0.24-0.64  0.40 0.23-0.70 0.000 
Fish 0.15 0.02-0.28  0.15 0.04-0.28  0.19 0.14-0.31  0.29 0.18-0.46  0.44 0.15-0.57 0.000 
Fruit 2.23 1.18- 3.46  1.41 0.39-2.81  2.79 1.92-4.20  3.30 1.71-4.58  3.42 2.06-4.39 0.000 
Vegetables 2.13 1.48-3.64  1.98 1.61-2.58  3.85 2.89-6.14  3.60 2.48-5.28  4.35 2.76-6.67 0.000 
Butter 0.00 0.00-1.01  0.29 0.00-2.00  1.00 0.01-2.00  0.00 0.00-1.00  0.29 0.00-2.00 0.009 
High fat dairy 0.30 0.02-1.01  1.23 0.58-2.89  0.73 0.15-2.08  0.72 0.14-1.29  1.06 0.61-2.86 0.000 
Low fat dairy 0.01 0.00-1.01  0.00 0.00-0.71  0.03 0.00-1.00  0.29 0.00-1.14  0.32 0.00-2.58 0.046 
Desserts/sweets 1.64 0.63-3.15  4.82 3.10-9.11  3.43 1.74-5.81  1.14 0.38-2.21  3.00 1.25-4.31 0.000 
White bread 0.79 0.04-2.02  1.03 0.30-2.08  0.48 0.17-2.04  0.10 0.03-0.30  0.49 0.29-1.14 0.000 
Wholegrain breakfast cereals 1.00 0.00-1.00  1.00 0.04-1.00  1.00 0.11-1.00  1.00 1.00-1.00  1.00 0.71-1.30 0.046 
Low consumption foods 
  
 
  
 
  
 
  
 
   
Chicken products 0.00 0.00- 0.01  0.00 0.00-0.03  0.00 0.00-0.01  0.00 0.00-0.00  0.00 0.00-0.03 0.009 
Fish products 0.03 0.00-0.14  0.01 0.00-0.03  0.03 0.01-0.14  0.00 0.00-0.01  0.01 0.00-0.14 0.000 
Soft drinks 0.01 0.00-0.29  0.14 0.00-0.93  0.01 0.00-0.29  0.00 0.00-0.02  0.02 0.00-0.15 0.005 
Savoury snacks 0.00 0.00-0.02  0.00 0.00-0.00  0.01 0.00-0.03  0.00 0.00-0.02  0.17 0.03-0.58 0.017 
Refined grain breakfast cereals 0.00 0.00-0.29  0.00 0.00-0.00  0.00 0.00-0.00  0.00 0.00-0.00  0.00 0.00-0.01 0.031 
Pasta/rice 0.01 0.00-0.05  0.00 0.00-0.03  0.03 0.01-0.14  0.06 0.02-0.17  0.34 0.20-0.57 0.000 
Salad dressing 0.01 0.00-0.15  0.04 0.00-0.29  0.10 0.01-0.30  0.15 0.03-0.29  0.31 0.21-0.61 0.000 
Processed  soups 0.03 0.00-0.29  0.02 0.00-0.25  0.01 0.00-0.14  0.00 0.00-0.03  0.01 0.00-0.28 0.023 
Ready meals 0.01 0.00-0.04  0.01 0.00-0.03  0.02 0.01-0.09  0.01 0.00-0.06  0.07 0.03-0.16 0.005 
Fresh Soups 0.00 0.00-0.06  0.10 0.00-0.29  0.29 0.12-0.73  0.14 0.00-0.29  0.14 0.00-0.29 0.000 
Probiotics 0.00 0.00-1.00  0.00 0.00-0.03  0.03 0.00-0.71  0.14 0.00-1.00  0.71 0.14-1.00 0.003 
Values represent median and interquartile ranges (IQR).  Differences between dietary patterns were evaluated using the Kruskal Wallis test. Other food groups analysed incl. meat products, chicken, eggs, potatoes, chips, dairy spreads, alcohol, brown 
bread and miscellaneous food items (jams, sauces etc) showed no significant difference (P>0.05) in intakes between the dietary pattern clusters and were excluded from the table 
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Table 3.  Poisson regression tests of associations between A) dietary glycaemic index and B) dietary 
glycaemic load (adjusted to 2000kcal) with MMSE score (adjusted for age, gender, diabetes HFD, 
hypertension and MNA score) 
  
Parameters Regression Coefficient RC x SD e
RC
 
Std. 
Error Z-value P-value 
A) Intercept -0.37 
 
0.69 1.11 -0.34 ns 
Glycaemic index 0.03 0.11 1.03 0.01 2.39 0.017 
Age 0.03 0.19 1.03 0.01 4.33 0.000 
Gender (female) 0.13 
 
1.14 0.09 1.40 ns 
Diabetes 0.48 
 
1.61 0.12 4.06 0.000 
Hypertension 0.24 
 
1.27 0.10 2.44 0.015 
HFD -0.81 -0.08 0.44 0.51 -1.59 ns 
MNA -0.09 -0.19 0.91 0.02 -4.78 0.000 
  
 
   
B) Intercept 0.20 
 
1.22 0.84 0.24 ns 
Glycaemic load 0.01 0.17 1.01 0.00 3.87 0.000 
Age 0.03 0.18 1.03 0.01 4.10 0.000 
Gender (female) 0.11 
 
1.12 0.09 1.28 ns 
Diabetes 0.47 
 
1.61 0.12 4.06 0.000 
Hypertension 0.22 
 
1.24 0.10 2.17 0.030 
HFD -0.99 -0.09 0.37 0.49 -2.03 0.042 
  
MNA -0.09 -0.19 0.91 0.02 -4.81 0.000 
Regression coefficients (RC) indicate the relative magnitude and direction of the association; A positive RC indicates that the explanatory variable is 
associated with an increase in MMSE errors, while a negative RC indicates that the explanatory variable is associated with fewer MMSE errors. HFD, 
healthy food diversity; MNA, Mini Nutritional Assessment; ns, non-significant (P>0.05); RC x SD, regression coefficient per increase with one 
standard deviation; eRC, exponentiated regression coefficient. 
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Table 4.  Logistic regression tests of associations between A) dietary glycaemic index and B) dietary 
glycaemic load (adjusted to 2000kcal) with cognitive impairment (MMSE score<28), adjusted for age, 
gender, diabetes, HFD hypertension and MNA score 
 
Parameters Regression Coefficient RC x SD 
eRC 
 
Std. 
Error Z-value P-value 
A) Intercept -5.92 
 
0.00 4.07 -1.45 ns 
 
Glycaemic index 0.09 0.37 1.10 0.04 2.15 0.032 
 
Age 0.06 0.39 1.06 0.02 2.43 0.015 
 
Gender (female) 0.28 
 
1.33 0.32 0.89 ns 
 
Diabetes 1.13 
 
3.11 0.51 2.23 0.026 
 
Hypertension -0.15 
 
0.86 0.35 -0.44 ns 
 
HFD 0.57 0.05 1.77 1.80 0.32 ns 
 
MNA -0.18 -0.37 0.84 0.08 -2.36 0.019 
   
 
 
   
B) Intercept -3.56 
 
0.03 3.15 -1.13 ns 
 
Glycaemic load 0.03 0.50 1.03 0.01 2.93 0.003 
 
Age 0.05 0.36 1.06 0.02 2.23 0.026 
 
Gender (female) 0.23 
 
1.26 0.32 0.72 ns 
 
Diabetes 1.19 
 
3.30 0.51 2.34 0.019 
 
Hypertension -0.05 
 
0.96 0.36 -0.13 ns 
 
HFD -0.20 -0.02 0.82 1.73 -0.12 ns 
 
MNA -0.19 -0.39 0.83 0.08 -2.42 0.015 
Regression coefficients indicate the relative magnitude and direction of the association; HFD, healthy food diversity; MNA, Mini Nutritional 
Assessment; ns, non-significant (P>0.05); eRC, exponentiated regression coefficient; RC x SD, regression coefficient per increase with one standard 
deviation
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Table 5.  Logistic regression tests of associations between A) dietary glycaemic index and B) dietary 
glycaemic load (adjusted to 2000kcal) with cognitive impairment (MMSE score<24), adjusted for age, 
gender, diabetes, HFD hypertension and MNA score) 
 
Parameters Regression Coefficient RC x SD e
RC
 
Std. 
Error Z-value P-value 
A) Intercept -6.54 
 
0.00 6.81 -0.96 ns 
Glycaemic index 0.09 0.36 1.10 0.07 1.26 ns 
Age 0.06 0.42 1.07 0.04 1.49 ns 
Gender (female) 0.50 
 
1.65 0.58 0.87 ns 
Diabetes 1.07 
 
2.91 0.66 1.61 ns 
Hypertension -0.85 
 
0.43 0.60 -1.42 ns 
HFD -3.35 -0.31 0.04 3.28 -1.02 ns 
MNA -0.19 -0.39 0.83 0.12 -1.60 ns 
 
 
B) Intercept -6.44 
 
0.00 5.19 -1.24 ns 
Glycaemic load 0.04 0.75 1.04 0.02 2.53 0.01 
Age 0.06 0.42 1.07 0.04 1.49 ns 
Gender (female) 0.52 
 
1.68 0.58 0.90 ns 
Diabetes 1.14 
 
3.13 0.68 1.69 0.09 
Hypertension -0.86 
 
0.42 0.62 -1.39 ns 
HFD -3.60 -0.34 0.03 3.12 -1.16 ns 
  
MNA -0.20 -0.43 0.81 0.12 -1.70 0.09 
Regression coefficients indicate the relative magnitude and direction of the association; HFD, healthy food diversity; MNA, Mini Nutritional 
Assessment; ns, non-significant (P>0.05); eRC, exponentiated regression coefficient; RC x SD, regression coefficient per increase with one standard 
deviation 
 
 
  
Figure 1.  Five dietary clusters revealed through h
and Ward’s linkage. Cluster 1
Irish’= green; Cluster 4
hierarchical tree are circled.
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ierarchical clustering with Euclidean distance metric 
 ‘low-fat Western =red; Cluster 2 ‘Western’= blue; Cluster 3
 ‘low-fat prudent’ =brown; Cluster 5 ‘prudent’= magenta
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Figure 2.  Comparison of glycaemic index, glycaemic load, healthy food diversity and MMSE score, 
between dietary pattern clusters (1=low-fat Western; 2=Western; 3=traditional Irish; 4=low-fat prudent; 
5=prudent). P value refers to the Kruskal-Wallis test performed across all five dietary pattern clusters. 
The Mann-Whitney test was performed for each pair-wise comparison. Open circles indicate outliers. 
*P≤0.05; ** P≤0.01; ***P≤0.001 
 
1 
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1.0  Abstract 
It is well recognised that certain therapeutic microbes, including Bifidobacterium 
longum subsp. infantis 35624, exert health benefits on the host. A number of different 
mechanisms by which they are proposed to improve health have been reported, 
including modulation of the host’s immune response. An area of ongoing debate is 
whether non-viable forms of probiotic strains have a role to play in conferring benefits 
to the host by influencing the host’s immune system. This study investigated the effect 
of both ‘viable’ and ‘non-viable’ Bifidobacterium strains in fermented milk products on 
the release of the cytokines IL-10 and TNF-α from peripheral blood mononuclear cells 
(PBMCs) in vitro. B. infantis 35624, B. breve UCC2003, B. longum 0103 and B. longum 
0106, were grown in a fortified whole-milk preparation and subjected to a number of 
lethal treatments (heat treatment, high pressure treatment and storage at low pH) in 
order to render the bacterial cells non-culturable. Freshly isolated PBMCs were then 
cultured in the presence of the lyophilised Bifidobacterium-fermented milk (BFM) 
(containing either ‘viable’ or ‘non-viable’ bifidobacteria) at different concentrations. 
The results show that BFM induces a strain-specific immune response in the PBMC 
assay. Furthermore, it was found the BFM could induce IL-10 and TNF-α production 
even after bifidobacterial cells were rendered non-culturable. However, the method used 
for killing the cells was found to play a significant role in the immune response, with 
extended storage at 4ºC being the best method for killing cells while maintaining 
immunomodulatory activity. This indicates that although the product is 
microbiologically inactive (contains no culturable cells), it may still be able to induce 
immunological effects and may therefore have beneficial applications in human health.  
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2.0  Introduction 
Probiotics are defined as live microorganisms which when administered in adequate 
amounts confer health benefits to the host (FAO/WHO, 2002). The most extensively 
studied and commonly used probiotic organisms are lactobacilli and bifidobacteria 
(Lammers et al., 2003; Senok et al., 2005) and dairy products are one of the main food 
vectors presently used for their delivery (Rivera-Espinoza & Gallardo-Navarro, 2010). 
Nowadays, the medical, health and commercial importance of probiotic products is well 
recognised and consequently, many products of this kind are available for consumption 
by both humans and animals. Indeed, the global market for probiotic products was 
estimated at $24.2 billion in 2011 and is expected to grow to $36.0 billion in 2017 
(MarketsandMarkets, 2013).  
Probiotics have been shown to play a role in the prevention and treatment of various 
diarrhoeal conditions as well as inflammatory diseases of the gastrointestinal tract (GIT) 
(Quigley, 2010; Sanders et al., 2013). Certain therapeutic microbes have been shown to 
be effective in the relief of symptoms caused by inflammatory bowel disease (IBD) and 
irritable bowel syndrome (IBS) (Quigley, 2007; Sanders et al., 2013). Bifidobacterium 
longum subsp. infantis 35624 (B. infantis 35624) is a commercial probiotic strain with 
well known anti-inflammatory properties (McCarthy et al., 2003; O'Mahony et al., 
2008) and has been reported, in two separate studies, to relieve many of the most 
troublesome symptoms of IBS (O'Mahony et al., 2005; Whorwell et al., 2006). 
Furthermore, B. infantis 35624 was also shown, in one of these studies, to normalise the 
baseline pro-inflammatory cytokine profile in peripheral blood (O'Mahony et al., 2005). 
A recent study found that oral administration of B. infantis 35624 resulted in 
significantly elevated IL-10 produced by peripheral blood mononuclear cells (PBMCs) 
as well as increased T regulatory cells, indicating that this strain induces a regulatory 
immune response in humans (Konieczna et al., 2012). In addition, oral administration of 
B. infantis 35624 has been shown to reduce systemic inflammatory biomarkers in both 
gastrointestinal and extra-intestinal inflammatory disorders (Groeger et al., 2013). 
It has been suggested that the minimum therapeutic dose for probiotics is 108-109 viable 
cells per day. This would require probiotic products to contain a minimum 106 colony 
forming units (CFU)/mL in a typical 100 mL delivery product in order to be effective 
(Kailasapathy and Chin, 2000). However, a problem with the practical application of 
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probiotics is that live cells in probiotic products will inevitably lose viability and the 
actual products will contain varying numbers of these cells (Shah et al., 1995). Indeed 
substantial research and development has been dedicated to processes and agents that 
can prolong their stability and viability in beverage/food products and remove the need 
for refrigeration (Ranadheera et al., 2010). There may also be substantial loss of 
viability of the organisms on passage through the relatively hostile environment of the 
GIT (Adams, 2010). Concerns have also been raised regarding the potentially 
detrimental effects of administering these as live agents, particularly to 
immunocompromised subjects (Kataria et al., 2009).  
An area of ongoing debate is whether the non-viable forms of beneficial bacterial strains 
in formulations have a role to play in conferring benefits to the consumer by influencing 
the host’s immune system (reviewed in: Adams, 2010; Kataria et al., 2009; Taverniti & 
Guglielmetti, 2011). Studies have proposed that the immunomodulatory effects exerted 
by non-viable probiotics may be due to their immunostimulatory DNA, cell wall 
components, peptidoglycan, intra and/or extra-cellular polysaccharide products (Hosono 
et al., 1997; Lammers et al., 2003; Rachmilewitz et al., 2004) and hence may be 
dependent on method of preparation (Hiramatsu et al., 2007). The technology described 
in the literature to render probiotic bacteria non-viable is usually heat treatment (Cross 
et al., 2004; Hiramatsu et al., 2007; Li et al., 2009; Matsuguchi et al., 2003; Xiao et al., 
2002; Zhang et al., 2005). However, because of the possible impact heat treatment has 
on cellular integrity and protein structure (Lopez et al., 2008) other studies have also 
used γ-irradiation (Rachmilewitz et al., 2004), UV light (Lopez et al., 2008) or 
sonication (Hiramatsu et al., 2007).  
The present study was based on the hypothesis that Bifidobacterium-fermented milks 
induce a strain-specific immune response and ‘non-viable’ forms of these 
Bifidobacterium-fermented milks can maintain this immunomodulatory activity. In the 
present study, fermented milk products containing B. infantis 35624, Bifidobacterium 
breve UCC2003 and two Bifidobacterium longum strains (0103 and 0106), were 
investigated for their ability to induce cytokine production (IL-10 and TNF-α) in an in 
vitro model of host response. In addition, the effects of three different methods (heat 
treatment, high pressure treatment and storage at low-pH) for killing the 
Bifidobacterium strains within the milk preparation were examined. The cytokine 
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response patterns of the non-viable (i.e. ‘dead’) cell preparations was compared to their 
viable (i.e. ‘live’) counterparts.  
Chapter 5 
 
144 
 
3.0  Materials and Methods 
3.1 Preparation of cultures for inoculation into malted milk 
The strains used in this study included B. longum infantis 35624, B. breve UCC2003, B. 
longum NCIMB 41713 (0103) and B. longum NCIMB 42020 (0106). All bacterial 
cultures were maintained in 40% glycerol and stored at -80°C. The -80°C strains were 
inoculated (2% v/v) into modified de Man, Rogosa and Sharpe medium (mMRS) 
comprising MRS medium (Oxoid, Hampshire, UK) supplemented with 0.05% (w/v) 
cysteine-HCl and incubated for 24 h at 37°C under anaerobic conditions (anaerobic jars 
with Anaerocult A gas packs; Merck, Darmstadt, Germany). At the end of incubation, 
the cultures were sub-cultured (2% v/v) into 150 mL mMRS and reincubated for a 
further 24 h. 
3.2 Milk preparation 
The fermentation substrate consisted of whole milk fortified with 2% (w/w) skimmed 
milk powder, 2% (w/w) sucrose and 2% (w/w) malt extract. Following preparation, the 
fermentation substrate was autoclaved at 115°C for 10 min in 500 mL aliquots. The 
substrate was allowed to cool to 37°C before being inoculated (2% v/v) with a fresh 
overnight culture of each strain and incubated for 15-16 h at 37°C. A milk control (i.e. 
whole milk fortified with 2% skimmed milk powder, 2% sucrose and 2% malt extract) 
that was not inoculated with Bifidobacterium was also included. Six independent 
batches of each Bifidobacterium-fermented milk (BFM) and milk control were used for 
subsequent experiments (3 independent batches for storage (4ºC and 37ºC) at low pH 
(pH 4.0-4.6) and 3 independent batches for heat and high pressure treatment). 
3.3 Lethal Treatment  
3.3.1 Storage at low pH  
Following fermentation the BFM preparations (containing ~108 CFU/mL of stationary 
phase cells) and the milk control were divided into approximately 250 mL volumes in 
sterile plastic containers (Sarstedt, Wexford, Ireland). These were then stored at 4°C or 
37°C over a period of time. Viable cell counts and pH were recorded prior to storage 
and at appropriate intervals over a number of days/weeks depending on the specific 
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strain and the storage temperature. The pH changes were monitored using a pH meter, 
model R720 (Reagecon, Co. Clare, Ireland), with a calibrated electrode (Schott, Mainz, 
Germany).  
3.3.2 High pressure (HP) treatment 
Aliquots (30 mL) of the BFM preparations and the milk control were dispensed into 
plastic vacuum bags and vacuum packed. Pressure treatments were carried out using a 
Stansted Fluid Power Iso-Lab 900 High Pressure Food Processor (Stansted Fluid Power 
Ltd., Stansted, Essex, UK). The medium for hydrostatic pressurization was a 9:1 
mixture of ethanol and castor oil. Samples were subjected to HP in the range 300 - 600 
MPa with holding times of 5 min at ambient temperature. Adiabatic heating on 
compression resulted in an increase in the temperature of the processing fluid (by up to 
15°C at 600 MPa). Viable-BFM samples were held at atmospheric pressure at ambient 
temperature for the duration of the treatment and plated together with HP treated 
samples for determination of the number of colony forming units (CFU) in each sample.  
3.3.3 Heat treatment 
Aliquots (12 mL) of the BFM preparations and milk control were dispensed into sterile 
test tubes and subjected to high temperature treatment. Samples were thermally treated 
in a water bath for 1 min at 72°C. In order to accurately determine the length of time the 
cells were exposed to the test temperature a thermometer was placed in a control test 
tube which contained 10 mL of BFM and timing commenced once the thermometer 
reached the desired temperature. Samples were immediately cooled for 15 min on ice. 
Viable-BFM samples were held at ambient temperature for the duration of the treatment 
(as a temperature control for the heat treatment), cooled on ice and plated together with 
heat-treated samples in order to determine cell viability.  
3.4 Determination of culture viability and quality control 
3.4.1 Determination of culture viability 
For the enumeration of culturable microorganisms, aliquots of milk were serially diluted 
in one-quarter strength Ringer’s solution (Merck). The number of colony forming units 
(CFU) of Bifidobacterium was determined by spread plating the appropriate dilutions in 
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duplicate on Reinforced Clostridial Agar (RCA, Oxoid) supplemented with 0.05% 
cysteine-HCl. RCA plates were incubated at 37°C for 48 h under anaerobic conditions 
(anaerobic jars with Anaerocult A gas packs). Contamination levels of the samples were 
also monitored. Undiluted samples were routinely spread plated on Yeast Extract 
Glucose Chloramphenicol agar (Merck) for yeast and mould determination (incubated 
aerobically at 30°C for 5 d); Baird-Parker agar + 1% (v/v) egg yolk tellurite emulsion 
for determination of staphylococci (incubated at 37°C for 24-48 h), Violet Red Bile 
(VRB, Merck) agar for determination of coliforms (incubated at 37°C for 24 h) and 
Tryptone Soy Agar (TSA, Oxoid) + 1% (w/v) yeast extract (Merck) for determination 
of contaminating aerobes (incubated at 30°C for 72 h followed by 48 h at 37°C). 
Bacterial counts are reported as log10CFU mL-1. 
3.4.2 Quality control – identification/confirmation of strains by polymerase chain 
reaction (PCR). 
Following enumeration of viable Bifidobacterium on RCA plates, a selection of 
colonies of each strain were picked and sub-cultured in mMRS medium for 24 h. A 
1 mL aliquot was transferred to a 2 mL stock bottle and centrifuged to pellet the cells. 
Total DNA was isolated from the pellets using Extract-N-AmpTM Tissue PCR Kit 
(Sigma). A strain specific ‘fingerprint’ (based on EPS genes) has previously been 
generated for each strain by Alimentary Health, Cork, Ireland. Each strain was screened 
for the presence/absence of a selection of these genes. Identification of samples was 
confirmed when the expected profiles were observed. PCR reactions were performed 
using GoTaq Green Master Mix (Promega (M7122). Primers were obtained from MWG 
Biotech (Eurofins, Germany). PCR conditions were as follows: 94°C for 4 min; 29 
cycles of 94°C for 45 sec, 52-56°C (adjusted for annealing temperature of individual 
primer pairs) for 45 sec and 72°C for 45 sec.  
3.5 Freeze drying 
Samples were placed in sterile Petri dishes and spread so as to obtain a film of 
approximately 0.5 cm thickness. The Petri dishes were stored on metal trays and placed 
in a -80°C freezer prior to freeze drying. Frozen samples were then freeze dried in a 
VirTis Genesis freeze drier, model 25ES (VirTis, New York) with a standard 
programme. Following freeze-drying, the powders were then ground in a sterile 
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stomacher bag and transferred immediately to sterile bottles and capped under 
atmospheric conditions. Freeze dried powders were stored at -20°C until use. The 
freeze-dried samples were resuspended in Ringers solution, diluted and subsequently 
plated. The number of culturable cells after freeze-drying was determined as log10CFU 
g-1.  
3.6 Determination of membrane integrity and total cell counts of freeze dried powders - 
LIVE/DEAD staining 
3.6.1 Extraction of bacterial cells from milk samples 
For the recovery of bacteria, 1 mL of the 1/10 (w/v) diluted freeze dried samples were 
thoroughly mixed in a microcentrifuge tube with 0.5 mL of a milk clearing solution 
[0.15M N-(2-acetoamido)imino-diacetic acid (ADA, chelating agent), 0.5% (w/v) 
Triton X-100 (non-ionic detergent)] (McClelland and Pinder, 1994).  The tubes were 
then centrifuged at 12,000 g for 5 min. After centrifugation a cream layer was formed 
on the top of a clear supernatant fluid, and a thick pellet was formed at the bottom. Both 
the cream layer and the supernatant were carefully removed leaving the pellet 
containing the microorganisms and residual milk particles behind. 
3.6.2 Staining of cells 
Staining was carried out using a LIVE/DEAD® BacLightTM bacterial viability kit 
(Molecular Probes, Leiden, The Netherlands) according to the manufacturer’s 
instructions. The LIVE/DEAD stain consists of a mixture of SYTO 9 and propidium 
iodide (PI) nucleic acid stains; these stains differ in their spectral characteristics and in 
their ability to penetrate the membranes of healthy cells. SYTO 9 stains bacteria with 
intact membranes a fluorescent green whereas bacteria with damaged membranes are 
stained red on uptake of PI. Briefly, the pellet containing the extracted microorganisms 
was resuspended in a final volume of 10 mL using a sterile 0.85% NaCl solution. A 
10 µL sample was then added to 977 µL 0.85% NaCl in a flow cytometry analysis tube. 
This was followed by 1.5 µL of SYTO 9 nucleic acid stain and 1.5 µL of PI stain. 
Samples were incubated for 15 min at room temperature and protected from light. 
Following staining, 10 µL of the microsphere standard beads (to facilitate counting) was 
added. The tubes were mixed well and analysed by flow cytometry (FCM) using a 
FACSCalibur flow cytometer (BD Biosciences, Heidelberg, Germany) and CellQuest 
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Pro data analysis software (BD Biosciences). Forward scatter (FSC), side scatter (SSC) 
and two fluorescent signals [SYTO-9-FL1 channel (green) and PI-FL3-channel (red)] 
were measured as per manufacturers’ instructions. 
3.7 Peripheral blood mononuclear cells (PBMC) isolation and cytokine induction assay 
BFM samples were assayed using the PBMC cytokine induction assay. For each batch 
of BFM, PBMCs were isolated from peripheral blood of 3 healthy volunteers. Briefly, 
blood was taken directly into sterile EDTA-containing vacutainers. Mononuclear cells 
were isolated from blood by density gradient centrifugation (1.077 g mL-1, 
Histopaque®, Sigma, Poole, Dorset, U.K.). After two washing steps, PBMCs were 
resuspended in complete media consisting of Dulbecco’s Minimum Essential Medium 
(DMEM; Gibco Life Technologies), 1% Penicillin Streptomycin (Sigma) and 10% 
Foetal Calf Serum (Sigma) at 1 x 106 cells/mL and 200 µL aliquots were transferred to 
96-well flat-bottomed plates. Aliquots of lyophilised BFM samples (100 mg) were 
resuspended 1/10 (w/v) in Dulbecco’s phosphate buffered saline (PBS; Sigma) and then 
serially diluted. PBMC’s were stimulated for 48 h at 37°C in 5% CO2 atmosphere with 
20µL aliquots of the different concentrations of BFM samples and malted milk control 
(final concentrations: 5 mg/mL, 2.5 mg/mL and 1 mg/mL which equated to a bacterial 
cell: PBMC ratio of 50:1, 25:1, 10:1). This range of concentrations was used to 
determine the dose which induced the maximum cytokine secretion. In each assay, a 
positive control, CH2007 (commercial product - lyophilised, B. infantis 35624 provided 
by Chr. Hansen), for which the cytokine profile is well established, was used to 
stimulate the PBMCs. Furthermore, a negative control (phosphate buffered saline) with 
no stimuli was also added to the PBMC cells. After stimulation, cell culture 
supernatants were harvested by centrifugation and stored at -80°C until cytokine levels 
were quantified.  
PBMC supernatants were thawed at 4ºC and analysed for cytokine (IL-10 and TNF-α) 
levels using Meso Scale Discovery (MSD; Gaithersburg, Maryland, USA) assays 
according to the manufacturer’s protocol and analyzed on a SECTOR 2400 instrument 
(MSD). All experiments were performed in triplicate. 
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3.8 Statistical analysis 
Data are expressed as means and standard errors or medians and interquartile range, as 
appropriate. Values are an average of triplicate independent experiments unless stated 
otherwise. All data were analysed using Graphpad Prism version 5.1 (GraphPad 
Software Inc.). Statistical comparisons were made with a one- or two-way ANOVA 
with a Bonferonni correction. For non-parametric data, statistical comparisons were 
made using the Kruskal Wallis test with a Dunn correction. Statistical significance was 
set at P<0.05 and significance levels were defined as *P<0.05, **P<0.01 and 
***P<0.001. 
4.0  Results 
4.1 Viability of bacteria during storage at 4°C and 37°C (pH effect) and following high 
pressure (HP) and heat treatment (HT) 
The BFM preparations had a pH of approximately 4.5-4.6, and contained 108-109 CFU 
mL-1 following 15-16 h fermentation at 37°C. The results indicate that storage 
temperature following fermentation has a significant effect on the pH and viable counts 
of the BFM preparations (Fig. 1). For samples stored at 4°C, there was no significant 
change in pH and the number of viable cells declined gradually over a period of 
9 weeks. For samples stored at 37°C, the number of viable cells declined more rapidly 
with no viable cells detected after a period of 7 d. As expected, there was a decrease in 
pH during storage due to the fermentation of residual sugars. A high pressure treatment 
of 400 MPa for 5 min (Table 1) and a heat treatment of 72ºC for 1 min were found to be 
sufficient to kill all detectable viable cells in BFM. 
4.2 Determination of culture viability, total cell counts and membrane integrity 
(LIVE/DEAD staining) of freeze dried powders 
The number of culturable cells after freeze-drying was determined as CFU/g. The 
viable-BFM powders contained approximately 7.3 to 8.5 log10 CFU per gram (Table 2). 
No culturable cells were detected in dead BFM powders. 
Flow cytometric analysis allowed enumeration of total bacterial cells in the freeze dried 
powders. These counts were used for calculating the bacterial cell: PBMC ratios in 
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subsequent experiments. Background fluorescence from residual milk particles was 
easily distinguished from bacterial cells and was excluded from the analysis. The 
number of total cells present in BFM after freeze-drying was determined as log10 
bacteria/g. Total counts ranged from 9.5 to 10.4 log10 bacteria/g (Table 3). Membrane 
permeability of the Bifidobacterium cells in BFM preparations was examined using the 
LIVE/DEAD stain on the freeze dried powders before and after the lethal treatments 
(Fig. 2). In general, treatment with either heat or high pressure increased the membrane 
permeability of the bifidobacteria, allowing access of the propidium iodide component, 
which increased the number cells which were stained red (DEAD or damaged) and 
decreased the number of cells which were stained green (LIVE). Storing the BFMs at 
37ºC significantly increased the membrane permeability of B. infantis 35624 only. On 
the other hand, storing the BFMs at 4ºC decreased membrane permeability, preventing 
access of the propidium iodide component which decreased the number of cells which 
were stained red and increased the number of cells which were stained green. Therefore 
although virtually all bifidobacteria cells had lost their culturability, a remarkable 
fraction of the population had retained a functional cell membrane.  
4.3 Secretion of cytokines by BFM 
All viable-BFMs, the malted milk control and CH2007 induced secretion of IL-10 and 
TNF-α, albeit to different extents (Fig. 3). The BFMs, with the exception of B. longum 
0103, stimulated the production of significantly more IL-10 than the milk control (Fig. 
3). CH2007 did not induce significantly more IL-10 than the milk control, indicating 
that the milk itself induces IL-10 in amounts comparable to the lyophilised commercial 
product. Milk fermented with B. infantis 35624 and B. longum 0106 appeared to be the 
most potent IL-10 inducers, provoking on average a 2-3 fold higher IL-10 secretion than 
the malted milk control. On the other hand, B. longum 0103 induced the lowest IL-10 
response.  
As regards TNF-α, B. breve UCC2003 and B. longum 0103 and CH2007 induced 
significantly more TNF-α than the milk control. B. infantis 35624 on the other hand 
induced TNF-α at comparable levels to the milk control. Similarly, B. longum 0106 only 
induced significantly more TNF-α than the milk control at the lowest dilution.  
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When cytokine profiles were expressed as ratios of IL-10:TNF-α (anti-
inflammatory/pro-inflammatory), distinct patterns emerged for the bifidobacterial 
strains (Fig. 4). At the lowest concentration (10 bacterial cells: PBMC), the fermented 
milks did not induce a significantly higher ratio of IL-10:TNF-α than the milk control. 
However, at a higher concentration (25 bacterial cells: PBMC) B. infantis 35624 
induced a significantly higher ratio of IL-10:TNF-α than the milk control (P<0.05), 
B. longum 0103 (P<0.001) and CH2007 (P<0.001) while B. longum 0106 induced a 
significantly higher ratio of IL-10:TNF-α than B. longum 0103 (P<0.001), and CH2007 
(P<0.001). At the highest concentration (50 bacterial cells: PBMC) B. infantis 35624 
induced a significantly higher ratio of IL-10:TNF-α than B. breve UCC2003 (P<0.01), 
B. longum 0103 (P<0.001) and CH2007 (P<0.001).   
The IL-10 and TNF-α response in PBMCs (Fig. 5 & 6) was measured after lethal 
treatment (storage at low pH, heat and high pressure) of the BFM and was also 
expressed as a ratio of IL-10:TNF-α (Fig. 7 & 8). In general, killing the bacterial cells 
by storing the BFM at 4°C (ST4-BFM) had no significant impact on the induction of IL-
10 or TNF-α (Fig. 5) nor on the ratio of IL-10:TNF-α (Fig. 7). However, storage at 37ºC 
significantly reduced the induction of IL-10 by B. breve UCC2003, compared to viable-
BFM, while it significantly increased the induction of TNF-a by B. longum 0106. 
Consequently, storage at 37ºC significantly reduced the ratio of IL10:TNF-α induced by 
both B. breve UCC2003 and B. longum 0106. Storage of the malted milk control at 4ºC 
and 37ºC had no significant impact on the induction of IL-10 or TNF-α in PBMCs 
The PBMC responses of heat-treated BFMs (HT-BFM) and high pressure-treated BFMs 
(HP-BFM) were also compared to the viable-BFM (Fig. 6). For B. infantis 35624, the 
HT-BFM induced a significantly lower IL-10 response while the HP-BFM induced a 
similar IL-10 and TNF-α response to the viable-BFM. Consequently, heat treatment was 
found to significantly reduce the ratio of IL-10:TNF-α induced by the B. infantis 35624 
while high pressure treatment had no significant impact on the ratio (Fig. 8).  
For B. breve UCC2003, the HT-BFM induced a lower IL-10 response which was 
significant for only one dilution (25 bacteria: PBMC; P<0.001). Similarly, the HP-BFM 
also induced a lower IL-10 response which was significant for two dilutions (25 
bacteria: PBMC; P<0.01 and 10 bacteria: PBMC; P<0.05). The HP and HT-BFM 
(B. breve UCC2003) both induced comparable levels of TNF-α to the viable 
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preparation, except for the lowest dilution (10 bacteria: PBMC) which induced 
significantly more TNF-α than the viable-BFM (P<0.05). For B. longum 0103, the HT-
BFM and HP-BFM induced comparable levels of IL-10 and TNF-α to the viable-BFM, 
as was the case for B. longum 0106. However, the HT-BFM (B. longum 0106) induced 
significantly less IL-10 than the viable-BFM for one dilution (25 bacteria: PBMC; 
P<0.05) and also induced significantly more BFM than the viable-BFM for the lowest 
dilution (10 bacteria: PBMC; P<0.001). Heat-treatment or high pressure-treatment of 
the malted milk control had no significant impact on the induction of IL-10 or TNF-α in 
PBMCs.  
5.0  Discussion 
In this study, the effect of four Bifidobacterium strains, grown in fermented milk, on the 
secretion of the cytokines IL-10 and TNF-α using human PBMCs as an in vitro model 
of host response was investigated. The Bifidobacterium strains were shown to induce 
cytokine production in a strain-specific manner, an observation also made in previous 
studies (Dong et al., 2011; López et al., 2010; Medina et al., 2007). This strain 
dependent induction of cytokines highlights the importance of strain identification and 
characterisation when assessing the immunomodulatory properties of potential probiotic 
bacteria. The malted milk control also induced cytokine production. Evidence suggests 
that major components of bovine milk (e.g. milk proteins such as α-casein and 
lactoferrin) have immunomodulatory effects, including modulation of the cytokine 
production by activated macrophages (reviewed in: Cross & Gill, 2000).  
The BFMs showed a dose-dependent change in their IL-10 and TNF-α stimulating 
capacity, which has been reported previously (Kekkonen et al., 2008). The stimulation 
of TNF-α was typically high at the lower doses of bacteria, while the IL-10 secretion 
increased with bacterial load. The IL-10/TNF- α ratio thus increases with increasing 
dose. The lowest dose yielded an IL-10/TNF- α ratio below 1, with no significant 
differences between the strains and the malted milk control. However, at higher doses, 
B. infantis 35624 stimulated a significantly higher IL-10/TNF-α ratio than either the 
milk control, B. breve UCC2003, B. longum 0103 or CH2007 (commercially prepared 
B. infantis 35624). As CH2007 is a commercially prepared product (Chr. Hansen), 
information on the composition of the fermentation medium is unavailable. It is 
therefore difficult to conclude why this commercial preparation stimulates a 
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significantly lower anti-inflammatory response compared to the B. infantis 35624 BFM. 
It has previously been shown that the former exerts an anti-inflammatory effect in vitro 
using the PBMC assay (Alimentary Health - data not shown) and also in vivo 
(Konieczna et al., 2012; O'Mahony et al., 2005). Although the present study has shown 
that B. infantis 35624 fermented milk induces a greater anti-inflammatory response than 
CH2007 in vitro, this does not guarantee similar functioning in vivo.  
It has been noted that although the PBMC model used in this study is not fully reflective 
of the in vivo situation in which intestinal bacteria interact with Peyer’s patches, 
M cells, dendritic cells, macrophages and T cells, it is useful as a screening tool to 
identify potential immunomodulatory traits of probiotic strains and to select probiotic 
strains for use in animal models and clinical trials (Dong et al., 2011; Kekkonen et al., 
2008). Therefore, the results from the present study may be useful in extrapolating to in 
vivo studies and for making predictions about the potential clinical uses of these 
probiotic products. This screening project was undertaken with the industry partner, 
Alimentary Health Ltd., where preliminary work identified IL-10 and TNF-α to be the 
best representative of an anti- and pro-inflammatory cytokine, respectively, due to their 
low coefficients of variation (CV) for between-subject variability in the PBMC assay 
(data not shown). IL-10 and TNF-α play opposing roles in inflammatory responses and 
their relative balance is of central relevance for regulating immune dysfunction (Dong et 
al., 2011). IL-10 is an anti-inflammatory cytokine that inhibits antigen presentation and 
the subsequent release of inflammatory cytokines, thereby controlling inflammatory 
responses to intestinal antigens and restoring tolerance of T cells to the intestinal 
microbiota (Lammers et al., 2003; Sanchez-Muñoz et al., 2008). TNF-α, on the other 
hand, is a pro-inflammatory cytokine involved in the stimulation of inflammatory 
cytokine production, enhancing the phagocytic/bactericidal properties of macrophages, 
and activating apoptotic pathways (Schottelius et al., 2004). Moreover, TNF- α has been 
found to be up-regulated in patients with IBD (Sanchez-Muñoz et al., 2008).  
A number of studies have indicated that viable Bifidobacterium strains are not always 
necessary for induction of immunomodulation in vitro (Hiramatsu et al., 2007; Hosono 
et al., 1997). We investigated whether the immunomodulatory effects observed during 
treatment with BFM could be maintained even after the Bifidobacterium cells had been 
rendered non-culturable by different lethal treatments. The methods employed here to 
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kill bacteria included heat treatment, high pressure treatment and storage at low pH. The 
heat treatment method used to kill the bacteria has been used previously where 
researchers have investigated its immunomodulatory effects both in vitro and in vivo 
(Cross et al., 2004; Hiramatsu et al., 2007; Li et al., 2009; Matsuguchi et al., 2003; 
Xiao et al., 2002; Zhang et al., 2005). However, to the best of our knowledge, high 
pressure treatment and storage at low pH have not been used as methods for killing 
bacteria when they are screened for their immunomodulatory properties either in vitro 
or in vivo. 
The effect of storage at a low pH on the Bifidobacterium cells was strongly dependent 
on the storage temperature. Storage of the BFM at 37°C resulted in a rapid decline of 
culturable cells, whereas storage at 4°C resulted in a more gradual decline. This rapid 
decline in culturable cells at the higher storage temperature can be explained, to some 
extent, by the additional decrease in pH (from approximately 4.6 to 4.0). Indeed, it has 
been found that most strains of bifidobacteria are sensitive to pH values below 4.6 
(Boylston et al., 2004; Modler, 1994) and similar to the present study, Modler (1994) 
found that a bifidobacterial population could decline from 109 to 0 in less than a week in 
a low pH yoghurt (pH 3.9–4.0). Staining with the fluorescent probes (SYTO-9 and 
propidium iodide (PI)) and subsequent analysis by flow cytometry revealed that storage 
at 37ºC increased the membrane permeability of bacterial cells while storage at 4ºC 
decreased membrane permeability, the reasons for which are unknown. It must be noted 
that the SYTO-9 and PI dyes can bind components from the medium in unpredictable 
ways, resulting in variation in staining efficiency between samples. Hence these results 
should be interpreted with caution. Nonetheless, it has previously been reported that 
Bifidobacterium cells (in a fermented oat drink) lose culturability when stored at 4ºC 
while maintaining an intact membrane (Lahtinen et al., 2006). Storage at low pH also 
had varying effects on the immunomodulatory capacity of the BFM depending on strain 
and storage temperature. In general, killing the cells by storage at 4ºC had no significant 
impact on the induction of IL-10 or TNF-α. However, storage at 37ºC reduced the IL-10 
signal induced by B. breve UCC2003 and increased the TNF-α signal induced by 
B. longum 0106. 
High pressure treatment was also used as a method to kill Bifidobacterium cells in the 
fermentates. In HP processing, food is subjected to pressures usually within the range of 
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300-700MPa and values of around 400MPa are usually effective in killing most of the 
vegetative bacteria (Chawla et al., 2011). The effects of pressure on microorganisms in 
food are determined by the temperature during pressure treatment, the food constituents 
and the physiological state of the microorganism (Chawla et al., 2011). Tsevdou & 
Taoukis (2011) recently assessed the effect of high hydrostatic pressure on the survival 
of Bifidobacterium spp. in broth and found that high pressure treatments of 200MPa at 
20-15°C for 10-15 min were not detrimental to the viability of the culture (Tsevdou and 
Taoukis, 2011). Consequently, we examined the effect of high pressure treatments 
>300MPa on viability of our strains in a milk product and a treatment of 400MPa for 5 
min was found to be sufficient to kill all culturable cells and increased membrane 
permeabilisation. Indeed, damage to cell membranes, is one of the main causes of death 
of microorganisms by high pressure treatment (Lado and Yousef, 2002). For B. infantis 
35624, B. longum 0106 and B. longum 0103 the high pressure treated BFM samples 
induced comparable IL-10 and TNF-α responses to the viable BFM. However, for B. 
breve UCC2003, high pressure treatment significantly decreased the induced IL-10 
signal and increased the TNF-α signal.  
Heat treatment of BFM in a water bath resulted in complete loss of viable cells and an 
increase in membrane permeability. Heat treatment of the B. infantis 35624–fermented 
milk samples resulted in a significant decrease in the levels of IL-10 induced in PBMCs. 
This may be explained by the impact that heat treatment has on cellular integrity and 
protein structure (Lopez et al., 2008). However, heat treated BFM induced comparable 
levels of TNF-α to the viable form. Similarly, for B. breve UCC2003 and B. longum 
0106, the HT-BFM induced a significantly lower IL-10 response and a higher TNF-α 
response compared to the viable BFM. However, for B. longum 0103, heat treatment 
had no affect on its ability to induce the cytokines, IL-10 and TNF-α.  
It has been reported previously that live bacteria are more potent inducers of cytokine 
production in mammalian leucocytes than killed forms (Cross et al., 2004; Miettinen et 
al., 1996). Cross et al. (2004) demonstrated that live L. casei Shirota induced a murine 
monocytes/macrophage cell line to secrete higher levels of IL-12 and TNF-α than those 
observed using a comparable number of heat killed bacilli. Similarly, Miettinen et al. 
(1996) demonstrated that several live lactic acid bacteria (LAB), but not gluteraldehyde-
fixed LAB, were potent inducers of TNF-α release from human PBMCs. However, in 
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contrast, a number of other studies have shown that the live condition is not necessary 
for bacteria to exert an immune response (Hiramatsu et al., 2007; Lammers et al., 
2003). Hiramatsu et al. (2007) found that live, ultra-sonic treated and heat treated 
Bifidobacterium co-cultured with murine Peyer’s patch cells induced IL-12p40 in vitro. 
In fact, the sonicated Bifidobacterium induced significantly more IL-12p40 than the live 
form in the murine Peyer’s patch cells. The authors concluded that disruption of 
bacterial cell walls following ultra-sonic treatment led to increased exposure of 
microbe-associated molecular patterns (MAMPS) such as peptidoglycans, lipoteichoic 
acids and DNA. Indeed, Lammers et al. (2003) have previously found that 
Bifidobacterium genomic DNA induced secretion of IL-10 by human PBMC.  
The present study showed that the stimulatory activity of the Bifidobacterium-fermented 
milk differed, depending on the particular strains, the concentrations and the treatments 
applied to render the bifidobacteria non-culturable. Of all of the methods employed in 
this study to render the bacterial cells non-culturable, storage at 4ºC appeared to be the 
best method for maintaining immunomodulatory activity in all Bifidobacterium strains. 
Storage at 37ºC resulted in a reduced anti-inflammatory signal, particularly in B. breve 
UCC2003 and B. longum 0106. Heat treatment reduced the anti-inflammatory signal of 
B. infantis 35624 and B. breve UCC2003 while high pressure treatment reduced the 
anti-inflammatory signal of B. longum 0103. Interestingly, the induction of both IL-10 
and TNF-α by the malted milk control was largely unchanged irrespective of the 
treatment used, indicating that the different treatments did not significantly affect the 
immunomodulatory capacity of the malted milk components. 
It would be interesting to know whether the strain specific cytokine release 
demonstrated in this study is related to EPS production of each strain. A number of 
studies have demonstrated the immunomodulatory capacity of EPS (Arena et al., 2006; 
Ciszek‐Lenda et al., 2011; Hidalgo-Cantabrana et al., 2012; López et al., 2012; Wu et 
al., 2010). However, the quantity of EPS produced in the BFM has not yet been 
determined and thus it is not possible to predict its effects. The only useful information 
available is the appearance of bifidobacteria colonies on Congo red agar. Indeed, B. 
infantis 35624 and B. longum 0106, which induced a higher IL-10/TNF-α ratio than B. 
breve UCC2003 and B. longum 0103, form whiter colonies which exhibit a more 
mucoid appearance on Congo red agar (data not shown). Nonetheless, several other 
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components produced from milk fermentation also may contribute to the 
immunomodulatory activity of the BFMs. It has been shown that supernatants of milk 
fermented by L. helveticus modulated the in vitro proliferation of lymphocytes by acting 
on cytokine production (Laffineur et al., 1996). In addition, cell-free extracts of the 
fermented milk product kefir were able to induce the in vivo production of cytokines by 
peritoneal macrophages and adherent cells isolated from Peyer’s patches (Vinderola et 
al., 2006). 
The intestine is a complex ecosystem in which the microbiota and the host interact in 
order to uphold an immunologically balanced intestinal inflammatory response 
(Dicksved and Willing, 2011; Lammers et al., 2003; Tamboli et al., 2004). Investigation 
into the mechanisms by which intestinal microorganisms, including ‘non-viable’ 
probiotics, regulate the immune response may allow formulation of probiotic 
supplements that are tailored for particular disorders based on their immunomodulatory 
properties (López et al., 2010). In this regard, characterising how the immune system 
responds to probiotic bacteria in vitro may give an indication as to the likely 
immunomodulatory events that can be triggered following probiotic administration in 
vivo. In general, BFMs containing dead cells stimulated levels of IL-10 and TNF-α 
which were comparable to those stimulated by BFM containing live cells. Taking into 
account that the manufacturing process and gastrointestinal passage affect bacterial 
viability, these results obtained in this study may indicate a potential therapeutic effect 
of non-viable bacteria ingested in BFM. Moreover, as well as eliminating shelf life 
problems, administration of non-viable microorganisms could reduce the risk of 
microbial translocation and infection, particularly in individuals with compromised gut 
barrier function. While the results have clearly shown that microbiologically inactive 
Bifidobacterium strains are capable of inducing a cytokine response upon direct 
interactions with PBMCs, the true in vivo picture needs to be fully determined taking 
into account the contributing roles of other commensal gut bacteria as well as the 
immunocompetent cells in the gut environment. However, this production of a 
microbiologically non-viable yet immunologically active probiotic product may have 
applications in human health and would have a noticeable advantage compared to other 
‘viable’ probiotics by allowing for the generation of safer more stable products (e.g. 
longer shelf life).  
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Table 1.  Inactivation of Bifidobacterium strains in a malted milk preparation by application of HP. 
Results are expressed as the mean (± standard error) of triplicate independent experiments 
Pressure 
Treatment 
Log10 CFU mL-1 
B. infantis  
35624 
B. breve  
UCC2003 
B. longum  
0103 
B. longum  
0106 
Atm x 5 min 8.76 ± 0.05 9.29 ± 0.02 8.92 ± 0.04 8.81 ± 0.08 
300 MPa  1.50 ± 0.62 2.05 ± 0.22 1.22 ± 0.27 1.24 ± 0.40 
400 MPa  <1.00 <1.00 <1.00 <1.00 
500 MPa  <1.00 <1.00 <1.00 <1.00 
600 MPa  <1.00 <1.00 <1.00 <1.00 
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Table 2. Culture viability of freeze-dried BFMs [Untreated BFM (Viable-BFM), BFM stored at 37°C (ST37-BFM), BFM stored at 4°C (ST4-BFM), heat-treated BFM (HT-
BFM) and high pressure-treated BFM (HP-BFM). Results are expressed as the mean (± standard error) of triplicate independent experiments 
 Log10 CFU g-1 
Strain viable-BFM ST37-BFM ST4-BFM viable-BFM HT-BFM HP-BFM 
B. infantis 35624 7.72 ± 0.30 <1.00 <1.00 7.32 ± 0.19 <1.00 <1.00 
B. breve UCC2003 7.99 ± 0.01 <1.00 <1.00 8.47 ± 0.01 <1.00 <1.00 
B. longum 0103 8.08 ± 0.24 <1.00 <1.00 7.95 ± 0.11 <1.00 <1.00 
B. longum 0106 8.19 ± 0.10 <1.00 <1.00 8.10 ± 0.0 <1.00 <1.00 
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Table 3. Total cell counts of freeze-dried BFMs [Untreated BFM (viable-BFM), BFM stored at 37°C (ST37-BFM), BFM stored at 4°C (ST4-BFM), heat-treated BFM (HT-
BFM) and high pressure-treated BFM (HP-BFM)]  enumerated using flow cytometry. Results are expressed as the mean (± standard error) of triplicate independent 
experiments.  
 Log10 bacteria g-1 
Strain viable-BFM ST37-BFM ST4-BFM viable-BFM HT-BFM HP-BFM 
B. infantis 35624 10.03 ± 0.08 10.09 ± 0.09 10.23 ± 0.13 9.92  ±  0.02 9.81 ± 0.09 9.80 ± 0.11 
B. breve UCC2003 9.89 ± 0.08 10.10 ± 0.05 10.30 ± 0.11 10.35 ± 0.08 10.04 ± 0.10 9.54 ±  0.13 
B. longum 0103 9.80 ± 0.13 9.87 ± 0.06 10.24 ± 0.08 9.65 ± 0.08 9.52 ± 0.04 9.47 ± 0.06 
B. longum 0106 9.95 ±  0.14 9.69 ± 0.07 10.09 ± 0.09 10.09 ± 0.16 9.76 ± 0.10 9.93 ± 0.01 
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Figure 1.  Changes in viable counts and pH of Bifidobacterium strains in fermented milk samples during 
storage at (A) 37°C and (B) 4°C: B. infantis 35624,  B. breve UCC2003,  B. longum 0103 and  
B. longum 0106. Results are expressed as the mean (± standard error) of  triplicate independent 
experiments 
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Figure 2.  Percent permeability of freeze-dried BFM samples using LIVE/DEAD staining and flow 
cytometry (  B. infantis 35624,  B. breve UCC2003,   B. longum 0103, and  B. longum 0106). 
Results are expressed as the mean (± standard error) of 3 independent assays.  A) Untreated BFM (viable-
BFM) is indicated with filled bars, BFM stored at 37°C (ST37-BFM) with open bars and BFM stored at 
4°C (ST4-BFM) with hatched bars. B) Untreated BFM (viable-BFM) is indicated with filled bars, heat-
treated BFM (HT-BFM) with open bars and high pressure-treated BFM (HP-BFM) with hatched bars. 
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Figure 3.  IL-10 and TNF-α production by PBMCs induced by untreated (viable) BFM (  B. infantis 
35624,  B. breve UCC2003,  B. longum 0103, and  B. longum 0106),   milk control and   
CH2007 after 48 h stimulation. Results are expressed as the mean (± standard error) of 3 independent 
assays, each done with PBMC’s from 3 different donors. P<0.05 (*) P<0.01 (**), P<0.001 (***) for BFM 
versus milk control as determined by two-way ANOVA with a Bonferonni correction.  
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Figure 4.  Effect of untreated (viable) BFM (  B. infantis 35624,  B. breve UCC2003,   B. longum 
0103, and   B. longum 0106),  milk control and  CH2007 on ratios of IL-10:TNF-α. Results are 
expressed as median and interquartile range (whiskers: min to max). P<0.05 (*), P<0.001 (***) for 
BFM/CH2007 versus milk control as determined by Kruskal Wallis test with a Dunn correction. 
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Figure 5.  IL-10 and TNF-α production by PBMCs induced by untreated (viable) or treated (non-viable) 
BFM (  B. infantis 35624,  B. breve UCC2003,   B. longum 0103, and   B. longum 0106) and  
milk control after 48 h stimulation. Results are expressed as the mean (± standard error) of 3 independent 
assays. P<0.05 (*) P<0.01 (**), P<0.001 (***) for treated BFM versus untreated BFM as determined by 
two-way ANOVA with a Bonferonni correction. Untreated BFM (viable-BFM) is indicated with filled 
bars, BFM stored at 37°C (ST37-BFM) with open bars and BFM stored at 4°C (ST4-BFM) with hatched 
bars. 
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Figure 6.  IL-10 and TNF-α production by PBMCs induced by viable or non-viable BFM (  B. infantis 
35624,  B. breve UCC2003,   B. longum 0103, and   B. longum 0106) and  malted milk control 
(no bacterial cells) after 48 h stimulation. Results are expressed as the mean (± standard error) of 3 
independent assays. Untreated BFM (viable-BFM) is indicated with filled bars, heat-treated BFM (HT-
BFM) with open bars and high pressure-treated BFM (HP-BFM) with hatched bars. P<0.05 (*) P<0.01 
(**), P<0.001 (***) for viable BFM versus non-viable BFM (HT-BFM or HP-BFM) as determined by 
two-way ANOVA with a Bonferonni correction 
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Figure 7.  Effect of untreated (viable) BFM and treated (non-viable) BFMs (BFM stored at 37°C and 
BFM stored at 4°C) on ratios of IL-10:TNF-α (  B. infantis 35624,  B. breve UCC2003,   B. longum 
0103,   B. longum 0106) and,  milk control). Results are expressed as median and interquartile range 
(whiskers: min to max).. P<0.05 (*) P<0.01 (**), P<0.001 (***) for treated BFM versus untreated BFMs 
(of same dilution) as determined by Kruskal Wallis test with a Dunn correction. Untreated BFM (viable-
BFM) is indicated with filled bars, BFM stored at 37°C (ST37-BFM) with open bars and BFM stored at 
4°C (ST4-BFM) with hatched bars. 
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Figure 8.  Effect of untreated (viable) BFM and untreated (non-viable) BFMs (heat-treated BFM and 
high pressure treated BFM) on ratios of IL-10:TNF-α (  B. infantis 35624,  B. breve UCC2003,   B. 
longum 0103,   B. longum 0106) and,  milk control). Results are expressed as median and interquartile 
range (whiskers: min to max).  P<0.05 (*) P<0.01 (**), P<0.001 (***) for treated BFM versus untreated 
BFMs (of same dilution) as determined by Kruskal Wallis test with a Dunn correction. Untreated BFM 
(viable-BFM) is indicated with filled bars, heat treated BFM (HT-BFM) with open bars and high pressure 
treated BFM (HP-BFM) with hatched bars. 
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1.0  Abstract 
The human gastrointestinal tract (GIT) harbours a complex microbial community which 
plays an intricate role in health and disease. Many species that make up the intestinal 
microbiota produce antimicrobial compounds which may confer a competitive 
advantage to producing organisms over other intestinal isolates, possibly facilitating 
dominance and aiding survival within the intestine. The objective of this study was to 
investigate the prevalence of antimicrobial production in the human gut microbiota and 
to mine this rich repository of metabolites for therapeutic potential. Faecal samples, 
obtained from 42 elderly subjects (≥65 yrs) and 7 non-elderly volunteers (22-57 yrs), 
were plated on to different growth media for the isolation of 1) total anaerobes; 2) non-
spore forming anaerobes; 3) Gram negative anaerobes; 4) total Enterobacteriaceae; and 
5) Bacteroides. Selected colonies from each plate were screened for inhibitory 
substances against four target organisms, Lactobacillus delbrueckii subsp. bulgaricus 
LMG 6901, Escherichia coli K-12, Bifidobacterium breve UCC2003, and Cronobacter 
sakazakii DPC6440. The data suggest that antimicrobial production by intestinal 
isolates against our chosen targets under the screening conditions used was not frequent 
(1.1% for E.coli K-12 and 0.2% for Lb. bulgaricus LMG6901). No isolates were found 
to inhibit B. breve UCC2003 and C. sakazakii DPC6440. Sixteen genetically distinct 
strains producing antimicrobial substances were investigated. A number of previously 
characterised bacteriocins including ABP-118 (from Lactobacillus salivarius), 
gassericin T (Lactobacillus gasseri), mutacin II (Streptococcus mutans) and enterocin 
L-50 and enterocin P (Enterococcus faecium) were identified. A number of E. coli 
strains were also isolated which produced heat labile antimicrobials, most likely colicins 
or microcins. Interestingly, a Lactobacillus crispatus strain was isolated and was found 
to produce a potentially novel heat labile antimicrobial compound which was resistant 
to protease activity in the cell-free supernatant. In conclusion, this extensive screening 
of the elderly faecal microbiota indicates that the frequency of isolating potentially new 
antimicrobial compounds is low.  
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2.0  Introduction 
It is estimated that the total microbial load of the human adult gastrointestinal tract 
(GIT) comprises 1013–1014 microbial cells (Gill et al., 2006), outnumbering human 
somatic and germ cells by a factor of ten (Quigley, 2010). The majority of bacteria are 
present in the large intestine where over 1000 different species are thought to reside 
(Ley et al., 2006; Qin et al., 2010). Here, they reach densities of 1011–1012 cells/mL of 
luminal content (Turroni et al., 2008).  
Microbes produce an array of antimicrobial compounds which include broad spectrum 
classical antibiotics, metabolic by-products such as lactic acid, lytic enzymes, several 
types of protein exotoxins, and bacteriocins (Riley & Wertz, 2002). Bacteriocins are 
defined as ribosomally synthesised antimicrobial peptides produced by numerous 
bacteria which exhibit inhibitory activity against bacteria, either in the same species 
(narrow spectrum) or across genera (broad spectrum) (Cotter et al., 2005). Producer 
organisms are immune to their own bacteriocin(s), a property that is mediated by 
specific immunity proteins (Cotter et al., 2005).  
Bacteriocins were first identified by Gratia in 1925 when a heat-labile substance in E. 
coli V culture supernatant was found to be toxic to Escherichia coli S (Gratia, 1925). 
Since then, hundreds of bacteriocins have been identified among most families of 
bacteria. It has been suggested that the vast majority of all bacteria and archaea 
probably produce at least one bacteriocin (Klaenhammer, 1988) which highlights the 
fundamental role that bacteriocins play in microbial systems (Gillor et al., 2009). 
However, their precise ecological role is an area of ongoing debate (Dobson et al., 
2012)  
 Bacteriocin production is thought to confer a competitive advantage on the producing 
strain, possibly allowing it to influence or to dominate complex microbial populations 
(O'Shea et al., 2009; Ryan et al., 1996; Ryan et al., 2001) such as those in the intestine. 
In fact, numerous bacteriocins from both Gram positive and Gram negative species 
resident within the large intestine have been isolated (Gordon & O'Brien, 2006; O'Shea 
et al., 2009; Rea et al., 2010). Indeed, it has been suggested that colicin production 
plays a significant role in the colonisation of E. coli in the GIT. Gillor et al. (2009) 
demonstrated that colicinogenic E. coli are able to persist in the large intestine of 
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streptomycin-treated mice for an extended period of time relative to their non-colicin 
producing counterparts. Similarly, bacteriocin production by the intestinal isolate 
Bifidobacterium longum subsp. longum DJ010A may be an important adaptation for GI 
survival. Simulated faecal competition studies revealed that B. longum DJ010A had a 
significantly increased ability to compete against Clostridium difficile and E. coli than 
did the non-producing isogenic variant B. longum DJO10-JH1. However, in vivo studies 
in an intestinal model would be necessary to verify this hypothesis (Lee et al., 2008).  
Bacteriocin production may be particularly important as killing peptides in vivo and a 
number of bacteriocins have shown potential for use in the control of gastrointestinal 
pathogens. Lactobacillus salivarius UCC118 produces a bacteriocin in vivo that was 
found to provide significant protection to mice against infection with Listeria 
monocytogenes (Corr et al., 2007). The faecal isolates, Lactococcus lactis MM19 and 
Pediococcus acidilactic MM33, producing the bacteriocins nisin Z and pediocin PA-
1/AcH, respectively were found to reduce intestinal colonization by vancomycin-
resistant enterococci (VRE) in a mouse model (Millette et al., 2008). Moreover, the 
relatively narrow killing spectrum of bacteriocins (Riley & Wertz, 2002) may reduce 
the collateral impact on the commensal flora typically seen with administration of 
antibiotics. A recent study reported that a narrow-spectrum bacteriocin, Thuricin CD, 
exhibited inhibitory activity against C. difficile (in an ex vivo model of the colon) which 
was as effective as conventional antibiotics (i.e. metronidazole and vancomycin) (Rea et 
al., 2010). Screening the intestinal microbial community may therefore be a practical 
approach for the isolation of novel bacteriocin producers which may have potential use 
as alternatives to antibiotics or as probiotics in the population. 
The present was based on a two-fold hypothesis: 1) that extensive screening would yield 
new antimicrobials with potential applications and; 2) that the extent of antimicrobial 
production would indicate that this feature must be a significant player in determining 
the balance of the gut microbiota. Hence, the objective of this study was to isolate 
culturable species from human faecal samples (collected from elderly subjects 
participating in the ELDERMET study and a group of non-elderly volunteers) and to 
investigate antimicrobial production by these isolates in vitro.  
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3.0  Materials and Methods 
3.1 Faecal sampling, storage and transport to laboratory 
Faecal samples were obtained from 42 elderly subjects (≥65 yrs) participating in the 
ELDERMET study. The subjects included patients from rehabilitation centres (n 4), 
healthy community-dwelling individuals (n 19), community-dwelling individuals taking 
antibiotics (n 17) and individuals hospitalised with C. difficile-associated diarrhoea (n 2) 
(Table 1). Faecal samples were also obtained from 7 non-elderly volunteers (5 males 
and 2 females, 22-57 yrs, mean age 33 yrs) who had not taken an antibiotic or probiotic 
in the previous 3 months. 
All faecal samples were collected into sterile containers and stored at 4ºC. ELDERMET 
samples were delivered to the ELDERMET clinics (Cork University Hospital/St. 
Finbarr’s Hospital, Cork). Upon delivery, approximately 4g of each faecal sample was 
immediately transferred to a sterile faecal specimen container (only fresh samples 
< 24 h old) and stored anaerobically in AnaeroGen W-Zip COMPACT pouches (Oxoid 
Ltd, Basingstoke, Hampshire, UK) at 4oC prior to dispatching on ice to the laboratory. 
Faecal samples from the non-elderly volunteers were delivered directly to the laboratory 
and stored anaerobically in Oxoid jars containing Anaerocult A (Merck KGaA, 
Darmstadt, Germany) as a reducing agent at 4oC. All samples were analysed within 24 h 
of arrival at the laboratory.   
3.2 Isolation and enumeration of anaerobic bacteria  
One gram of faecal sample was diluted ten-fold with 50 mM potassium phosphate 
buffer (pH 7) supplemented with 0.05% (w/v) cysteine hydrochloride (Sigma, Poole, 
Dorset, U.K) in a Seward stomacher bag. The sample was mixed well in the buffer, 
filtered to remove any large particles and debris, and transferred immediately to an 
anaerobic chamber containing an anoxic atmosphere (10% H2, 10% CO2, 80% N2).  The 
homogenised faecal samples were then serially diluted. 
Dilutions were spread-plated (100 µL) onto 5 different growth media (Table 2) and 
incubated anaerobically at 37°C. Antibiotic stocks were dissolved in distilled water and 
filter sterilized (0.45µM). Plates were examined after 1-3 days. If growth was sufficient, 
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colonies were enumerated. Bacterial counts were recorded as colony forming units 
(CFU) per gram of faeces. 
3.3 Screening anaerobic faecal isolates for anti-microbial production 
3.3.1 Bacterial strains and growth media  
All strains were maintained as 40% (v/v) glycerol stock at -80°C. Lactic acid bacteria 
(LAB) strains were grown anaerobically at 37ºC on de Man, Rogosa, and Sharpe (MRS; 
Difco Laboratories, Detroit, MI, USA) medium supplemented with 0.05% (w/v) 
cysteine hydrochloride (Sigma Chemical Co., St. Louis, MO, USA). All other bacterial 
strains were grown aerobically on brain-heart infusion (BHI) medium (Merck). Agar 
media were prepared by addition of 1.5% (w/v) agar to the medium; overlay agar 
contained 0.75% (w/v) agar. Anaerobic conditions were maintained in Oxoid jars 
containing Anaerocult A (Merck) as a reducing agent.  
3.3.2 Antimicrobial screening assay 
From each of the selective agar plates (VRBD, NAT, NAV and modified Bile Esculin 
Agar), 100 colonies were screened for inhibitory substances by the deferred antagonism 
plate test (Tagg et al., 1976). Briefly, isolates were spot inoculated onto the surface of a 
non selective agar plate (Table 3) and incubated anaerobically overnight at 37°C. Fifty 
different isolates arranged in a grid pattern were inoculated onto a single plate.  
Following incubation, colonies were overlaid with the indicator strains Escherichia coli 
K-12 (49 samples), Lb. delbrueckii subsp. bulgaricus LMG 6901 (47 samples), 
Bifidobacterium breve UCC2003 (21 samples) and Cronobacter sakazakii DPC6440 
(19 samples). Wilkins Chalgren agar plates were overlaid directly. The overlaid plates 
were incubated at 37oC for 24 h. Inhibitory activity was demonstrated by a clear zone 
around the colonies. Colonies surrounded by zones of inhibition were then sub-cultured 
back onto fresh medium to purify. These colonies were then stocked for later 
characterisation. 
3.3.3 Cell-free-supernatant assay  
Antimicrobial activity in the cell-free supernatant (CFS) of the isolates was confirmed 
using the agar well diffusion method (Ryan et al., 1996). To eliminate inhibition of the 
Chapter 6 
181 
 
indicator strains being due to acid production, the CFS was adjusted to pH 6.8-7.0 with 
1M NaOH then filter sterilised (0.45µM). Antimicrobial activity of the neutralised CFS 
was assessed against a selection of bacterial strains (Lb. bulgaricus LMG 6901, E. coli 
K-12, B. breve UCC2003, C. sakazakii DPC6440, Listeria innocua DPC 3572, Listeria 
monocytogenes DPC3785, Staphylococcus aureus DPC 5245, Salmonella typhimurium 
DPC 6452, S. typhimurium DPC 6046 and E. coli DPC 6239. The antimicrobial activity 
of Lb. crispatus for checked against a further 20 indicator stains (Table 4). Plates were 
examined for inhibition of growth following 24 h incubation.  A clear zone of inhibition 
was recorded as positive.  
3.3.4 Effect of enzymes, heat and pH  
The proteinaceous nature of the inhibitor was demonstrated by its sensitivity to the 
proteolytic enzyme, proteinase K from Tritirachium album as described previously (Rea 
et al., 2010). The neutralised CFS of Lb. crispatus was also treated with additional 
proteolytic enzymes, trypsin, α-chymotrypsin, pronase, protease and pepsin (all 
enzymes obtained from Sigma).  
Filter sterilized catalase (Sigma) was added to the neutralised CFS to evaluate if 
hydrogen peroxide (H2O2) was involved in the antimicrobial activity of the culture 
supernatants. The CFS was treated with catalase (25mg mL-1) for 3 h at 37°C.  
Neutralised CFS (1 mL) was incubated in a heating block at 80°C for 15 and 30 min and 
at 100°C for 30 min to evaluate the heat stability of the inhibitory substances, The CFS 
of the Lactobacillus crispatus strain was further treated at 45, 50, 55, 60, 65, 70, 75 and 
80ºC for 15 min.  
The pH of the CFS was adjusted to a selection of values between 2.0 and 12.0 using 
1M NaOH and 1M HCl in order to evaluate the effect of pH on the antimicrobial 
activity of Lb. crispatus. These samples were incubated at room temperature for 3-4h. 
The residual activity of all treated samples was then assayed against the appropriate 
indicator strain. Untreated, neutralised CFS was used as a positive control. 
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3.3.5 Dialysis 
In order to estimate the molecular weight of the Lb. crispatus antimicrobial, the CFS 
was subjected to dialysis. Briefly the CFS was placed in cellulose dialysis tubing (12-
4,000 Da cut-off; Spectrum® Laboratories) then dialysed against 1 L volumes of 
phosphate buffered saline at 4°C, with three buffer changes over 24h. The dialysate was 
tested for the presence of antibacterial activity using the agar well diffusion method, as 
described above. 
3.4 Genetic characterisation of bacterial isolates with anti-microbial properties  
3.4.1 Genomic DNA extraction 
Cells in 2 mL of an overnight culture were sedimented by centrifugation. DNA was 
extracted using GenEluteTM Bacterial Genomic DNA Kit (Sigma) following the 
manufacturer’s instructions. 
3.4.2 Gene sequencing analysis to identify bacterial isolates  
The 16S eubacterial ribosomal DNA (rDNA) primers, CO1 and CO2 (Table 5) were 
used to generate an approximate 1.5-kb 16S rDNA fragment (Simpson et al., 2003). The 
sequence of the 16S rRNA gene was determined by Sanger sequencing (Beckam 
Coulter, Essex, UK) and was used to identify the isolates using a National Centre for 
Biotechnology Information (NCBI) BLAST (basic local alignment search tool) database 
search (http://blast.ncbi.nlm.nih.gov). Comparison of the 16S rRNA gene sequences 
obtained using the BLAST program allowed assignment of a strain to a particular 
species. In general, when 16S rRNA gene similarity values exceed 97%, the strains are 
considered to belong to the same species (Stackebrandt & Goebel, 1994; Wall et al., 
2007). For Enterococcus isolates, further PCR analysis was used to distinguish the 
species present using previously published species-specific primers (Table 5) (Jackson 
et al., 2004).  
3.4.3 Random amplification of polymorphic DNA (RAPD) PCR on E.coli isolates 
RAPD PCR was performed on the antimicrobial producing E. coli isolates in an initial 
attempt to distinguish and group them. Good discrimination was found with the random 
primer, P1 (Simpson et al., 2002) which was therefore used in this genetic screen. 
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3.4.4 Pulsed Field Gel Electrophoresis (PFGE) of bacterial isolates 
PFGE analysis was performed using the restriction endonuclease Xba1, as previously 
described (Ribot et al., 2006) to confirm the genetic groupings of E. coli isolates 
exhibiting distinct RAPD PCR fingerprints and to make a final grouping. The 
Salmonella serotype Braenderup H9812 standard was used for comparison between 
gels. For Lactobacillus and Enterococcus isolates, PFGE was performed as previously 
described (Simpson et al., 2002) using the ApaI enzyme. A low-range molecular weight 
DNA marker (9.42-194.0 Kb; New England Biolabs, Beverly, MA, USA) was used to 
determine band size. Electrophoresis was performed in a Bio-Rad CHEF-DR III 
instrument (Bio-Rad Laboratories, Richmond, CA, USA). For each PFGE pattern, one 
strain was selected for further analysis.  
3.4.5 Bacteriocin-encoding gene sequencing to identify bacteriocins 
The presence of bacteriocin encoding genes was studied by PCR amplification with 
primers specific for the structural genes of previously characterised bacteriocins (Table 
5). All PCR reactions were performed using a G-Storm PCR machine (Mason 
Technologies). PCR products were purified using a QIAquick PCR purification kit 
(Qiagen) and sequenced by Beckham Coulter Genomics. The DNA sequences were 
compiled and analysed using the Lasergene 7 software package (DNAstar Inc., 
Madison, WI). BLASTP (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to find 
homologous proteins to the nucleotide coding regions within the nucleotide sequence. 
3.5 Matrix-assisted laser desorption/ionization time-of-flight (MALDI TOF) Mass 
Spectrometry to confirm presence of bacteriocins 
MALDI-TOF mass spectrometry is a method which allows accurate determination of 
peptide masses and has been used to confirm the presence of bacteriocins (Mills et al., 
2011). Mass spectrometry in all cases was performed with an Axima TOF2 MALDI 
TOF mass spectrometer (Shimadzu Biotech, Manchester, UK) as described previously 
(Field et al., 2008). The antimicrobial peptide of S. mutans was detected using colony 
mass spectrometry. Briefly, colonies were collected from a mMRS agar plate using a 
sterile plastic loop, mixed with 70% (v/v) propan-2-ol (IPA) containing 0.1% (v/v) 
trifluoric acid (TFA), vortexed 3 times and centrifuged. The supernatant was removed 
and used for analysis.  
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The antimicrobial peptides of Lb. gasseri and Lb. salivarius were detected using a larger 
scale preparation - a 40 mL overnight culture of the producing strain. Cells were 
harvested by centrifugation, resuspended in 70% IPA 0.1% TFA and stirred at room 
temperature for 3-4 h. Cells were removed by centrifugation and the propan-2-ol was 
removed by rotary evaporation. The resultant preparation was applied to a Strata C18 
solid phase extraction (SPE) column (Phenomenex, Cheshire, UK) pre-equilibrated with 
methanol and water. The column was washed with 30% (v/v) ethanol and the 
antimicrobial peptides were subsequently eluted with 70% IPA 0.1% TFA.  
The antimicrobial peptide of E. faecium was detected in the CFS. A 2L overnight 
culture of E. faecium EM345 N-2 was centrifuged and the supernatant was passed 
through a column containing 60 g hydrophobic XAD beads (Amberlite XAD16, 
Phenomenex, Chesire, UK). The column was washed with 30% (v/v) ethanol and the 
antimicrobial peptides were eluted with 70% IPA 0.1% TFA. The propan-2-ol was 
removed by rotary evaporation and the resultant preparation was applied to a SPE 
column as described above. Following elution, the propan-2-ol was removed by rotary 
evaporation and the sample was applied to a Grace Vydac C8 semi-preparation column 
(10 mm x 250 mm) running a 25-65% acetonitrile 0.1% (vol/vol) TFA gradient over 
45 min. Individual fractions were assayed by well diffusion using the sensitive indicator 
strain, L. bulgaricus LMG 6901. MALDI-TOF mass spectrometry was performed to 
determine fractions containing the peptides of interest.  
3.6 Statistical Methods 
The Mann Whitney test was applied using PASW Statistics (version 18), to determine 
differences in bacterial counts between the elderly group and the non-elderly volunteers. 
Statistical significance was accepted at P<0.05. 
4.0  Results 
4.1 Isolation and enumeration of anaerobic bacteria 
In total, 49 faecal samples (42 ELDERMET samples and 7 non-ELDERMET samples) 
were obtained for microbiological analysis. Total levels (CFU/g faeces) of cultivable 
anaerobes, non-spore forming anaerobes (non-clostridial anaerobes), Gram negative 
anaerobes, Bacteroides group and Enterobacteriaceae were enumerated on selective 
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media for 47 of these subjects. Faecal samples from 2 elderly subjects were processed 
but bacterial counts were not recorded as the samples were not processed within the 
appropriate time period. There was a large inter-individual variation in the levels of 
bacteria recovered from faecal samples (Fig. 1). Enterobacteriaceae levels showed the 
most variation with counts ranging from 4.00 to 10.18 log10 CFU/g faeces. Significantly 
higher numbers of total anaerobes were detected in the non-elderly group than in the 
elderly group (P<0.05). Median numbers of total anaerobes in the non-elderly group 
and the elderly group were 10.36 log10 CFU/g faeces and 9.99 log10 CFU/g, 
respectively.  
4.2 Screening anaerobic faecal isolates for anti-microbial production 
4.2.1 Screening assay 
Bacterial isolates were screened for antimicrobial activity against Lb. bulgaricus LMG 
6901, E. coli K-12, B. breve UCC2003 and C. sakazakii DPC 6440 (Table 6). Lb. 
bulgaricus LMG 6901 and E. coli K-12 were chosen for the initial screening as the 
former is a Gram positive antimicrobial-sensitive, acid-resistant strain (Casey et al., 
2004) while the latter is a Gram negative strain which has been shown to be sensitive to 
colicins (Gordon and O'Brien, 2006). B. breve UCC2003 is a Gram positive gut 
commensal bacterium while C. sakazakii DPC 6440 is a Gram negative pathogen, 
which has been responsible for illness in infants fed contaminated infant formula 
(Gurtler et al., 2005).  
In total, over 23,000 isolates from 47 faecal samples were screened against Lb. 
bulgaricus LMG 6901. Antimicrobial activity was detected from a total of 49 isolates 
from 8 different subjects as indicated by zones of clearing in deferred antagonism 
assays (for example, see Fig. 2), representing an isolation frequency of 0.2% in the 
initial screening.  
Over 24,000 isolates from 49 faecal samples were screened against E. coli K-12. Of 
these, 259 isolates from 12 different subjects produced zones of inhibition against 
E. coli K-12 representing an isolation frequency of 1.1% in the initial screening. For a 
number of individuals, a high incidence of antimicrobial production among the 
Enterobacteriaceae family was discovered (Table 7). For one subject, EM338, 70 out of 
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the 74 Enterobacteriaceae isolates examined, produced inhibitory activity against E. 
coli K-12. (Fig. 3). 
Colonies showing zones of inhibition against B. breve UCC2003 and C. sakazakii DPC 
6440 were not detected in this study. 
4.2.2 Cell-free supernatant assay 
All the bacterial isolates were collected and purified using general microbiological 
purification methods. Antimicrobial activity was confirmed in the neutralised CFS of 62 
isolates (42 with activity against E. coli K-12 and 20 with activity against Lb. 
bulgaricus LMG 6901) which demonstrated the presence of potential bacteriocins.  
4.3 Characterisation of bacterial isolates with anti-microbial properties 
4.3.1 Identification of bacterial isolates 
The 62 antimicrobial producers were identified through analysis of the 16S rRNA DNA 
sequence of each isolate. Enterococcus strains had their identity confirmed using 
species-specific PCR amplification. Isolates were identified as follows: Lb. salivarius 
(10), Lb. gasseri (4), Lb. crispatus (2), Enterococcus faecium (3), Streptococcus mutans 
(1), and E. coli (42). 
4.3.2 RAPD PCR on E. coli isolates 
RAPD analysis was performed on the antimicrobial-producing E. coli isolates. Primer 
P1 generally generated 5–7 DNA fragments ranging in size from 100 bp to 1.5 kb per 
isolate. RAPD PCR was performed on the 42 E. coli isolates obtained from the 
12 elderly subjects. RAPD PCR grouped these isolates into approximately 15 genotypes 
(Fig. 4) and the profiling revealed that most of the faecal samples potentially contained 
one dominant strain type. Only four of the subjects appeared to harbour multiple strains, 
with sample EM338 having what appeared to be 3 genetically distinct strains and 
samples, EM357, EM362 and EM371 each having two genetically distinct strains. In 
addition, isolates from two separate individuals with the same RAPD PCR profile were 
found on only two occasions.  
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4.3.3 PFGE strain discrimination of E. coli isolates 
PFGE has been shown to have a higher discriminatory power than RAPD-PCR. 
Therefore, to confirm the genetic groupings of all faecal isolates and to make a final 
grouping, PFGE analysis was performed using the restriction endonuclease, XbaI. 
PFGE grouped the isolates into approximately 11 genotypes (for example, see Fig. 5). 
Indeed a number of isolates which appeared to have different RAPD fingerprinting 
patterns had identical PFGE fingerprinting patterns. In another case, two strains which 
appeared to have the same RAPD fingerprinting pattern showed different patterns when 
PFGE was performed.  
This analysis revealed that most of the faecal samples potentially contained one 
dominant strain type. One subject harboured two different strains. Isolates from two 
separate individuals with the same PFGE profile were found on only two occasions.  
4.3.4 PFGE strain discrimination of Lactobacillus/Enterococcus isolates 
PFGE analysis (using Apa1 restriction endonuclease) was performed on the 
antimicrobial-producing Lactobacillus (16 strains) and Enterococcus strains (3 strains) 
to distinguish and group them. PFGE analysis grouped Lactobacillus strains into 3 
genotypes (for example, see Fig. 6). This analysis revealed that subject EM307 
contained one dominant antimicrobial producing Lb. salivarius strain type. In addition, 
this particular strain was also found in subject EM366. As regards the antimicrobial-
producing Lb. gasseri, one strain was found in both subject EM350 and subject EM351. 
Similarly, a single E. faecium was found in two subjects (EM345 and SP006)  
4.3.5 Effect of enzymes, heat and pH 
Treatment of the CFS with the proteolytic enzyme, proteinase K resulted in loss of 
antibacterial activity suggesting the antimicrobials have a proteinaceous moiety (Table 
8). However, for the Lb. crispatus strains there was no loss of antimicrobial activity. 
The CFS of this strain was further treated with additional proteolytic enzymes, pepsin, 
pronase and protease and these also failed to eliminate activity. α-chymotrypsin and 
trypsin both inhibited the indicator strain and were therefore deemed inappropriate for 
use. The antimicrobials of a number of bacterial strains (E. coli and Lb. crispatus) were 
found to be heat labile, others were found to be heat stable up to 100ºC for 30 min 
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(Table 8). Further investigation revealed that the antimicrobial activity of Lb. crispatus 
was lost after heat treatment at ~60ºC for 15 min. Furthermore, adjustment of the pH of 
the CFS of Lb. crispatus resulted in loss of antimicrobial activity at pH 2.0 and pH 11.0. 
The antimicrobial activity remained in membrane dialysis tubing with a cut-off pore 
size of 12-14 kDa indicating it was large in size.  
4.3.6 Inhibitory Spectrum 
The inhibitory spectrum of the 16 genetically distinct strains (Lb. gasseri, Lb. 
salivarius, Lb. crispatus, E. faecium, S. mutans and E. coli strains) was investigated. 
The Lb. salivarius and the E. faecium isolates were shown to inhibit L. innocua and L. 
monocytogenes in addition to Lb. bulgaricus (Table 9). Lb. crispatus did not inhibit any 
of the additional indicator strains used.  
4.3.7 Identification of bacteriocins 
The presence of structural genes for a number of known bacteriocins was identified in 
the DNA of the isolates and the actual production of the bacteriocin was confirmed 
using MALDI-TOF mass spectrometry. For example, PCR and amplicons sequence 
analysis of Lb. gasseri confirmed the presence of the structural gene for gassericin T. 
MALDI-TOF mass spectrometry was then used to confirm the presence of a peptide of 
5542 Da which corresponds to the molecular mass gassericin T (http://bactibase.pfba-
lab-tun.org/BAC117) (see Fig. 7). Table 9 displays a summary of the faecal isolates 
exhibiting antimicrobial activity. 
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5.0   Discussion 
In the present study, we investigated the culturable microbiota of 42 elderly subjects 
(≥65 yrs) participating in the ELDERMET project and 7 non-elderly volunteers (22-57 
yrs). Culture-based techniques have been routinely used to determine the bacterial 
composition of faeces (Hopkins et al., 2001; O’Sullivan et al., 2011) and the estimate of 
cultivability of gastrointestinal bacteria is approximately 10–50% (Adlerberth and 
Wold, 2009; O'Toole and Claesson, 2010). It has recently been reported that the 
majority of intestinal bacterial taxa are actually culturable under controlled anaerobic 
conditions and that usage of culture media that more accurately replicates the gut 
environment will facilitate further exploration of the human gut microbiota in vitro 
(Goodman et al., 2011). The bacterial numbers recovered in this study correspond well 
with previous culture-based studies on human faecal microbiota (Bouhnik et al., 2007; 
Delgado et al., 2006; Guigoz et al., 2002; Hayashi et al., 2002; Holdeman et al., 1976; 
Hopkins et al., 2001; Mättö et al., 2005; Meijer-Severs & Van Santen, 1986; O’Sullivan 
et al., 2011; Woodmansey et al., 2004). The non-elderly volunteers had significantly 
more total anaerobes in their faeces compared to elderly subjects. Indeed, it has been 
widely documented that the elderly microbiota differs from that of younger adults 
(Claesson et al., 2011) and just under half of our elderly group were on antibiotics 
which have been shown to dramatically disturb the composition of the microbiota 
(Woodmansey et al., 2004). However, there was no significant difference in the levels 
of cultivable non-spore forming anaerobes, Gram negative anaerobes, 
Enterobacteriaceae and Bacteroides between the elderly and the non-elderly group.  
Faecal bacteria were screened for isolates with the ability to inhibit the growth of 1) a 
Lactobacillus bulgaricus strain, 2) a Bifidobacterium breve strain, 3) an E. coli strain 
and 4) a Cronobacter sakazakii strain. Although this study was extensive, a limited 
number of bacteriocin-producing bacteria were isolated. We recovered 49 isolates (from 
8 subjects) with inhibitory activity against Lb. bulgaricus LMG 6901 (0.2% frequency) 
and 20 of these isolates had activity in the cell-free supernatant (CFS). Two hundred 
and fifty nine isolates (from 12 subjects) displayed inhibitory activity against an E. coli 
K-12 (1.1% frequency) and 42 of these isolates showed activity in the CFS. No isolates 
were shown to inhibit B. breve UCC2003 and C. sakazakii DPC 6440. Indeed, only a 
limited number of bacteriocin producing-Bifidobacterium strains have been isolated 
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previously (Martinez et al., 2013). Additionally, B. breve UCC2003 has been shown to 
produce EPS (Fanning et al., 2012) which may offer some protection to cells against 
antimicrobial agents (Sutherland, 2001). Cronobacter on the other hand, is not typically 
found in the normal mammalian intestinal tract, which may be a plausible reason as to 
why no bacteriocins of intestinal origin were found to target this pathogen in the present 
study.  
The frequency of isolation of antimicrobial producing isolates between elderly and non-
elderly subjects and antibiotic-treated and non-antibiotic treated individuals were 
compared. Isolates derived from elderly faecal samples showed more inhibitory activity 
against E. coli compared to the isolates derived from non-elderly subjects. 
Antimicrobial producing isolates with activity against Lb. bulgaricus were more 
frequently isolated from non-antibiotic treated individuals compared to antibiotic-
treated individuals. Nonetheless, these observations should be interpreted with caution 
given the limited number of non-elderly subjects that were sampled in this study. 
The overall low frequency of isolation of bacteriocin-producing bacteria found in the 
present study may be due to number of inherent limitations incurred by using culture-
based screening methods (O'Shea et al., 2009): 1) the genes responsible for bacteriocin 
production are typically tightly regulated – therefore, bacteriocin production may go 
undetected under conditions where the responsible operons are switched off 
(Kleerebezem, 2004); 2) bacteriocins generally have a narrow spectrum of inhibitory 
activity and might not be detected using only a low number of indicator strains for 
screening (De Vuyst et al., 2004) and; 3) culture-based methods can limit the screening 
study to the “easy-to-culture” intestinal bacteria. Therefore these culture methods are 
likely to only allow for the detection of a small fraction of potential bacteriocin-
producing bacteria in the intestine. In order to overcome these limitations, culture-
independent, genomic mining tools, such as BAGEL, may be employed more frequently 
in the future (de Jong et al., 2010; De Jong et al., 2006). 
In the present study, 42 E. coli isolates were found to inhibit E. coli K-12 in the CFS. 
Although E. coli does not represent a major group of bacteria of the intestinal 
microbiota, it is a normal and ecologically important inhabitant of the human gut 
(Blum-Oehler et al., 2003). Molecular fingerprinting using PFGE revealed 11 
genetically distinct E. coli strains, indicating a high incidence of repeated isolation of 
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antimicrobial producing strains, particularly within individual intestinal samples. Indeed 
for one subject, 70 out the 74 Enterobacteriaceae isolates inhibited the indicator stain E. 
coli K12. This high incidence of an antimicrobial producing E. coli in the gut supports 
the theory of dominance within complex ecosystems as a consequence of antimicrobial 
production.  
Although the antimicrobial compounds produced by the E. coli strains were not 
identified, it is likely that these heat-labile peptides are colicins or microcins, well 
characterised bacteriocins produced by and active against strains of E. coli and several 
related species in the Enterobacteriaceae family (O'Shea et al., 2012). Colicins have a 
narrow spectrum mainly targeting strains of the same species, whereas microcins have 
activity against a wider spectrum of strains (Šmajs et al., 2012). To date, approximately 
26 colicins and 14 microcin types have been identified (Rebuffat, 2011; Šmajs et al., 
2010). In a recent paper, Smajs et al. (2010) claimed that 55% of over 411 E coli 
isolates from human sources produced colicins. Gordon & O’Brien (2006) found that 
38% of human E. coli strains produce colicins. Although the ecological meaning of 
colicinogeny is largely unknown (Gordon & O'Brien, 2006), it is generally believed that 
colicins participate in the intraspecific or interspecific competition in the colon 
microbiota facilitating its introduction into novel habitats (Šmarda & Obdržálek, 2001).  
The 42 isolates with activity against Lb. bulgaricus LMG 6901 were reduced to 5 
genetically distinct strains through further characterisation. One of the isolates, E. 
faecium, was found to have inhibitory activity against Lb. bulgaricus LMG 6901, L. 
innocua DPC 3572 and L. monocytogenes DPC 3785. Enterococci are natural 
inhabitants of the GIT and produce an impressive array of different bacteriocins (Franz 
et al., 2007). In the present study, the E. faecium was found to produce both enterocin 
L-50 and enterocin P, as described previously (Cintas et al., 2000).  
One isolate, Streptococcus mutans which inhibited growth of Lb. bulgaricus LMG 6901 
was found to product mutacin II. S. mutans is generally not associated with gut derived 
organisms but is found to inhabit the oral cavity where it is generally accepted as one of 
the principal aetiological agents of dental caries (Kamiya et al., 2005). A previous study 
by our group also isolated a mutacin II-producing S. mutans strain from another elderly 
faecal sample (Lakshminarayanan et al., 2013). Mutacins are likely to confer an 
ecological advantage in diverse bacterial communities (Kamiya et al., 2005). Indeed, 
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researchers have found a strong correlation between the ability of a S. mutans strain to 
colonise the oral cavity and the production of the bacteriocin mutacin 1140 (Hillman, 
2002).  
A number isolates with inhibitory activity against Lb. bulgaricus LMG 6901 were 
identified as lactobacilli. Lactobacillus spp. are thought to play a fundamental role in 
stabilization of the microflora by providing an important microbial defence against 
intestinal colonisation by exogenous pathogenic microorganisms (Song et al., 1999). 
This screening study resulted in the isolation of a Lb. gasseri strain producing the 
bacteriocin, gassericin T. Lb. gasseri appears to be one of the main species of 
lactobacilli that inhabits the human GIT (Delgado et al., 2007) and gassericin T is a 
broad-spectrum bacteriocin which has previously been isolated from human faeces 
(Kawai et al., 2000; Lakshminarayanan et al., 2013). Another faecal isolate, Lb. 
salivarius, showed inhibitory activity against Lb. bulgaricus LMG 6901, L. innocua 
DPC 3572 and L. monocytogenes DPC 3785 and was found to produce ABP-118. ABP-
118, a two component class II bacteriocin produced by the probiotic bacterium Lb. 
salivarius subsp. salivarius UCC118, was originally isolated from a human intestinal 
tract. Most notably, Corr et al. (2007) found that Lb. salivarius UCC118 provided 
protection against L. monocytogenes in mice and this inhibition was shown to be the 
direct results of the production of ABP118.  
A Lb. crispatus strain with inhibitory activity against Lb. bulgaricus LMG 6901 was 
also isolated in this study. Lb. crispatus is one of the predominant hydrogen peroxide 
(H2O2) producing species found in the vagina and is under development as a probiotic 
for the treatment of bacterial vaginosis (Antonio & Hillier, 2003; Hemmerling et al., 
2010).  Lb. crispatus has also been previously isolated from faecal samples (Song et al., 
1999) and the protective effects of dietary supplementation of Lb. crispatus on 
experimentally induced colitis in mice has been investigated (Castagliuolo et al., 2005). 
The antimicrobial activity appeared to be heat labile, narrow spectrum and insensitive to 
protease inactivation in the CFS. In addition, the antimicrobial agent appeared to be 
large (>10 kDa), which is atypical of Class I and Class II bacteriocins (Cotter et al., 
2005). A bacteriocin produced by a Lb. crispatus, crispacin A, has been characterised 
(Tahara and Kanatani, 1997). However, in contrast to the antimicrobial isolated in the 
present study, crispacin A was small in size (5393 Da), heat stable and sensitive to 
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proteolytic enzymes. Further work will aim to identify and characterise the 
antimicrobial compound produced by Lb. crispatus. 
In conclusion, this screening system resulted in the isolation of a number common 
intestinal species (E. coli, Lb. salivarius, E. faecium) with antimicrobial activity, but 
more significantly also selected for S. mutans, a species not normally detected among 
the human intestinal microbial community. Compounds that inhibit growth or kill 
gastrointestinal pathogens such as L. monocytogenes were produced by bacteria residing 
in the intestine of elderly Irish subjects. Interestingly, a Lactobacillus crispatus strain 
(EM-LC1) was isolated which was found to produce a potentially novel heat labile 
antimicrobial compound which was resistant to protease activity in the cell-free 
supernatant. The present work increases our knowledge regarding antimicrobial 
production among intestinal bacteria and suggests that perhaps the culture-based 
isolation of antimicrobials is now limited in its potential to isolate novel bacteriocin-
producers as indicated by the repeated isolation of previously characterised bacteriocins 
in this extensive screening study. 
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Table 1.  Stratification of ELDERMET subjects (n=42) 
Major property Details No. of subjects 
Community  
 
subjects living independently in the 
community. 
7 
Day hospital/Out-patients  
 
subjects from the Elderly Services Day 
Hospital, St. Finbarr’s Hospital & Out-
Patients Clinic, Cork University Hospital. 
12 
Antibiotic-treated Community 
  
subjects living independently in the 
community who have received an oral 
antibiotic within 4 weeks of collection of 
sample. 
17 
Rehab/In-patients 
 
community-dwelling subjects, recruited 
from the rehabilitation wards during their 
in-patient stay. 
4 
Clostridium difficile-infected subjects hospitalised with Clostridium 
difficile–associated diarrhoea (CDAD) 
2 
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Table 2.  Growth medium used to enumerate anaerobic bacteria from faecal samples 
aOxoid Ltd; bOxoid Ltd. The supplement contains nalidixic acid as the selective agent. The medium is particularly useful for the 
recovery of non-sporing Gram-positive anaerobes since the presence of ‘Tween 80’ stimulates their growth; cCruinn Diagnostics, 
Dublin, Ireland; dOxoid Ltd. The supplement contains nalidixic acid and vancomycin as the selective agents making the medium 
selective for Gram negative bacteria; eMerck; fSigma. Selective inhibition of facultative anaerobes and most gram-negative 
anaerobic organisms is obtained by the presence of gentamicin and bile;  gDuchefa Biochemie, Haarlem, The Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
Agar   Selective for Incubation 
Time 
Wilkins-Chalgen (WC) anaerobe agara  Total anaerobes 48h 
NAT medium (Wilkins Chalgren with N-S 
anaerobe selective supplement)b + 0.1% 
Tween 80 + 5% (v/v) defibrinated horse 
bloodc  
 
 Non-spore forming anaerobes 48h 
NAV medium (Wilkins Chalgren with G-N 
anaerobe selective supplement)d + 5% (v/v) 
defibrinated horse bloodc 
 
 Gram negative anaerobes 48h 
Violet Red Bile Dextrose (VRBD) agare  Total Enterobacteriaceae 24h 
Bile Esculin Agar (BEA)f with 100 µg/mL 
gentamicinf, 7.5 µg/mL vancomycing and 
10µg/mL Heminf 
 Bacteroides  
 
72h 
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Table 3.  Media used for the deferred antagonism plate test 
Isolation Media: Re-spot 100 colonies on to: 
VRBD agar   Brucella Agara supplemented with 
Heminb (5µg/mL) and Vitamin K1b 
(1µg/mL) 
NAT medium  Wilkins-Chalgren (WC) anaerobe agarb 
NAV medium  Wilkins-Chalgren (WC) anaerobe agar 
Modified Bile Esculin Agar (BEA) Brucella Agar supplemented with Hemin 
(5µg/mL) and Vitamin K1 (1µg/mL)  
aBeckton Dickinson Microbiology Systems. Cockeysville, Md. bSigma 
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Table 4.  Indicator strains used for characterisation of Lb. crispatus antimicrobial 
Indicator Strain Culture 
Medium 
Growth 
Temperature 
(ºC) 
Condition 
Lactococcus lactis HP GM17 30 Aerobic 
Lactococcus lactis MG1363 GM17 30 Aerobic 
Enterococcus casseliflavus 5053 GM17 37 Aerobic 
Enterococcus durans 5133 GM17 37 Aerobic 
Enterococcus faecium 5119 GM17 37 Aerobic 
Staphylococcus aureus DPC5247 BHI 37 Aerobic 
Streptococcus agalactiae ATCC 13813 BHI 37 Aerobic 
Lactobacillus salivarius AH4231 MRS 37 Anaerobic 
Lactobacillus salivarius UCC119 mMRS 37 Anaerobic 
Lactobacillus salivarius UCC118 mMRS 37 Anaerobic 
Lactobacillus fermentum L34 mMRS 37 Anaerobic 
Lactobacillus plantarum WCFS1 mMRS 37 Anaerobic 
Lactobacillus plantarum NCIMB 8826 mMRS 37 Anaerobic 
Lactobacillus paracasei B636-43364 mMRS 37 Anaerobic 
Lactobacillus casei Shirota mMRS 37 Anaerobic 
Lactobacillus sakei LMG2313 mMRS 37 Anaerobic 
Lactobacillus reuteri DSM20016 mMRS 37 Anaerobic 
Lactobacillus acidophilus ATCC4356 mMRS 37 Anaerobic 
Lactobacillus johnsonii DSM 20553 mMRS 37 Anaerobic 
Lactobacillus rhamnosus CCUG 36679 mMRS 37 Anaerobic 
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Table 5.  Primers used in this study 
*Primers were obtained from Sigma 
 
Primer* Sequence (5 ́ to 3)́ Specificity Amplicon size  
(bp) 
Annealing temp. 
(ºC) 
References 
CO1 AGTTTGATCCTGGCTCAG 16S rRNA gene 1500 50 (Simpson et al., 2003) 
CO2 TACCTTGTTACGACT     
P1 ACGCGCCCT RAPD primer - 36 (Simpson et al., 2002) 
Gass T – F TGGATTTAAATTGCCTGAAAC Gassericin T gene 645 58 (Lakshminarayanan et al., 2013) 
Gass T – R CATTCCCCCACTTGTTTCC     
118α - F ATGATGAAGGAATTTACAG ABP 118 gene 700 50 (Barrett et al., 2007) 
118im -R CCACGCTCTCACATAAC     
FM1 GAAAAAACAATAGAAGAATTAT E. faecium sodA  gene 215 55 (Jackson et al., 2004) 
FM2 TGCTTTTTTGAATTCTTCTTTA     
Mutacin II – F AACGCAGTAGTTTCTTTGAA Mutacin II gene 444 52 (Kamiya et al., 2005) 
Mutacin II – R TTCCGGTAAGTACATAGTGC     
Ent P – F GATGCAGCTACGCGTTCATATGG Enterocin P gene 138 56 This study 
Ent P – R ATGTCCCATACCTGCCAAACCA     
Ent L-50 – F GTGGAAAGCTAGTATTTGCAAC Enterocin L-50 gene 511 49 (Dezwaan et al., 2007) 
Ent L-50 – R AGCGTTAAGCCGAATGTTTACAC     
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Table 6.  Frequency of isolation of antimicrobial producing isolates from elderly and non-elderly individuals against Gram positive and Gram negative indicator strains  
 
 E. coli K-12 Lb. bulgaricus LMG 6901 B. breve UCC 2003 C. sakazakii DPC 6440 
Total subjects (n 49) No. of Isolates 259/24420 (1.06%) 49/23180 (0.21%) 0/9361 0/9230 
 No. of subjects 12/49 (24.50%) 8/47 (17.02%) 0/21 0/19 
Elderly subjects (n 42)  No. of Isolates 259/20720 (1.25%) 48/20580 (0.23%) 0/9061 0/9230 
 
No. of subjects 12/42 (28.57%) 7/42 (16.67%) 0/20 0/19 
Antibiotic  group (n 18) No. of Isolates 30/8862 (0.34%) 2/9044 (0.02%) - - 
 
No. of subjects 5/18 (27.78%) 1/18 (5.56%) - - 
Non-antibiotic group (n 24) No. of Isolates 229/11858 (1.93%) 46/11536 (0.4%) - - 
 
No. of subjects 7/24 (29.17%) 6/24 (25%) - - 
Non-elderly subjects (n 7) No. of Isolates 0/3700 1/2600 (0.04%) 0/300 0/0 
 
No. of subjects 0/7 1/5 (20.0%) 0/1 0/0 
 
Chapter 6 
200 
 
Table 7.  Subjects (n 12) showing inhibitory activity against E. coli K-12 within the Enterobactericeae 
family 
Subject Category Enterobactericeae 
Counta 
Colonies 
picked for 
screening 
No. of colonies 
producing zones 
of  inhibitionb 
Frequency 
% 
EM338 Rehab 6.8 x 106 74 70 94.6 
EM350 Rehab 8.9 x 106 100 6 6 
EM352 Community (antibiotic) 1.3 x 108 100 1 1 
EM354 Day Hospital 2.9 x 107 100 3 3 
EM355 Day Hospital 5.2 x 105 50 25 50 
EM357 Day Hospital 1.7 x 107 100 41 41 
EM362 (T3) Community 1.4 x 107 100 63 63 
EM371 Day Hospital 9.7 x 108 100 6 6 
EM372 Community (antibiotic) 7.8 x 107 75 6 8 
EM376 Community (antibiotic) 5.6 x 106 50 9 18 
EM377 Community (antibiotic) 2.9 x 107 100 7 7 
EM381 Community (antibiotic) 5.1 x 107 50 3 6 
aCFU/g faeces;  bzones of inhibition against the indicator strain E. coli K-12 
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Table 8.  Effect of enzymes and heat treatment on antimicrobial activity in anaerobic isolates 
Strain ID Identification No treatment 
Proteinase K 
treatment 
Heat treatment 
80ºC x 15 min 80ºC x 30 min 100ºC x 30 min 
EM338 V-8 E. coli 9 - - - - 
EM350 V-2 E. coli 10 - - - - 
EM352 V-1 E. coli 13 - - - - 
EM354 V-1 E. coli 13 - 8 8 - 
EM355 V-1 E. coli 11 - 7 6.5 - 
EM357 V-1 E. coli 13 - - - - 
EM362 V-2 E. coli 9 - 6.5 S - 
EM371 V-1 E. coli 9 - - - - 
EM372 V-1 E. coli 10 - - - - 
EM376 V-1 E. coli 10 - S - - 
EM381 V-1 E. coli 10 - - - - 
EM345 N-1 E. faecium 13 - 12 12 12 
EM350 N-1 Lb. gasseri 16 - 14 14 14 
EM307 NAT-1 Lb. salivarius 15 - 14 14.5 14.5 
EM307 WC-1 S. mutans 10 - 10 9 11.5 
EM367 WC-2 Lb. crispatus 10 10 - - - 
The diameters of the zones of inhibition, including the diameter of the well, which was approximately 5 mm; -: no zone of inhibition; S: slight zone of inhibition around periphery of well 
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Table 9.  Overview of faecal isolates exhibiting antimicrobial activity  
Strains a Strain IDs Activity against Heat 
stability 
Enzyme sensitivity Bacteriocin Identificationb 
Lb. 
salivarius 
EM307NAT1 Lb. bulgaricus LMG 6901, 
 L. innocua DPC 3572, 
 L. monocytogenes DPC 3785 
stable sensitive to proteinase K ABP-118 
Lb. 
crispatus 
EM-LC1 Lb. bulgaricus LMG 6901 
 
labile resistant to proteinase K, protease 
and  pepsin 
ND 
Lb. gasseri EM350N1 Lb. bulgaricus LMG 6901 
 
stable sensitive to proteinase K  Gassericin T 
E. faecium EM345N1 Lb. bulgaricus LMG 6901,  
 L. innocua DPC 3572,             
 L. monocytogenes DPC 3785 
stable sensitive to proteinase K  Enterocin L-50 A/B & Enterocin P 
S. mutans EM307WC1 Lb. bulgaricus LMG 6901 
 
stable sensitive to proteinase K  Mutacin II 
E. coli EM338V8, EM350V2, 
EM352V1, EM354V1, 
EM355V1, EM357V1, 
EM362V2, EM371V1, 
EM372V1, EM376V1, 
EM381V1  
E. coli K-12 labile sensitive to proteinase K  ND 
a identified by 16S rRNA gene analysis; b identified by bacteriocin structural gene sequencing and confirmed using MALDI-TOF-MS; ND: not determined 
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Figure 1.  Levels of total anaerobes (yellow boxes), non-spore forming anaerobes (blue boxes), Gram 
negative anaerobes (red boxes), Bacteroides (purple boxes) and total Enterobacteriaceae (green boxes), 
in faecal samples from 40 elderly subjects and 7 non-elderly subjects +, mean value; *, P<0.05 
comparisons between elderly and non-elderly subjects (Mann-Whitney test) 
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Figure 2.  Faecal isolates (from NAT plate) showing zones of inhibition against L. bulgaricus LMG 6901 
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Figure 3.  VRBD isolates from one subject (EM338) showing zones of inhibition against E. coli K-12 
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Figure 4.  Genetic fingerprinting by RAPD PCR of E. coli isolates.  This gel illustrates 14 of the 15 
RAPD profiles from 9 different subjects. (M = molecular weight marker) 
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Figure 5.  PFGE profiles generated using XbaI of a selection of ELDERMET E. coli isolates, with 
antimicrobial activity against E. coli K-12. (M = molecular weight marker, Salmonella serotype 
Braenderup H9812) 
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Figure 6.  PFGE profiles of a selection of ELDERMET Lactobacillus isolates, with anti-microbial 
activity against Lb. bulgaricus LMG6901 (M = molecular weight marker; Apa1 restriction enzyme) 
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Figure 7.  A) Genetic organization of a segment of the gassericin T biosynthetic gene cluster, including 
the structural genes (Gat A) and the predicted peptide sequence of the inhibitor from  Lb. gasseri EM350 
N-1. B) MALDI-TOF-mass spectrometry data of gassericin T produced by Lb.  gasseri (EM350 N-1)  
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1.0  Abstract 
Lactobacilli are Gram positive prokaryotes that naturally colonise the human gastro-
intestinal tract (GIT) and vagina. Although not numerically dominant in the complex 
intestinal microbiota, they are considered as key commensals that promote a healthy 
GIT. The draft genome sequence of an elderly-derived faecal isolate, Lb. crispatus EM-
LC1, which exhibited antimicrobial activity in vitro, was determined. The genome is 
composed of 1,862,161 bp with a G+C content of 36.9 %. It is predicted to contain 
1,827 putative coding DNA sequences (CDSs) representing an 87.6% coding density. 
The genome contains 45 transfer RNA genes. No rRNA locus was assembled due to 
exclusion of repetitive sequence from the assembly.  In silico analyses predicted 26 
transposase genes and a locus for a type I R/M system. Considerable transporter and 
fermentative capacities expected for organisms residing within the nutrient-rich 
conditions of the GIT were encoded on the genome. Several mucus-binding proteins, S-
layer proteins and a fibronectin-binding protein, implicated in adhesion to human 
intestinal cells, were identified. Two scaffolds were identified which bear the 
characteristics of integrated plasmids. Analysis of these two regions revealed the 
presence of a toxin/antitoxin system, of the zeta/epsilon family. Among the Lb. 
crispatus species with publically available genome sequences, Lb. crispatus ST1 is the 
only strain with a complete genome sequence available. The comparison of EM-LC1 to 
ST1 revealed 135 protein-encoding genes that were present in EM-LC1 but not in ST1. 
Among them are genes related to bacteriocin (helveticin) production, genes that code 
for a toxin/antitoxin system as well as a large number of genes encoding hypothetical 
proteins.  
 
Chapter 7 
219 
 
2.0  Introduction 
The lactic acid bacteria (LAB) are low G+C, Gram positive bacteria that produce lactic 
acid as the major fermentation end-product of sugars (Lahtinen et al., 2011). The LAB 
include a number of genera, the largest of which is the genus Lactobacillus. The 
lactobacilli encompass a considerable number of different species that display a 
relatively large degree of diversity (Claesson et al., 2007). A recent taxonomic revision 
of the Lactobacillus genus, based on 16S rRNA sequence analysis, indentified over 150 
species (Salvetti et al., 2012). Members of this genus are described as fastidious 
organisms frequently found in nutritionally-rich environments such as food and soil as 
well as the mouth, gastrointestinal and genital tract of humans and many animals 
(Salvetti et al., 2012). Indeed, the lactobacilli are considered a subdominant member of 
the human gut microbiota and some species are considered to have probiotic properties, 
offering a beneficial role in maintaining the health status of the host (Klaenhammer, 
2000). The most well known members of this group are classified as the ‘acidophilus 
complex’, composed of several species of closely related lactobacilli that have 
historically been isolated from the gastrointestinal tract of humans and animals 
(Altermann et al., 2005). They include Lb. acidophilus, Lb. gasseri, Lb. johnsonii, Lb. 
amylovorus, Lb. gallinarum and Lb. crispatus (Altermann et al., 2005; Forde et al., 
2011). Of these, Lb. acidophilus remains to be one of the most widely recognised and is 
a commercially distributed probiotic culture (Altermann et al., 2005). However more 
recently, interest in Lb. crispatus has been increasing. Indeed, Lb. crispatus can persist 
in the gastrointestinal tract (Walter, 2008) and is among the most prevalent species of 
the Lactobacillus-dominated human vaginal microbiota (Ma et al., 2012; Witkin et al., 
2007). Lb. crispatus strain CTV-05, a vaginally derived H2O2-producing strain, is a 
probiotic that is currently being evaluated for the treatment and prevention of bacterial 
vaginosis (Hemmerling et al., 2010).  
LAB are renowned for their production of antimicrobial peptides (bacteriocins), which 
display great diversity with respect to structure and mode of action varying from 
extensively post-translationally modified lantibiotics such as nisin to large unmodified 
heat labile proteins such as helveticin (De Vuyst, 2012). Bacteriocin production may be 
particularly important as killing-peptides in vivo. Lactobacillus salivarius UCC118 
produces a bacteriocin in vivo that was found to provide significant protection to mice 
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against infection with Listeria monocytogenes (Corr et al., 2007). Bacteriocin 
production may also confer a competitive advantage to the producing strain by allowing 
it to dominate complex microbial populations (O'Shea et al., 2009). Hence, bacteriocin 
production is considered a probiotic trait as it may aid probiotic survival within the 
intestine (Dobson et al., 2012).  
The determination of the complete genome sequence of an organism represents a crucial 
step in moving towards a better understanding of the organism in question. 
Haemophilus influenza was the first available microbial genome sequence (Fleischmann 
et al., 1995). Since then, the number of complete genome sequences is increasing 
rapidly, due to the availability of next-generation sequencing technologies at affordable 
costs. The genomes of over 200 Lactobacillus strains have been sequenced according to 
the Genomes Online Database (GOLD; www.genomesonline.org). These genome 
sequencing projects have paved the way for an improved understanding of lactobacilli 
and their probiotic properties (Claesson et al., 2007; Ventura et al., 2008). Many Lb. 
crispatus strains have been subjected to genome analyses. Lb. crispatus ST1, a chicken 
crop isolate (Ojala et al., 2010), has its genome fully sequenced, while a further nine 
strains have draft genome sequences available. 
Lb. crispatus EM-LC1 was isolated following an extensive screening programme of 
faecal samples obtained from elderly subjects participating in the ELDERMET project 
(http://eldermet.ucc.ie). The aim of this screening programme was to identify 
bacteriocin-producing intestinal bacteria. Lb. crispatus EM-LC1 exerted inhibitory 
activity against Lb. delbrueckii subsp. bulgaricus LMG6901 in vitro (Chapter 6), which 
on initial phenotypic analysis, appeared to be due to bacteriocin production. However, 
further characterisation indicated that the antimicrobial agent was heat labile and 
insensitive to protease (proteinase K, protease, pronase and pepsin) inactivation in the 
cell-free supernatant. The present study was based on the hypothesis that a genome 
sequencing approach could be used to identify genes responsible for what initially 
appeared to be an atypical bacteriocin-like antimicrobial activity exhibited by Lb. 
crispatus EM-LC1  
 Indeed, the genome sequence of this strain will provide a genomic platform for 
investigation of Lb. crispatus antimicrobial activity and will elucidate the genetic basis 
for its potential probiotic traits. 
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3.0  Materials and Methods 
3.1 Organism 
Lactobacillus crispatus EM-LC1 was originally isolated from a faecal sample obtained 
from a community-dwelling, elderly male subject (EM367), aged 80 y. This isolate 
exhibited antimicrobial activity in the cell-free supernatant (CFS) against Lb. 
delbrueckii subsp. bulgaricus LMG6901 (Chapter 6). Lb. crispatus ST1 is a chicken 
crop isolate which was obtained from University of Helsinki, Finland. This isolate did 
not exhibit antimicrobial activity in CFS against Lb. bulgaricus LMG6901 (Chapter 6). 
The genome sequence of this strain is publically available online (Ojala et al., 2010).  
3.2 Genomic DNA isolation 
EM-LC1 was grown overnight (~18 hours) in modified de Man, Rogosa, and Sharpe 
(mMRS) broth comprising MRS medium (Difco Laboratories, Detroit, MI, USA) 
supplemented with 0.05% (w/v) cysteine hydrochloride. DNA was extracted from 
15 mL of a fresh overnight culture. Briefly, the culture was sedimented by 
centrifugation and the resulting cell pellet was resuspended in 5 mL TE buffer 
(10mM Tris-HCl; 1mM EDTA; pH 8.0) and stored overnight at -20ºC. The cell 
suspension was thawed, treated with 5 mL of 30 mg mL-1 lysozyme and incubated for 
60-90 min at 37ºC. Sodium dodecyl sulfate (SDS) was added to a final concentration of 
1% before adding 50 µL of a proteinase K solution (100mg/mL) and incubating at 55ºC 
for 30-60 min, with occasional mixing. The sample was treated with 0.1 volume of 
5M sodium chloride followed by 0.1 volume of 5M sodium perchlorate. A further 
0.5 volume of phenol/chloroform (25:24:1 phenol:chloroform:isoamyl alcohol) was 
added and mixed at room temperature on a shaking platform for 30 min. The solution 
was centrifuged at 3,200 g for 10 min and the aqueous phase was treated with 
0.1 volume 3M sodium acetate and 2 volumes of ice cold 96% ethanol was added 
slowly. DNA (white thread like mass) was spooled out using a glass hook, dipped in 
70% ethanol for 30-60 s, air dried to remove residual ethanol, and resuspended in 
TE buffer (pH 8.0). DNA was applied to a 1% agarose gel and visualized by UV 
illumination after ethidium bromide staining. 
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3.3 Genome sequencing and annotation 
The genome was sequenced at Macrogen (Seoul, South Korea) on the Illumina 
platform, generating a paired-end library containing 35,397,530 reads of 101bp. The 
data were assembled into 54 scaffolds using the de novo assembly program Velvet 
(Zerbino & Birney, 2008). MAUVE was used to reorder scaffolds based on the 
reference genome of Lb. crispatus ST1 (Ojala et al., 2010). tRNA genes were identified 
using tRNA-scan SE (Lowe & Eddy, 1997). Protein coding regions were predicted 
using Metagene (Noguchi et al., 2006) and annotation was subsequently performed on 
the basis of BLASTP (Altschul et al., 1990) analysis against a non-redundant protein 
database (nr) provided by the National Centre for Biotechnology Information (NCBI) 
(Wheeler et al., 2007). This automated annotation was then manually inspected in the 
graphical user interface, Artemis (Rutherford et al., 2000). A functional classification 
was also applied by using the clusters of orthologous proteins (COG) database (Cut off: 
E value <1 x 10-4 and 50% identity over at least 50% of both protein sequences) 
(Tatusov et al., 2001). Metabolic predictions were made by KAAS (KEGG Automatic 
Annotation Server (Moriya et al., 2007). rRNA loci were detected on the basis of 
BLASTn searches. Pseudogenes were not determined due to the draft nature of the 
genome sequence.  
Accession numbers: This draft whole genome shotgun project has been deposited in 
GenBank under the accession no. AXLM00000000. The version described in this paper 
is the first version, AXLM01000000. The complete genome sequence of Lb. crispatus 
ST1 (accession number NC_014106) (Ojala et al., 2010) was obtained from Genbank 
(http://www.ncbi.nlm.nih.gov/nuccore/NC_014106.1).  
3.4 Genome comparisons 
Whole genome nucleotide alignments were generated using BLASTn (blast version 
2.2.21). Alignments were then visualised using the Artemis Comparison Tool (ACT) 
(Carver et al., 2005). Genome sequence alignments were also performed at DNA level 
using the MUMmer package (Kurtz et al., 2004). Identification of orthologs, paralogs 
and unique genes was performed following a preliminary step consisting of the 
comparison of each protein against all other proteins using BLASTP analysis (Altschul 
et al., 1990) (Cut off: E value <1 x 10-4 and 50% identity over at least 50% of both 
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protein sequences), then all proteins were clustered into protein families using MCL 
(graph theory-based Markov clustering algorithm) (van Dongen, 2000). 
4.0  Results and Discussion 
4.1 General genome features 
The Lb. crispatus EM-LC1 draft genome sequence consists of 1,862,161 bp with an 
overall G+C content of 36.9 % (Table 1), a value similar to that of other Lactobacillus 
genomes (Cremonesi et al., 2012; Ojala et al., 2010). All predicted genes, proteins, 
enzymes and their functions are putative. In silico analyses revealed that the genome 
contains 1,827 protein-encoding genes, representing a coding density of 87.6%, and 
with an average gene length of 893bp. No rRNA locus was assembled due to exclusion 
of repetitive sequence from the assembly. We identified forty-five tRNA-encoding 
genes representing 16 amino acids and twenty seven transposase-encoding genes (Fig. 
1).  
Functional classification of the predicted genes by Clusters of Orthologous Groups 
(COGs) of genes (Tatusov et al., 2001) showed that 1383 (75.7%) of predicted protein-
encoding genes were homologous to known gene families, including 155 (8.5%) 
identified as ‘general function prediction only’ and 130 (7.1%) poorly characterised 
gene functions designated as ‘function unknown’, while 444 (24.3%) do not have any 
COG association (Fig. 2).  
4.2 Comparative genomics 
As Lb. crispatus ST1 (a chicken crop isolate) is the only strain among the Lb. crispatus 
species with a complete genome sequence available, it was used in a comparison study 
with Lb. crispatus EM-LC1. At a summary statistical level, the genomes of Lb. 
crispatus ST1 and Lb. crispatus EM-LC1 are relatively similar (Table 1). Lb. crispatus 
ST1 and Lb. crispatus EM-LC1 have the same G+C content of approximately 37%. 
However, Lb. crispatus ST1 has a larger genome size of 2.04 Mbp. In addition, Lb. 
crispatus ST1 has a higher number of coding sequences and rRNA loci but this 
difference may be a reflection of the draft nature of the genome sequence of Lb. 
crispatus EM-LC1. Further comparative analysis revealed a high degree of synteny 
between the genomes (Fig. 3). Lb. crispatus EM-LC1 contained 135 genes which were 
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absent in Lb. crispatus ST1 at the cut-off value for orthology imposed for their proteins 
(Table 2). The EM-LC1 specific proteins included those for a zeta/epsilon family 
toxin/antitoxin system and genes related to bacteriocin (helveticin) production which 
will be further discussed below. As expected, a large proportion of the unique proteins 
corresponded to hypothetical proteins.  
4.3 Integrated plasmids 
Two scaffolds containing two probable integrated plasmids were identified in the 
genome sequence of EM-LC1, as indicated by the presence of the plasmid-associated 
genes (Table 3). Scaffold #16, consisted of 25,460 bp (G+C content, 42.9%) and 
Scaffold #43, consisted of 10,242 bp (G+C content, 37.4%). The latter was found to 
encode a putative toxin-antitoxin (TA) system of the zeta/epsilon family (Ojala et al., 
2010).  
4.4 Gastrointestinal-related genes 
EM-LC1 has a number of putative genes that have been highlighted (Altermann et al., 
2005; Cremonesi et al., 2012; Pridmore et al., 2004) as encoding features likely to 
contribute to the ability of lactobacilli to colonize and interact with the intestinal 
mucosa and microbiota. In EM-LC1, five genes encoding mucus-binding proteins and 
one gene encoding a fibronectin-binding protein were found. These proteins are 
common to lactobacilli that colonise the gastrointestinal tract and are thought to play an 
important role in adhesion to the intestinal mucus layer (Azcarate-Peril et al., 2008; 
Kankainen et al., 2009). In addition, 8 genes encoding S-layer proteins were identified. 
As the outermost component of the cell wall in several species of Lactobacillus 
(Åvall‐Jääskeläinen & Palva, 2005; Beganović et al., 2011; Chen et al., 2007; 
Konstantinov et al., 2008; Sun et al., 2013), S-layers are considered to protect the cell in 
hostile environments and aid in the maintenance of cell integrity (Åvall‐Jääskeläinen & 
Palva, 2005). Recently, the S-layer proteins of Lb. crispatus were shown to be involved 
in its adherence to intestinal epithelial cells and may be involved in the competitive 
exclusion of pathogens (Chen et al., 2007; Sun et al., 2013). The genome of EM-LC1 
harbours a gene for a sortase-like protein (Lc367_1071). Sortase enzymes function by 
anchoring proteins containing the characteristic substrate LPxTG motif to the 
Chapter 7 
225 
 
peptidoglycan of the cell wall. Indeed, a number of genes in EM-LC1 were annotated as 
LPxTG motif cell wall anchors (Lc367_1028 and Lc367_1769).  
The genome contains a number of predicted proteins assigned to COGs in the 
carbohydrate transport metabolism category, accounting for approximately 9.1% of the 
total predicted proteins. Lb. crispatus is currently regarded as homofermentative 
(Charalampopoulos & Rastall, 2009), meaning that sugars can be fermented only via the 
Embden-Meyerhof-Parnas pathway. The genome sequence encodes a variety of genes 
associated with carbohydrate utilisation, including 29 putative genes related to the 
phosphotransferase systems (PTS), by which the sugars are transported into the 
cytoplasm and phosphorylated. Putative PTS transporters were identified for cellobiose, 
mannose, sucrose, mannitol, α-glucoside, glucose, glucitol/sorbitol, β-glucoside, and 
fructose. A number of other genes related to ABC-type sugar transport systems and 
permeases were also identified.  
Intestinal commensal bacteria must also be able to endure a range of physiological 
stresses. Indeed, the ability of bacteria to respond to stresses such as those encountered 
during gastric and intestinal transit is key to their survival. The EM-LC1 genome 
encodes a number of stress resistance proteins including those predicted to confer 
resistance to heat (Lc367_0124), cold (Lc367_0766), alkali (Lc367_1131 and 
Lc367_1146) and phage shock proteins (Lc367_1357). In addition, two genes contained 
conserved domains that can identify them as putatively involved in the general stress 
responses (Lc367_0067 and Lc367_0710, universal stress protein family, USP). One 
gene encoding a putative bile salt hydrolase was identified in the genome sequence of 
EM-LC1 and is likely to be involved in the ability of Lb. crispatus to tolerate bile and to 
survive in the human gut environment.  
4.5 Polysaccharide biosynthesis cluster 
Many lactobacilli produce extracellular polysaccharides (EPS). Although the 
physiological role that EPS plays in the bacterial ecology of the commensal LAB still 
remains uncertain, a number of biologically significant roles, including stress resistance, 
adhesion, and interaction with the immune system have been attributed to EPS 
production (Prasanna et al., 2012). A predicted exopolysaccharide (EPS) cluster was 
identified in the genome sequence of EM-LC1, which was similar to an equivalent 
Chapter 7 
226 
 
cluster in Lb. crispatus ST1 (Ojala et al., 2010). The EM-LC1 EPS cluster spans 
15,085 bp and incorporates 16 predicted coding sequences including putative genes for 
a number of glycosyl transferases, a polysaccharide transporter, EPS biosynthesis 
proteins and a number of hypothetical proteins (Table 4). The EPS gene cluster exhibits 
an atypical G+C content of 31.6%. This suggests that acquisition of the L. crispatus 
EPS encoding region may have been by horizontal gene transfer in the intestinal 
environment and perhaps some particular selective pressure was required to promote 
acquisition from an outside genus. However, EM-LC1 was found to not produce EPS in 
vitro when grown on Congo red agar, MRS + 10% glucose and MRS + 10% sucrose 
(data not shown) indicating that the EPS cluster may be non-functional. However, it 
must be noted that EPS production in lactobacilli is known to be heavily dependent on 
culture factors such as the type of carbohydrate in the medium (Raftis et al., 2011), 
variations of which were not tested in this preliminary analysis.  
4.6 Prophages, R/M systems and Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) 
Phage and phage remnants are found in the genomes of most LAB and play a prominent 
role in species-to-species and strain-to-strain variability (Schroeter & Klaenhammer, 
2009). Prophage and their remnants can also encode genes directing phenotypes 
important for host survival and functions. The genome of EM-LC1 contains no 
complete prophage, similar to Lb. crispatus ST1. However, single ORFs with 
similarities to phage-genes were identified (Lc367_ 0662, Lc367_ 0684).  
The genome of Lb. crispatus EM-LC1 was also assessed for the presence of phage 
protection systems. The genome was screened for potential restriction/modification 
(R/M) systems. R/M systems are associated with the restriction of foreign DNA and are 
the most common systems used to degrade unmodified phage DNA (Azcarate-Peril et 
al., 2008; Labrie et al., 2010). The EM-LC1 genome contains a complete type I 
restriction modification (R/M) system (Lc367_1030, Lc367_1031 and Lc367_1032) and 
an independent putative restriction endonuclease (Lc367_0032). Type I R/M systems 
encode three subunits: a subunit for methylase activity (Lc367_1031), a subunit 
containing the specificity domain (Lc367_1032) and a third subunit which functions as 
the restriction unit (Lc367_1030). Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR)-associated proteins, which provide acquired immunity against 
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viruses, are absent in the EM-LC1 genome. In contrast, Lb. crispatus ST1 was found to 
encode CRISPR-associated proteins. 
4.7 Toxin-antitoxin systems 
Toxin-antitoxin (TA) systems are widely distributed on plasmids and chromosomes of 
prokaryotes, and some often have them in multiple copies (Fozo et al., 2010). In 
contrast to Lb. crispatus ST1, a complete putative TA system of the epsilon/zeta family 
was encoded in Lb. crispatus EM-LC1 (Lc367_1801 and Lc367_1802). The 
zeta/epsilon module consists of the labile antitoxin protein, epsilon (Lc367_1801), 
which interferes with the action of the long-living zeta toxin through protein complex 
formation (Lioy et al., 2012). However, upon antitoxin degradation, the toxin induces 
cell stasis/death. Zeta toxins target bacterial cell wall synthesis and dependent on the 
physiological state of bacteria, zeta poisoning can either induce a lytic or bacteriostatic 
phenotype (Mutschler & Meinhart, 2013). Whilst initially identified as plasmid 
maintenance systems that ensure stable inheritance, TA systems have also been linked 
with numerous functions, including growth modulation, genome maintenance, and 
stress response (Mutschler et al., 2011; Mutschler & Meinhart, 2013).  
Another putative TA locus, a toxin of the Txe/YoeB family (Lc367_1479) and an 
antitoxin of the RelB/DinJ family (Lc367_1478) was also identified in the genome. A 
similar type TA locus was identified in the genome sequence of Lb. crispatus ST1. In 
addition, a number of individual antitoxin genes of the RelB/DinJ family (Lc367_0449, 
Lc367_0453 and Lc367_1242) were encoded in the genome which did not have ORFs 
corresponding to the toxin associated with them as reported previously (Fozo et al., 
2010). 
4.8 Amino acid biosynthesis and proteolytic activity 
Through de novo synthesis and inter-conversions, Lb. crispatus appears to be able to 
synthesize 3 of the 20 amino acids (serine, glycine, and cysteine) (Fig. 4 and Fig. 5). 
Present in the genome is the gene predicted to encode the enzyme L-serine dehydratase 
(EC. 4.3.1.17) which catalyses the conversion of pyruvate into serine. Serine in turn can 
be converted into glycine by glycine hydroxymethyltransferase (EC. 2.1.2.1). Lb. 
crispatus is also potentially capable of converting pyruvate to L-cysteine using the 
enzyme cystine lyase (EC. 4.4.1.8).  A high degree of auxotrophy has been found in 
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other lactobacilli commonly residing in the human gastrointestinal tract, such as Lb. 
acidophilus (Altermann et al., 2005), and Lb. gasseri (Azcarate-Peril et al., 2008) and 
Lb. johnsonii (Pridmore et al., 2004). Indeed, Lb. johnsonii has been shown to 
completely lack genes encoding biosynthetic pathways for amino acids. This highlights 
the dependence this bacterium has on extracellular sources of amino acids that are likely 
to be present in the intestinal milieu.  
Because EM-LC1 is highly dependent on exogenous amino acids for growth, it is 
therefore not surprising that it possesses a large number of peptidase- and protease-
encoding genes to release these from proteinaceous substrates in the GIT. The 
proteolytic system of LAB usually consists of a cell wall-associated serine proteinase, 
transport systems specific for di-, tri- and oligopeptides and a multitude of intracellular 
peptidases (Slattery et al., 2010). Lb. crispatus EM-LC1 does not appear to encode the 
main enzyme required for large polypeptide utilisation, the extracellular protease that is 
involved in the primary breakdown of proteins. However, Lb. crispatus EM-LC1 has 
uptake systems for peptides, which are the main protein-degradation products. In silico 
analysis of the predicted transporters revealed the presence of a number of ATP-binding 
cassette (ABC)-type transporters translocating both oligopeptides and amino acids. 
Once internalised, the peptides are degraded by a variety of peptidases, which have been 
extensively studied in LAB (Savijoki et al., 2006). Lb. crispatus EM-LC1 was shown to 
encode a number of putative endopeptidases, proline peptidases, aminopeptidases and 
dipeptidases. 
4.9 Bacteriocins 
Lactic acid bacteria produce several antimicrobial compounds, including organic acids 
(lactic and acetic acid), hydrogen peroxide and bacteriocins. Bacteriocins are defined as 
ribosomally synthesised antimicrobial peptides that are active against other mainly 
closely-related bacteria (Cotter et al., 2005; Riley and Wertz, 2002). Lb. crispatus EM-
LC1 exerts bacteriocin-like antimicrobial activity against Lb. delbrueckii subsp. 
bulgaricus LMG6901 in vitro (Chapter 6), which on phenotypic analysis, appeared heat 
labile and insensitive to protease inactivation in the cell-free supernatant.  
The draft genome sequence of Lb. crispatus EM-LC1 identified a number of 
bacteriocin-type putative genes. EM-LC1 contains three putative helveticin genes with 
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homology to the helveticin J structural gene from Lb. helveticus 481 (Joerger & 
Klaenhammer, 1990). The predicted amino acid sequences of Lc367_1308, Lc367_1692 
and Lc367_1716 have, respectively, approximately 36%, 57% and 77% amino acid 
identity to helveticin J (Fig. 6). The genomes of Lb. delbrueckii subsp. bulgaricus ND02 
(Sun et al., 2011), Lb. amylovorus GRL1112 (Kant et al., 2011), Lb. gigeriorum CRBIP 
24.85T (Cousin et al., 2012) and Lb. acidophilus NCFM (Altermann et al., 2005) also 
harbour homologs of helveticin, indicating that such homologs are widespread in 
lactobacilli. It is interesting to note that two homologs of helveticin J are also present in 
Lb. crispatus ST1 (36% and 75% amino acid identity) (Ojala et al., 2010) (Fig. 7). 
However, Lb. crispatus ST1 did not exert the same antimicrobial activity as Lb. 
crispatus EM-LC1 in vitro (unpublished data).  
The helveticin J bacteriocin reported by Joerger and Klaenhammer in Lb helveticus 481 
is a large heat labile bacteriocin that inhibits the growth of a small number of 
Lactobacillus species (Joerger & Klaenhammer, 1986). Joerger and Klaenhammer also 
reported the existence of a second open reading frame, ORF2, that appeared to be co-
transcribed with the helveticin J ORF (Joerger & Klaenhammer, 1990). The EM-LC1 
helveticin J homologs, Lc367_1692 and Lc367_1716, each have an ORF homologous to 
ORF2 (Lc367_1693 and Lc367_1715, respectively) associated with it, while 
Lc367_1308 does not. Indeed Lc367_1693 and Lc367_1715 show strong similarity 
(72% and 71% amino acid identity) to the helveticin J ORF2 (Fig. 8). Interestingly, the 
two helveticin J homologs of Lb. crispatus ST1 do not have a second ORF associated 
with them. It has been speculated that ORF2 may encode a protein which binds to 
helveticin J and facilitates its export from the cell (Fremaux & Klaenhammer, 1994). 
The absence of ORF2 in Lb. crispatus ST1 may be responsible for its lack of 
antimicrobial activity compared to Lb. crispatus EM-LC1. 
Analysis of the genome of Lb. crispatus EM-LC1 also identified another region 
containing genes associated with bacteriocin production, the genetic organisation of 
which was typical of class II bacteriocins (Altermann et al., 2005; Dobson et al., 2007; 
Forde et al., 2011) (Fig. 9). Class II bacteriocins are small (<10kDa), heat-stable 
peptides which undergo removal of a leader peptide during export and activation. The 
bacteriocin-like region identified in EM-LC1 is composed of putative genes that show 
homology to the predicted regulatory and export systems of the class II bacteriocin, 
Chapter 7 
230 
 
lactacin B, encoded by Lb. acidophilus (Altermann et al., 2005; Dobson et al., 2007). 
Although genes encoding a sensor histidine kinase and response regulator (Lc367_1534 
and Lc367_1533) and transport apparatus comprising accessory proteins (Lc367_1530 
and Lc367_1529) and ATP-binding cassette (ABC) transporters (Lc367_1532 and 
Lc367_1531) were recognised, no genes homologous to known bacteriocin structural 
peptides were identified. Similar to the lactacin B operon (Altermann et al., 2005; 
Dobson et al., 2007), the region appeared to be organised into three clusters: a 
regulation cluster encoding a histidine kinase and a response regulator protein, an export 
cluster containing the ABC transporters and accessory proteins and a final cluster 
composed of proteins of unknown functionality. Unlike the lactacin B operon, the 
Lb. crispatus EM-LC1 locus did not possess a putative ‘production complex’ preceding 
the regulation and export machinery (Fig. 9). This production complex of Lb. 
acidophilus NCFM contains four unknown proteins, one of which is hypothesised to act 
as an inducing peptide (Dobson et al., 2007). Further downstream of the regulation and 
export cluster of EM-LC1, are the genes encoding four hypothetical proteins. Three of 
these four unknown proteins, Lc367_1526, Lc367_1527 and Lc367_1528 encode a 
putative double-glycine leader motif of 16, 18 and 19 amino acids, respectively. 
Interestingly, Lb. crispatus ST1 did not encode putative proteins homologous to 
Lc367_1526, Lc367_1527 and Lc367_1528. The putative protein Lc367_1528 was 
homologous (74% amino acid identity) to one of the unknown proteins in the lactacin B 
cluster (LBA1792) of Lb. acidophilus NCFM (Altermann et al., 2005; Dobson et al., 
2007). The double-glycine motif acts as a proteolytic site for ABC transporter and 
accessory protein, indicating that these putative genes are likely to encode proteins that 
are exported from the cell using this ABC transporter complex (Dobson et al., 2007). 
Whether the bacteriocin-type locus of EM-LC1 is active remains to be seen. Perhaps 
these genes may be the remains of a class II-like bacteriocin gene cluster. It has been 
found previously that many LAB can contain remnants of bacteriocin gene clusters on 
both the chromosome and resident plasmids (Møretrø et al., 2005; Vaughan et al., 
2003). 
5.0  Conclusion 
Several species of the genus Lactobacillus are known to produce bacteriocins (Barrett et 
al., 2007; De Vuyst et al., 2004; Fremaux & Klaenhammer, 1994; Kawai et al., 2000; 
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Zamfir et al., 1999). However, little is known about the antimicrobial activities of Lb. 
crispatus. Although Lb. crispatus is phylogenetically related to Lb. acidophilus 
(Charalampopoulos & Rastall, 2009) a species which is especially known to produce the 
bacteriocins (Anjum et al., 2013; Zamfir et al., 1999), to our knowledge, only one study 
has reported the production of a bacteriocin by a Lb. crispatus strain (Tahara & 
Kanatani, 1997). Lb. crispatus EM-LC1 is an elderly faecal isolate which exhibited 
narrow-spectrum antimicrobial activity, against Lb. delbrueckii subsp. bulgaricus LMG 
6901, in vitro. Interestingly, this antimicrobial activity is not exhibited by the chicken 
crop isolate, Lb. crispatus ST1 (Ojala et al., 2010). While in silico analysis of the draft 
genome sequence of Lb. crispatus EM-LC1 revealed significant similarities to the 
genome of Lb. crispatus ST1, a series of genes specific to EM-LC1 were identified. In 
particular, genes related to helveticin production were exclusively present in Lb. 
crispatus EM-LC1 as well as a number of hypothetical proteins located in a class II 
bacteriocin-like locus which may be responsible for the observed antimicrobial activity.  
Genome sequencing of EM-LC1 has also revealed a number of other interesting 
findings. A predicted EPS biosynthetic cluster, a complete type I R/M system, a 
complete TA system and individual phage-like genes were also identified. As expected 
a number of genes related to carbohydrate utilisation and genes implicated in adhesion 
to human intestinal cells were identified and are likely to contribute to the ability of Lb. 
crispatus to colonize intestinal mucosa. 
In conclusion, this draft genome sequence has paved the way for the identification of 
the potentially novel antimicrobial agent produced by Lb. crispatus EM-LC1 and has 
also shed light on some additional genome features. The genome sequence provides a 
basis for future comparisons with other Lb. crispatus faecal isolates. Genomic safety 
evaluation of this faecal isolate, as previously described in probiotic strains (Wei et al., 
2012; Zhang et al., 2012) may also prove worthwhile to identify potential antibiotic 
resistance or virulence-associated genes which may be of interest in future studies.  
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Table 1.  Major genomic features of Lb. crispatus EM-LC1 and Lb. crispatus ST1 
Strain Lb. crispatus EM-LC1 Lb. crispatus ST1 
Genome size (bp) 1,862,161 2,043,160 
G+C content (%) 37 37 
Coding genes 1, 827 2,024 
Coding density (%)  87.6 88.6  
Average gene length (bp) 893 895 
rRNA loci - 4 
tRNAs 45 64 
Transposase 26 62 
CRISPR loci 0 1 
Scaffolds 54 1 
Status of assembly draft finished 
Source human faeces chicken crop 
Genbank accession number N/A NC_014106  
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Table 2.  Lb. crispatus EM-LC1 specific proteins as determined by comparison to Lb. crispatus ST1                                                                                                                              
Locus_tag (s) Predicted function 
Lc367_0017 hypothetical protein 
Lc367_0192 hypothetical protein 
Lc367_0238 hypothetical protein 
Lc367_0291 deoxyribose-phosphate adolase 
Lc367_0297 CoA transferase 
Lc367_0298 formyl coA transferase 
Lc367_0303 hypothetical protein 
Lc367_0348 hypothetical protein 
Lc367_0356 hypothetical protein 
Lc367_0374 hypothetical protein 
Lc367_0382 ammonium transporter 
Lc367_0413 hypothetical protein 
Lc367_0442 transposase 
Lc367_0443 transposase 
Lc367_0444 hypothetical protein 
Lc367_0446 hypothetical protein 
Lc367_0447 hypothetical protein 
Lc367_0451 hypothetical protein 
Lc367_0454 hypothetical protein 
Lc367_0460 hypothetical protein 
Lc367_0461 LtrC-like protein 
Lc367_0465 glycogen synthase 
Lc367_0466 glucan phosphorylase 
Lc367_0467 Pullulanase (partial) 
Lc367_0474 hypothetical protein 
Lc367_0475 hypothetical protein 
Lc367_0476 hypothetical protein 
Lc367_0477 hypothetical protein 
Lc367_0479 hypothetical protein 
Lc367_0480 hypothetical protein 
Lc367_0481 hypothetical protein 
Lc367_0483 hypothetical protein 
Lc367_0664 hypothetical protein 
Lc367_0666 hypothetical protein 
Lc367_0670 hypothetical protein 
Lc367_0683 hypothetical protein 
Lc367_0685 hypothetical protein 
Lc367_0720 hypothetical protein 
Lc367_0721 hypothetical protein 
Lc367_0722 hypothetical protein 
Lc367_0723 hypothetical protein 
Lc367_0724 hypothetical protein 
Lc367_0957 hypothetical protein 
Lc367_0963 hypothetical protein 
Lc367_0966 cytidine deaminase 
Lc367_1030 type I R/M system, restriction subunit  
Lc367_1032 type I R/M system, specificity subunit 
Lc367_1039 conserved hypothetical protein 
Lc367_1041 sugar-phosphate isomerase 
Lc367_1042 acetyltransferase 
Lc367_1063 hypothetical protein 
Lc367_1064 hypothetical protein 
Lc367_1115 transcriptional regulator 
Lc367_1213 dihydroxyacetone kinase, phosphotransfer 
Lc367_1215 dihydroxyacetone kinase, DhaK subunit 
Lc367_1221 CoA-transferase 
Lc367_1222 deoxygenase/reductase 
Lc367_1223 crotonase/enoyl CoA hydratase 
Lc367_1313 hypothetical protein 
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Lc367_1324 hypothetical protein 
Lc367_1327 hypothetical protein 
Lc367_1339 predicted ATPase  
Lc367_1428 hypothetical protein 
Lc367_1429 HesA/MoeB/ThiF family protein 
Lc367_1430 hypothetical protein 
Lc367_1453 hypothetical protein 
Lc367_1465 glycosyl transferase 
Lc367_1466 glycosyl transferase 
Lc367_1467 hypothetical protein 
Lc367_1526 hypothetical protein 
Lc367_1527 hypothetical protein 
Lc367_1528 hypothetical protein 
Lc367_1530 bacteriocin secretion accessory protein 
Lc367_1545 conserved hypothetical protein 
Lc367_1671 conserved hypothetical protein 
Lc367_1673 hypothetical protein 
Lc367_1718 hypothetical protein 
Lc367_1731 hypothetical protein 
Lc367_1732 hypothetical protein 
Lc367_1734 hypothetical protein 
Lc367_1737 hypothetical protein 
Lc367_1738 conserved hypothetical protein 
Lc367_1739 hypothetical protein 
Lc367_1741 conserved hypothetical protein 
Lc367_1746 hypothetical protein 
Lc367_1749 ribonucleotide reductase 
Lc367_1777 hypothetical protein 
Lc367_1780 N-acetylmannosamine-6-phosphate epimerase 
Lc367_1782 transcriptional regulator 
Lc367_1786 hypothetical protein 
Lc367_1789 transcriptional regulator 
Lc367_1791 hypothetical protein 
Lc367_1795 hypothetical protein 
Lc367_1796 conserved hypothetical protein 
Lc367_1797 conserved hypothetical protein 
Lc367_1798 hypothetical protein 
Lc367_1801 
antidote of epsilon-zeta postsegregational 
killing system 
Lc367_1820 hypothetical protein 
Lc367_1825 conserved hypothetical protein 
Lc367_1826 conserved hypothetical protein 
Lc367_1827 hypothetical protein 
Lc367_1828 conserved hypothetical protein 
Lc367_1829 zinc-dependent metallopeptidase 
Lc367_1840 membrane protein 
Lc367_0455/Lc367_1802 putative ATPase/zeta toxin 
Lc367_0456/Lc367_1803 hypothetical protein 
Lc367_0457/Lc367_1804 hypothetical protein 
Lc367_0463/Lc367_0464 glucose1phosphate adenyltransferase 
Lc367_0660/Lc367_0681 hypothetical protein 
Lc367_0661/Lc367_0682 hypothetical protein 
Lc367_0662/Lc367_0684 prophage DNA packaging protein 
Lc367_0663/Lc367_0665 hypothetical protein 
Lc367_0667/Lc367_0686 hypothetical protein 
Lc367_0668/Lc367_0687 hypothetical protein 
Lc367_1693/Lc367_1715 helveticin ORF2 
Lc367_1747/Lc367_1748 hypothetical protein 
Lc367_0669/Lc367_0688/Lc367_1776 integrase/recombinase 
Lc367_0458/Lc367_1805/Lc367_1806/Lc367_1807 nickase 
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Table 3.  Scaffolds containing potential integrated plasmids 
Scaffold  Locus Tag Predicted function Position Size 
(kb) 
#16   453021..478481 25.5 
 Lc367_0441 pullulanase   
 Lc367_0442 transposase   
 Lc367_0443 transposase   
 Lc367_0444 hypothetical protein   
 Lc367_0445 resolvase   
 Lc367_0446 hypothetical protein   
 Lc367_0447 hypothetical protein   
 Lc367_0448 hypothetical protein   
 Lc367_0449 addiction molecule antitoxin, RelB/DinJ 
family 
  
 Lc367_0450 chromosome partitioning protein, ParA   
 Lc367_0451 hypothetical protein   
 Lc367_0452 replication initiator protein, RepA   
 Lc367_0453 addiction molecule antitoxin, RelB/DinJ 
family 
  
 Lc367_0454 hypothetical protein   
 Lc367_0455 putative ATPase   
 Lc367_0456 hypothetical protein   
 Lc367_0457 hypothetical protein   
 Lc367_0458 nickase   
 Lc367_0459 DNA topoisomerase   
 Lc367_0460 hypothetical protein   
 Lc367_0461 LtrC-like protein   
 Lc367_0462 glycogen brancing enzyme   
 Lc367_0463 glucose-1-phosphate adenylyltransferase   
 Lc367_0464 glucose-1-phosphate adenylyltransferase   
 Lc367_0465 glycogen synthase   
 Lc367_0466 glucan phosphorylase   
 Lc367_0467 pullulanase (partial)   
#43   1834667..1844909 10.2 
 Lc367_1795 hypothetical protein   
 Lc367_1796 conserved hypothetical protein   
 Lc367_1797 conserved hypothetical protein   
 Lc367_1798 hypothetical protein   
 Lc367_1799 replication initiator a, n terminal   
 Lc367_1800 conserved hypothetical protein   
 Lc367_1801 antidote of zeta-epsilon postsegregational 
killing system 
  
 Lc367_1802 zeta toxin protein   
 Lc367_1803 hypothetical protein   
 Lc367_1804 conserved hypothetical protein   
 Lc367_1805 nickase (partial)   
 Lc367_1806 nickase (partial)   
 Lc367_1807 nickase (partial)    
 Lc367_1808 large conductance mechanosensitive channel   
 Lc367_1809 transposase   
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Table 4. Predicted EPS cluster 
Locus Tag(s) Predicted function 
Lc367_1462 acetyl transferase 
Lc367_1463 polysaccharide transporter, PST family 
Lc367_1464 UDP-galactopyranose mutase 
Lc367_1465 hypothetical protein 
Lc367_1466 hypothetical protein 
Lc367_1467 hypothetical protein 
Lc367_1468 hypothetical protein 
Lc367_1469 glycosyl transferase 
Lc367_1470 glycosyl transferase 
Lc367_1471 glycosyl transferase 
Lc367_1472 glycosyl transferase 
Lc367_1473 phospho-glucosyltransferase 
Lc367_1474 exopolysaccharide biosynthesis protein 
Lc367_1475 exopolysaccharide biosynthesis protein 
Lc367_1476 exopolysaccharide biosynthesis protein 
Lc367_1477 exopolysaccharide biosynthesis protein 
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Figure 1.  Genome-atlas view of the Lb. crispatus EM-LC1 draft genome sequence.  From outside to 
inside: Lb. crispatus genes on the forward strand (green); genes on the reverse strand (red); tRNAs 
(orange); putative integrated plasmids (purple); helveticin genes (black); putative class II bacteriocin gene 
cluster (turquoise); polysaccharide biosynthesis cluster (yellow); G+C % (light blue -  below mean and 
dark blue – above mean) and GC skew 
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Figure 3.  Comparison of the genomes of two Lb. crispatus strains. Top panel: MUMMER plot (DNA-
DNA) of Lb. crispatus ST1 (horizontal axis) and Lb. crispatus EM-LC1 (vertical axis) genomes. Red dots 
represent regions of homology between the genomes and which are in the same orientation.  Blue dots 
represent homology between the genomes in the opposite orientation.  Bottom panel: ACT comparison 
(DNA-DNA) of Lb. crispatus ST1 (top) and Lb. crispatus EM-LC1 (bottom). Homologous genomic 
sequences are indicated by red lines. Blue lines indicate homologous genomic sequences in reverse 
orientation. White indicates regions without homology in the other genome. 
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Figure 4.  Partial metabolic map of Lb. crispatus EM-LC1, showing the predicted interconversions of 
pyruvate, serine and glycine. Enzyme labels in green boxes represent those for which the corresponding 
gene was annotated in the genome  
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Figure 5.  Partial metabolic map of Lb. crispatus EM-LC1, showing the predicted interconversion of 
pyruvate and L-cysteine.  Enzyme labels in green boxes represent those for which the corresponding gene 
was annotated in the genome. 
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Figure 9.  Comparison of the lactacin B cluster of Lb. acidophilus NCFM with the locus encoding a 
putative Class II bacteriocin cluster of Lb. crispatus EM-LC1. Figure not drawn to scale.  ORFs of 
unknown function are represented by navy shaded arrows. 
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Understanding the role of diet in determining human health and disease is a major 
objective of modern nutrition. Indeed, diet and nutrition have been recognised for many 
years as important factors in the promotion and maintenance of good health throughout 
the entire life course. More recently, the activities of the microbial community that 
inhabits the intestine and its role in maintaining health has been the subject of extensive 
research. This complex community has been shown to play a key role in numerous 
metabolic, physiological, nutritional and immunological processes (Brestoff & Artis, 
2013; O'Hara & Shanahan, 2006) and perturbations in the composition or function of 
the microbiota have been linked to undesirable health conditions including 
inflammatory and metabolic disorders (Power et al., 2013a; Power et al., 2013b). 
Recent evidence illustrating the impact of diet on the gut microbiota (Claesson et al., 
2012; De Filippo et al., 2010; Wu et al., 2011) highlights this complex community as a 
potentially new dietary target for the treatment and prevention of disease. Moreover, as 
this internal ecosystem has been shown to be a rich repository for functional food 
ingredients (e.g. conjugated linoleic acid and exopolysaccharide), probiotics and even 
new drugs (Shanahan, 2010), the necessity of incorporating studies of this microbiota 
into contemporary nutritional research is obvious.  
The overall hypothesis of this thesis was that diet and the intestinal microbiota 
independently and jointly contribute to health in the elderly and that the investigation of 
habitual dietary patterns and functional microbiota components, can lead to the 
identification of specific effector mechanisms.  
The first section of this thesis investigated the dietary intake of elderly subjects 
participating in the ELDERMET project (Chapter 3). ELDERMET is an Irish project 
that aims to determine how diet and lifestyle influence, and are influenced by, the 
bacteria in your gut, and how this knowledge can be used to promote health in the 
elderly Irish population. A relatively recent publication by the ELDERMET consortium 
found that the diversity and composition of the microbiota of elderly subjects is mainly 
driven by diet, and the microbiota, in turn, may significantly influence inflammatory 
tone and health status in this vulnerable population group (Claesson et al., 2012). As 
Poor dietary habits and inadequate nutrient intakes are of particular concern in the 
elderly (Stanga, 2009), the aim of Chapter 3 was to assess, in great detail, the dietary 
intakes of Irish community-dwelling elderly individuals in order to identify subgroups 
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of individuals at nutritional risk. In this chapter, it was demonstrated that community-
dwelling, elderly individuals are compliant with a number of food group 
recommendations. Indeed, fruit and vegetables were consumed regularly among this 
elderly group indicating an awareness of their positive health effects.  However, intakes 
of dairy produce were inadequate and over-consumption of foods high in fat and/or 
sugar in the elderly may be contributing to the high rate of overweight/obesity in this 
population group as well as displacing more nutrient dense foods from the diet. 
Although malnutrition was not detected among the community-dwelling study 
participants, sub-optimal intakes of several micronutrients were identified, particularly 
among males, supporting the hypothesis that there are indeed subgroups within the 
elderly population at nutritional risk.   
Following on from the dietary assessment of community-dwelling elderly, the aim of 
Chapter 4 was to gain more insight into the role of dietary intake as a determinant of 
cognitive function in the elderly. Ageing is associated with a loss of cognitive 
performance and an increased risk of dementia, which, in addition to other age-related 
chronic disease, is expected to place growing demands on health and long-term care 
providers (World Health Organisation/National Institute of Health, 2011). The findings 
in this study indicate a role for diet-related factors in successful brain ageing. It appears 
that western-type dietary patterns and more specifically high glycaemic index 
(GI)/glycaemic load (GL) diets are associated with reduced cognitive function in the 
elderly. Indeed, the results of this study generate a new hypothesis and represent a 
valuable contribution to a better understanding of the link between dietary factors and 
cognition in the elderly. Nonetheless, additional prospective investigations, intervention 
and mechanistic studies are required in order to give a definitive answer as to whether a 
low GI/GL diet can prevent cognitive decline in the elderly and to elucidate the 
underlying biological mechanisms.  
While previous studies by the ELDERMET consortium (Claesson et al., 2012) have 
recommended the promotion of healthy ageing by nutritional interventions which target 
the gut microbiota, the studies described above also emphasise the requirement for 
interventions to improve dairy consumption and micronutrient intakes and reduce 
dietary fat intakes among community-dwelling older adults. Moreover, there may also 
be a rationale for the promotion of a low glycaemic index diet in order to promote 
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healthier brain ageing. Indeed these findings present both challenges and opportunities 
for the food industry and healthcare policy makers, to devise age-specific dietary 
recommendations and to develop attractive, healthy and innovative products and/or 
fortified meals tailored for the elderly. However, it must be noted that in addition to the 
assessment of the elderly diet and the nutrition–ageing relationship, successful 
nutritional policies and dietary interventions for healthy ageing require a lucid 
understanding of what is driving the elderly to adopt specific diets (Irz et al., 2013). It is 
necessary to understand their food habits; how they choose their food and how or if they 
take into account the impact of food on their health (Delaney & McCarthy, 2011) in 
order to learn what can be done at population or individual level to increase the 
healthiness of their diets.  
While the primary role of diet is to provide enough nutrients to meet metabolic 
requirements, recently, the focus of scientific investigations has moved to the 
hypothesis that, beyond meeting nutrition needs, diet may modulate various 
physiological functions which may play a role in health and disease (Granato et al., 
2010). Foods which promote health beyond providing basic nutrition are termed 
‘functional foods’ (Sanders, 1998). Of these foods, probiotics, found mostly in dairy 
products, can exert positive effects on overall health. The probiotic market is lucrative 
and fast growing and product innovations are expected to play a major role in increasing 
the share of the market players. Indeed, Alimentary Health Ltd. is the foundation 
industry partner of the Alimentary Pharmabiotic Centre based at University College 
Cork and is focused on the discovery, development and commercialisation of 
proprietary probiotic and pharmabiotic treatments for gastrointestinal disorders and 
other inflammatory conditions. With this in mind, a collaborative project with 
Alimentary Health Ltd. (Chapter 5) was undertaken to test the hypothesis that 
Bifidobacterium-fermented milk products (BFMs) containing ‘dead’ cells could 
stimulate levels of IL-10 and TNF-α comparable to those stimulated by BFMs 
containing ‘live’ cells. Human peripheral blood mononuclear cells were used as an in 
vitro model in this study. Indeed, characterising how the innate immune system 
responds to probiotic bacteria in vitro may give an indication as to the likely 
immunomodulatory events that can be triggered following probiotic administration in 
vivo. Depending on the strain and the mode of killing used, BFMs containing dead cells 
stimulated levels of IL-10 and TNF-α which were comparable to those stimulated by 
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BFM containing live cells. As well as eliminating shelf life problems, administration of 
such a product containing non-viable microorganisms could reduce the risk of microbial 
translocation and infection. Nonetheless, the true in vivo picture needs to be fully 
determined taking into account the contributing roles of other commensal gut bacteria as 
well as the immunocompetent cells in the gut environment.  
In the final section of this thesis, an extensive screening study of the elderly-derived 
faecal microbiota was carried out in order to examine the prevalence of antimicrobial 
production by intestinal bacteria and to mine this rich repository of metabolites for 
novel antimicrobials (Chapter 6). This screening system resulted in the isolation of a 
number common intestinal species (Escherichia coli, Lactobacillus salivarius, 
Enterococcus faecium) with antimicrobial activity, but also selected for Streptococcus 
mutans, a species not normally detected among the human intestinal microbial 
community (Kamiya et al., 2005). The repeated isolation of previously characterised 
bacteriocins in this extensive screening study suggests that the culture-based isolation of 
antimicrobials is perhaps limited in its potential to isolate novel bacteriocin-producers. 
One major obstacle with such an approach is that bacteriocin production is an unstable 
trait and may be influenced by a number of environmental factors (e.g. temperature and 
growth medium). Indeed, the genes responsible for bacteriocin production are typically 
tightly regulated and bacteriocin production may go undetected under conditions where 
the responsible operons are switched off (Kleerebezem, 2004). Furthermore, 
bacteriocins generally have a narrow spectrum of inhibitory activity and might not be 
detected using only a low number of indicator strains for screening. Future screening 
studies may benefit from use of a wider range of indicator organisms, particular genera 
that dominate the gut microbiota (e.g. Bacteroides, Clostridium and Ruminococcus 
species) (Qin et al., 2010). Alternatively, culture-independent, genomic mining tools, 
such as BAGEL, may be employed (De Jong et al., 2006) which would circumvent the 
inherent limitations of these type of culture-based screening methods.  However, the 
annotation of bacteriocin-like genes in the genome of a particular strain is insufficient 
evidence to infer bacteriocin production and a laboratory based confirmation of the 
phenotype is also required. This study resulted in the isolation of a Lactobacillus 
crispatus strain (EM-LC1) producing a potentially novel heat labile antimicrobial 
compound which was resistant to protease activity in the cell-free supernatant. A 
genome sequencing approach was applied to attempt to identify loci which may be 
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responsible for what initially appeared to be an atypical bacteriocin-like antimicrobial 
activity. 
Genome sequences of commensal bacteria are fundamentally important in 
understanding the evolution of bacteria including strategies for adaptation to new niches 
and overcoming competitors (Ahmed, 2009) as well as having a significant predictive-
value which can be exploited to inform and direct research hypotheses. We compared 
the genome sequence of Lb. crispatus EM-LC1 to the publicly available genome 
sequence of Lb. crispatus ST1 (a chicken crop isolate which does not exhibit 
antimicrobial activity in vitro) in order to identify genes which may be responsible for 
the antimicrobial activity. While the genome sequences were shown to exhibit a high 
degree of similarity, a number of genes were identified which were unique to Lb. 
crispatus EM-LC1, in particular, genes related to bacteriocin (helveticin) production. 
This information has provided numerous leads for subsequent bacteriocin purification 
work which is currently ongoing. As well as paving the way for the identification of the 
potentially novel antimicrobial agent, the genomic characterization of this commensal 
intestinal bacterium plays an important role in deepening our understanding of its 
metabolic capacities (carbohydrate utilisation, etc.) and will enable functional and 
comparative genomic studies to be carried out in the future. 
In conclusion, the work presented in this thesis represents another advance in 
nutrition/microbiota-based research. Indeed this work has provided a considerable 
amount of evidence supporting the general hypothesis that the investigation of habitual 
dietary patterns and functional microbiota components could lead to the identification of 
the specific mechanisms linking both the diet and the intestinal microbiota with health 
in the elderly.  Research related to the dietary intakes of community-dwelling elderly 
subjects may be used in the development of future public health interventions to 
improve diet and health of older adults while the research related to the 
immunomodulatory effect of ‘dead’ probiotics may be employed to generate 
commercial outputs in the future. Screening the faecal-derived microbiota resulted in 
the isolation of a potentially novel bacteriocin-producing strain and the subsequent 
genome sequence of this strain has highlighted a number of genes which may be 
responsible for the observed antimicrobial activity. Moreover, the genome sequence 
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provides a basis for future comparisons with other Lactobacillus faecal isolates, helping 
to expand our knowledge of their relationship with mankind.  
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